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Riassunto 
 
Il ruolo dell’alimentazione nel contribuire allo stato di salute sta ricevendo una sempre maggiore 
attenzione. Inoltre, le proprietà degli alimenti possono essere migliorate con l’aggiunta di 
ingredienti funzionali, tra cui probiotici e prebiotici, in grado di agire sul microbiota intestinale. 
L'obiettivo di questa ricerca è stato quello di sviluppare una nuova pasta funzionale integrale, 
contenente un microrganismo probiotico sporigeno, il ceppo Bacillus coagulans GBI-30, 6086 
(BC30) e β-glucani d’orzo, e di valutare le sue proprietà microbiologiche, e gli effetti del suo 
consumo sul microbiota intestinale, in due contesti, il diabete di tipo 1 (T1D) e l’obesità. 
In fase di messa a punto del prodotto funzionale, è stata innanzitutto valutata la stabilità del 
ceppo probiotico, utilizzando metodi microbiologici classici e analisi di qPCR. I risultati hanno 
mostrato come il ceppo risulti stabile nei processi di produzione e cottura della pasta, e sia in 
grado di sopravvivere al transito nel tratto gastrointestinale. 
Nell’ambito del diabete, è stato effettuato, in primo luogo, uno studio caso-controllo, volto ad 
indagare eventuali differenze del microbiota intestinale di bambini sani e bambini a rischio di 
sviluppare T1D. Le analisi di PCR-DGGE hanno mostrato come alcune specie risultino 
caratteristiche della condizione di pre-diabete. In un secondo studio, gli effetti 
dell'amministrazione della pasta funzionale e dei suoi ingredienti (in termini di modulazione 
della composizione microbica e produzione di acidi grassi a catena corta) sono stati valutati in un 
modello in vitro del colon, TIM-2, sul microbiota fecale di bambini con diversa suscettibilità al 
T1D. Sono state individuate specifiche relazioni dieta-effetto sul microbiota, anche ampliando le 
informazioni disponibili rispetto al ceppo probiotico e ai β-glucani. 
Infine, è stato valutato l'impatto del consumo della pasta funzionale in uno studio clinico che ha 
coinvolto soggetti sovrappeso/obesi. Le analisi di PCR-DGGE e qPCR hanno mostrato come il 
nuovo prodotto non abbia modificato in modo sostanziale la composizione microbica intestinale, 
e non abbia portato ad aumenti di specifici gruppi microbici correlati ai diversi ingredienti della 
pasta funzionale nella totalità dei soggetti, a causa della marcata variabilità individuale. 
Stratificando la popolazione in sottogruppi più omogenei, e correlando i dati microbiologici e 
clinici, sono comunque emersi alcuni risultati interessanti relativi al nuovo prodotto. 
In conclusione, questo lavoro ha mostrato come la nuova pasta funzionale costituisca un prodotto 
di alta qualità per le sue proprietà nutritive, e per gli effetti positivi osservati sia in vitro a livello 
del microbiota intestinale, sia dai risultati clinici e microbiologici. Ulteriori studi saranno utili 
per approfondire ed ampliare le conoscenze acquisite. 
  
 
Abstract 
 
Foods are not intended anymore only as sources of nutrients and energy, but also as factors that 
can influence health status. In this perspective, food properties can be improved by the addition 
of functional ingredients, e.g. probiotics and prebiotics, that can positively act on gut microbiota. 
Thus, the aim of the present research was the development of a novel whole grain functional 
pasta, added with the spore-forming probiotic Bacillus coagulans GBI-30, 6086 (BC30) and β-
glucans from barley, and the investigation of its microbiological properties and effects on gut 
microbiota, in two contests, type 1 diabetes (T1D) and obesity condition. 
In particular, the stability of the probiotic strain was investigated during the development of the 
functional product, through conventional plating and qPCR analyses, providing evidences related 
to its viability following pasta-manufacturing and cooking processes, as well as to its survival to 
the transit through the gastrointestinal tract. 
In type 1 diabetes contest, a case-control study was firstly performed for assessing differences in 
gut microbiota composition between children at risk for T1D and healthy children. PCR-DGGE 
analyses showed that certain species were characteristics of the pre-diabetes condition. Then, the 
effects (i.e. modulation of microbiota composition and short-chain fatty acid production) of the 
administration of the functional pasta and its ingredients were investigated with respect to fecal 
microbiota from children with different susceptibility to T1D, using the TIM-2 model of the 
proximal colon. Specific diet-microbiota relationships were individuated, also expanding 
available information about the probiotic and prebiotic ingredients. 
Finally, the impact of the consumption of the functional pasta was investigated in a clinical trial 
involving overweight/obese subjects, through PCR-DGGE analyses and qPCR. The novel 
product did not substantially affect gut microbiota composition, and, in the total group of 
subjects, it did not caused increases of specific microbial groups reported to be modulated by the 
different functional pasta ingredients, due to the high inter-individual variability. Stratifying the 
population in smaller, more homogeneous groups, and correlating microbiological and clinical 
data allowed to unveil some interesting findings related to the new product. 
In conclusion, the present research indicated that the novel developed pasta constitutes a high-
quality product for its nutritional properties, and for positive effects observed both in vitro at the 
gut microbiota level, and from clinical and microbiological results. However, further studies will 
be helpful to deepen achieved knowledge on this new product. 
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1. Introduction 
 
The concept of functional food has emerged as a result of extensive research on the relationship 
between diet and health. Even if a unified definition has not yet been established (Bigliardi and 
Galati, 2013), the idea is that “a functional food consists in, or appears similar to, a conventional 
food. It is part of a standard diet and is consumed on a regular basis, in normal quantities. It has 
proven health benefits that reduce the risk of specific chronic diseases or beneficially affect 
target functions beyond its basic nutritional functions” (Doyond and Lebreque, 2008). Thus, a 
certain functional food can be introduced with the diet, e.g. in substitution to a conventional 
food, representing a successful strategy for the introduction of component with beneficial effects 
on the health. Probiotics and prebiotics constitute functional ingredients able to act on gut 
microbiota, and can be used in the development of functional foods. 
In the following sections general aspects relative to probiotics and prebiotics, with a specific 
focus on the strain Bacillus coagulans GBI-30, 6086 and β-glucans, and the development of new 
functional products will be presented. In addition, a short overview on gut microbiota, its 
involvement in diseases, and its modulation through the diet will be provided. 
 
Probiotics 
According to the currently adopted definition, probiotics are defined as “live microorganisms 
that, when administrated in adequate amounts, confer a health benefit on the host” (FAO/WHO, 
2002; Hill et al., 2014). This implies that a probiotic microorganism should fulfil different 
criteria e.g. being present in adequate number of viable cells in a product, being able to survive 
the transit through the gastrointestinal tract, and providing a specific health benefit to the host 
(Collado et al., 2009). The mechanisms through which probiotics exert their effects can include 
competitive exclusion of pathogens due to production of antimicrobial compounds and inhibitory 
agents, e.g. bacteriocins, and competition for nutrients and adhesion sites, enhancement of the 
intestinal barrier function, pH modification, modulation of inflammatory responses through 
interaction with immune cells in the gut (Collado et al., 2009; Papadimitriou et al., 2015). 
Probiotics have been applied in many contests, resulting active in the treatment of intestinal 
diseases, for example intestinal bowel disease (IBD), infectious diarrhoea, antibiotic-associated 
diarrhoea, Crohn’s disease, and also at a systemic level, e.g. allergic diseases (Collado et al., 
2009; Iannitti and Palmieri et al., 2010). 
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However, these mechanism and effects can not being generalised. In fact, probiotic properties 
represent strain-specific features, that means that effects have to be investigated case by case 
(Power et al., 2014). At the same, this indicates that taxonomic identification is essential to 
connect a strain to a specific effect on health and to safety issues. From the safety point of view, 
at the European level, a probiotic strain must be included among the species of the QPS 
(Qualified Presumption of Safety) list, drafted by the European Food Safety Authority (EFSA) 
(EFSA, 2007). 
Traditionally, most of bacterial probiotic strains belong to the genera Lactobacillus and 
Bifidobacterium, but strains belonging to other genera e.g. Enterococcus, Lactococcus, 
Leuconostoc, Pediococcus and Bacillus are also available. In particular, Bacillus strains have 
been used as probiotics for at least 60 years, considering that the Italian product Enterogermina, 
a Bacillus clausii preparation, was registered in 1958 as an OTC medicinal supplement (Cutting, 
2011). The genus Bacillus present the specific characteristic of forming spores, very resistant 
structures able to withstand adverse environmental conditions, e.g. extremes of heat, UV 
radiation, exposure to solvents, enzymes. Spores are dehydrated and, when exposed to 
appropriate nutrients, will germinate, in a process requiring just few minutes, in which water 
enters the spores, breaks the spore coats, making vegetative cell able to resume and grow 
(Cutting, 2011). Thanks to their spore-forming nature, probiotics belonging to the genus Bacillus 
present improved characteristics of resistance with respect to other non spore-former probiotics; 
in fact, they are able to resist to high temperatures, they can be stored at room temperature in a 
desiccated form without any deleterious effect on viability, and they can resist to low pH of the 
gastric barrier (Cutting, 2011). 
 
The strain Bacillus coagulans GBI-30, 6086 (BC30) 
Bacillus coagulans was first isolated from coagulated milk by Hammer in 1915 (Hammer, 1915), 
later described in 1933 by Horowitz-Wlassowa and Nowotelnow as Lactobacillus sporogenes, 
and subsequently reclassified as B. coagulans. From a taxonomic point of view, this species 
belong to phylum Firmicutes, and to the family of Bacillaceae. Strains belonging to this species 
are Gram-positive bacteria, spore-forming, rod-shaped, facultative anaerobes, and they produce 
lactic acid from fermentation of maltose, mannitol, raffinose, sucrose and trehalose (De Vecchi 
and Drago, 2006). The species B. coagulans is considered a safe species, since it is included in 
the QPS list edited by EFSA (EFSA, 2007), updated to the 4th revision in 2016. 
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Among strains belonging to this species, the strain B. coagulans GBI-30, 6086 (BC30) is one of 
the most studied and characterised one. Bacillus coagulans BC30 is a commercial, patented 
probiotic strain, produced by the company Ganeden Biotech, and it received GRAS (Generally 
Recognized As Safe) status from U.S. FDA in 2012, following presentation of toxicological 
studies (Endres et al., 2009; Endres et al., 2011). Moreover, the genome of the strain has been 
recently sequenced (Orrù et al., 2014), and integrated phenotypic and genomic analyses have 
confirmed the safety of the strain (Salvetti et al., 2016).  
This probiotic microorganism is available as dietary supplement, and moreover, it has already 
been included in a broad range of food products and beverages available in U.S. market. 
The effects of this probiotic strain on the host health have been investigated in several in vitro, in 
animal model and in humana studies. This strain has been reported to have beneficial effects at 
different levels. Regarding to the gastrointestinal (GI) compartment, B.coagulans BC30 resulted 
effective in the treatment of symptoms related to gastrointestinal disorders, such as IBS and 
intestinal gas (Dolin, 2009; Hun, 2009; Kalman et al., 2009), and it could act as a coadjuvant in 
the response towards pathogens in colitis (Fitzpatrick et al., 2012). It can act at a systemic level 
against specific autoimmune diseases, such as rheumatoid arthritis, alleviating the symptoms, 
positively acting on inflammatory markers, and improving the overall health and motor skills of 
patients (Mandel et al., 2010), and it has been shown to enhance the immunological response in 
common viral infections of the respiratory tract (Kimmel et al., 2010). Bacillus coagulans BC30 
has also been recently reported to reduce exercise-induced muscle damage, improving recovery, 
and maintaining physical performances subsequent to damaging exercise (Jäger et al., 2016). 
Up to now, few studies investigated the effects of the probiotic strain on the modulation of the 
intestinal microbiota. In the in vitro study of Honda and colleagues (2011) the probiotic strain 
did not influence the components of microbiota, while in following studies modulations of some 
microbial groups were showed. In particular, B. coagulans BC30 showed an effect in increasing 
the levels of Clostridium lituseburense, Eubacterium rectale and Faecalibacterium praunsnitzii, 
when administered together with a prebiotic, i.e. FOS, in an in vitro study with microbiota from 
healthy older people (Nyangale et al., 2014). Moreover, in a clinical trial involving healthy 
elderly individuals, the administration of the probiotic strain significantly increased the levels of 
F. praunsnitzii (Nyangale et al., 2015). 
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Prebiotics 
Prebiotics are substrates that selectively promote the proliferation and/or activity of microbial 
bacteria that reside in the colon. They are defined as “selectively fermented ingredients that 
allow specific changes, both in the composition and/or activity in the GI microbiota, that confer 
benefits upon host well-being and health” (Gibson et al., 2010). In order to be classified as a 
prebiotic, a food component must be neither hydrolysed by the host enzymes nor absorbed in the 
upper part of the GI tract, and it must be a selective substrate for one or a limited number of 
beneficial bacteria in the colon (Roberfroid et al., 2010). 
Most commonly employed prebiotics belong to the category of dietary fibre, in particular soluble 
fibre that includes inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS), 
xylooligosaccarides, β-glucans, resistant starch (Gibson et al., 2010). 
The effects of prebiotics are attributed to the stimulation of beneficial bacteria, historically 
correlated to the genus Bifidobacterium and Lactobacillus (Cummings et al., 2001), but also 
species such as Ruminococcus bromii, Roseburia intestinalis, Eubacterium rectale and 
Faecalibacterium prausnitzii, belonging to cluster IV and XIV of clostridia, should be 
considered as emerging candidates (Conlon and Bird, 2015). In fact, since these microorganisms 
can influence the production of short-chain fatty acids (SCFA), they represent important 
contributors to host health (Conlon and Bird, 2015). 
The role of prebiotics in promoting health and reducing risk of gut and systemic diseases have 
been deeply reviewed (Gibson et al., 2010; Clark et al., 2012) and consistent evidences related to 
the improvement of bowel and immune function, and metabolic health in humans have been 
found (Conlon and Bird, 2015). Even if only a limited number of clinical trials have explored the 
effect of prebiotics on microbiota composition and metabolic markers simultaneously, these 
studies demonstrated the modulation of gut microbiota and the parallel improvement of insulin 
sensitivity, low-grade chronic inflammation, and lipid metabolism (Brahe et al., 2016).  
 
β-glucans 
The β-glucans are a group of non-starch polysaccharides, that represent the soluble fibre fraction 
contained in the aleurone and subaleurone layer of different cereals and, in particular, barley and 
oat (Arena et al., 2014). Different studies investigating the prebiotic potential of β-glucans in 
vitro and in humana are available. A functional pasta enriched in β-glucans from barley showed 
positive effect in vitro on the proliferation of four probiotic strains belonging to the genus 
Lactobacillus (Arena et al., 2014). An increase of Lactobacillus spp., together with an increase 
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in Bifidobacterium spp. was reported in an in vitro study in which β-glucans from barley were 
inoculated with fecal microbiota (Hughes et al., 2008). Moreover, Zhao and Cheung (2011) 
indicated how β-glucans from different sources, such as seaweed, barley, mushrooms, showed a 
bifidogenic effect comparable with that obtained by using inulin (Zhao and Cheung, 2011). 
Finally, two clinical trials dealing with β-glucans consumption reported a significant increase in 
the level of Bifidobacterium spp. (Mårtensson et al., 2005; Mitsou et al., 2010), that was more 
pronounced in older subjects (Mitsou et al., 2010). These researches confirmed the bifidogenic 
effect of barley β-glucan previously shown in vitro. In a third study, no modulation related to the 
genus Bifidobacterium were observed after the consumption of a pasta containing β-glucans 
from barley, while clostridial species, e.g. Roseburia hominis and Ruminococcus spp. increased 
(De Angelis et al., 2015). 
At a systemic level, evidences from literature highlight the positive effects of β-glucans on 
conditions related to the metabolic syndrome, i.e. obesity, hypertension, hyperglicemia, and 
dyslipidemia (Cloetens et al., 2012; El Khoury et al., 2012). Recently, EFSA released a positive 
opinion on claims regarding effects of β-glucans in lowering post-priandal glucose and 
cholesterol levels (EFSA, 2011). Regarding effects on cholesterol levels, a minimum daily intake 
of 3 g of β-glucans from oats and/or barley is recommended to provide these health benefits, 
while regarding effects on post-priandal glucose, this claim can be used only for foods 
containing a minimum amount of 4 g of β-glucans from oats and/or barley with respect to 30 g of 
available carbohydrates in a meal (EFSA, 2011). 
 
Non-dairy functional foods 
Probiotics and prebiotics can be used as ingredients in the development of new functional 
products. From an historical perspective, dairy products represented the most widespread vehicle 
for the incorporation of probiotics in foods. In recent years, the food industry interest has 
expanded to non-dairy products as an alternative to traditional ones, such as foods derived from 
cereals (Gobbetti et al., 2010). The incorporation of probiotic bacteria in cereal-based products 
represents a new challenge for the food industry. In fact, technological processes of food 
production should guarantee the stability and viability of added probiotics. Furthermore, the 
maintenance of the probiotic strain at high level during storage has to be assessed, together with 
the preservation of food sensory properties and nutritional values (Charalampopoulos et al., 
2002). 
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From a nutritional point of view, cereals represent appealing products for the development of 
functional foods since they are rich in components, i.e. fibre, proteins, minerals and vitamins, 
necessary for human health (Charalampopoulos et al., 2002). Moreover, the non-digestible 
components of cereals can act as a prebiotic, constituting the substrate for the growth of 
microorganisms present in the colon. In particular, whole grain cereals can exert positive effects 
in protection against chronic human diseases such as cardiovascular disease, cancer, diabetes and 
obesity (Tuohy et al., 2012). Fibre and polyphenols bound to the fibre constitute the two main 
classes of bioactive compounds of whole grain that can interact with the gut microbiota, with 
fibre representing the main energy source for colonic fermentation (Tuohy et al., 2012), able to 
stimulate the growth of specific bacterial groups, e.g. Bifidobacterium spp. (Cooper et al., 2015). 
 
The gut microbiota: characteristics and functions 
The human body harbours a complex and dynamic consortium of at least 100 trillion 
microorganisms (Jones et al., 2014), considered in the past to exceed the number of human cells 
in proportion 10:1, and now, basing on recent estimation, evaluated to be in a ratio of about 1:1 
(Sender et al., 2016). Altogether the microorganisms residing inside the human body and on its 
surface constitute our microbiota, while the set of genes that they encode is defined microbiome 
and can participate in different functions that are essential for the host (Jones et al., 2014). 
The most broadly colonised organ is the gastrointestinal tract, in which the colon alone is 
estimated to account for over 70% of all the microbes in the human body (Sekirov et al., 2010), 
with a concentration of about 1011 CFU/ml (Sender et al., 2016). Hundreds to thousands species 
reside in the adult intestinal microbiota, mainly belonging to the Firmicutes and Bacteroidetes 
phyla (Human Microbiome Project Consortium, 2012). Firmicutes include genera Clostridium, 
Enterococcus, Lactobacillus e Ruminococcus, while genera Bacteroides and Prevotella belong to 
phylum Bacteroidetes. Other gut representative phyla are Actinobacteria, that includes genus 
Bifidobacterium), Proteobacteria and Verrucomicrobia (Sekirov et al., 2010). A variety of 
distinct microbial habitats occur from the small intestine to the colon, due to chemical and 
nutrient gradients, as well as community differences are present over the cross-sectional axis of 
the gut (Donaldson et al., 2016). 
The adult gut microbiota is considered as relative stable, since a core of approximately 40 
bacterial species, that represents about 75% of the gut microbiota in terms of abundance, persists 
for at least 1 year in individuals (Martínez et al., 2013b), and during 5 years approximately 60% 
of microbiota composition in an individual is maintained (Faith et al., 2013). 
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Considering numbers of total species found in gut microbiota, and average core species per 
individual, inter-individual variability in the composition of the microbiota can be particularly 
pronounced. In the perspective of highlighting a sort of phylogenetic core shared among 
individuals, a recent study has proposed a classification of the human gut microbiota in three 
different “enterotypes”, each of them characterised by the predominance of a certain bacterial 
genus, and in particular, Bacteroides, Prevotella, and Ruminococcus (Arumugam et al., 2011). 
However, since it has been discussed how this classification could provide an oversimplified 
vision, a continuum or “gradient” of species has been subsequently proposed (Jeffery et al., 
2012). In addition, metagenomics studies suggested that, rather than a phylogenetic core, 
individuals share a functional core (Human Microbiome Project Consortium, 2012; Power et al., 
2014). In fact, a high degree of functional redundancy among resident microorganisms in the 
gastrointestinal tract has been observed (Louis et al., 2010). As a results, most of the activities 
and effects of gut microbiota are not strictly dependent on the content in species, but derive from 
the presence of a diversified microbiota (Human Microbiome Project Consortium, 2012). 
The gut microbiota exert a broad range of different functions that contribute to host physiology. 
One of the primary activities of resident microbiota consist in the fermentation of non-digestible 
carbohydrates, with parallel energy production (Flint et al., 2012). Thanks to the metabolic 
activity of the microbial community, the human body is able to have access to the calories 
contained in the non-digestible polysaccharides of the diet; in fact, commensal bacteria can 
degrade these complex carbohydrate substrates in short-chain fatty acid (SCFA) and volatile 
substances (e.g. carbon dioxide, hydrogen) (Flint et al., 2012). Acetate, propionate and butyrate 
represent important substrates for maintaining the integrity of the intestinal epithelium (Jones et 
al., 2014). In particular, butyrate is the preferred energy source used by colonocytes, it is 
involved in the regulation of colonocyte differentiation, in the maintenance of mucosal integrity, 
and in the modulation of intestinal inflammation (Conlon and Bird, 2015).  
Acetate and propionate enter into the systemic circulation and reach the liver and peripheral 
organs, where they are substrates for gluconeogenesis and lipogenesis (Tremaroli and Bäckhed, 
2012). The energy obtained from the breakdown of carbohydrates by the intestinal 
microorganisms can become crucial in the case of metabolic syndrome including obesity; in this 
condition, an increase in SCFA production was reported (Teixeira et al., 2012). The synthesis of 
short-chain fatty acids, defined saccharolytic fermentation, causes a lowering of the intestinal 
pH, thus representing an efficient defence system against pathogenic microorganisms (Flint et 
al., 2012). 
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The intestinal bacterial community has also an important function in the development and 
regulation of the host immune system. In fact, bacterial colonisation is necessary for the 
structural and functional development of the immune system associated with the intestinal 
mucosa (gut-associated lymphoid tissue, GALT). Studies in germ-free animals showed an 
underdeveloped mucosal immune system, e.g. reduced gut secretory IgA and defects in gut-
associated lymphoid tissue development (Jones et al., 2014). In addition, commensal gut 
microbiota represent an important line of resistance against colonisation of exogenous 
microorganisms and also of pathogens, through competition for intestinal epithelial receptor sites 
and substrates, and production of antimicrobial substances (Sekirov et al., 2010). 
Finally, gut microbiota is involved in the production of vitamins, metabolism of steroids and 
cholesterol through the transformation of bile acids, metabolism of polyphenolic compounds and 
activation of bioactive compounds (Conlon and Bird, 2015; Sekirov et al., 2010; Tremaroli and 
Bäckhed, 2012). 
In most cases, studies about gut microbiota are performed on fecal samples, that require a easy, 
not invasive collection procedure, and represent an acceptable approximation of colonic 
microbiota, primarily because they are representative of the inter-individual variability (Brahe et 
al., 2016). A broad range of techniques are available for exploring microbiota diversity, most of 
them relying in culture-independent approaches; this methods are less laborious and time-
effective than conventional culture-dependent approaches, since nucleic acids are directly 
isolated from gut/fecal matrices, with no prior isolation (Fraher et al., 2012). These techniques 
are based, in a large measure, on the analysis of the sequence of the 16S rRNA gene, and provide 
information about the microbial diversity of a sample, and/or the amount of specific bacterial 
groups. Among these, techniques aimed at revealing and quantifying specific target, defined a 
priori, are available, e.g. quantitative real-time PCR (qPCR). In principle, these kind of analysis 
can be carried out at all phylogenetic levels, according to the primer pair used. Complex 
communities can be investigated with fingerprint techniques, e.g. denaturing gradient gel 
electrophoresis (PCR-DGGE), or with high-throughput techniques, e.g. 16S rRNA gene 
profiling, that can provide a complete overview of the composition of studied populations, with 
no pre-defined target. Finally, the gold standard of culture-independent analysis is represented by 
the WMS (whole-metagenome sequencing), which allows to completely characterise samples 
with respect both to composition and function (Fraher et al., 2012).  
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Influence of the diet on gut microbiota 
Even considering the general stability of gut microbiota, transient environmental perturbations 
caused by dietary changes, antibiotic use, or diseases can result in significant variations in 
microbial populations of the gut ecosystem (Jones et al., 2014). 
In particular, diet represent one of the key factor in gut microbiota modulation. Numerous 
studies in recent years attempted to clarify the effects that diet can have on the intestinal 
communities, at different levels, from dietary patterns to consumption of specific foods or food 
components (Graf et al., 2015). For example, regarding dietary pattern-associated microbiota, 
individuals with a diet characterised by a high protein intake were associated with a Bacteroides-
type community, while individuals with a plant-based diet, i.e. a higher fibre intake, showed a 
Prevotella-type community (Wu et al., 2011). In another study, analyses of fecal microbiota 
from Italian and African children showed how composition differed relevantly in the two groups, 
e.g. Prevotella spp. were more abundant in the African children than in the Italian children, in 
association with a higher fibre intake (De Filippo et al., 2010). 
Among various dietary patterns, the Mediterranean diet (MD), recognised from UNESCO as an 
intangible cultural heritage, is considered as one of the healthiest diets, because associated with a 
lower risk of incidence of certain diseases such as cancer, cardiovascular diseases and metabolic 
diseases including diabetes and obesity (Del Chierico et al., 2014). Studies on faecal samples 
from individuals following this diet showed a higher concentration of short-chain fatty acids, and 
increased levels of Prevotella (De Filippis et al., 2015). 
Beside long-term dietary patterns, modulation of gut microbiota following consumption of 
different foods (e.g. whole grain, fruits and nuts, vegetables and legumes) or specific food 
ingredients (e.g. fiber/carbohydrates, fat, protein) have been also carried out (Graf et al., 2015; 
Portune et al., 2017). 
Microbiota can quickly and dramatically change in composition and gene expression following 
switch to a different dietary pattern, e.g. from a plant- to an animal-based diets (David et al., 
2014), or in response to a specific diet component, e.g. resistant starch or non-starch 
polysaccharides, within a couple of day (Walker et al., 2011). However, dietary interventions 
probably have a greater impact on the functionality than on the composition of the microbiota 
per se. In fact, short-term dietary interventions do not profoundly change the microbiota 
composition, but the microbial gene expression and the functional profiles seem to rapidly adapt 
to changes in diet (Graf et al., 2015). 
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Dysbiosis condition and pathologies 
In a healthy status, the human host lives in a state of natural balance with the inhabitants of his 
gastrointestinal tract. This homeostasis is maintained despite inter-individual variations in 
microbial composition, as well as short-term intra-individual fluctuations in response to 
environmental factors. This balance can be disrupted, and quantitative and qualitative changes at 
the level of microbial communities can affect their metabolic capacity leading to a condition of 
dysbiosis. Dysbiosis can derive from antibiotic use, diet, or can be related to different diseases, 
including autoimmune disease, inflammatory bowel diseases (IDB), obesity, diabetes (Jones et 
al., 2014). 
One of the common trends observed in dysbiosis is the reduction in microbial diversity, that has 
been reported in the contest of metabolic syndrome (Le Chatelier et al., 2013), IBD, elderly 
patients with inflammation, individuals after oral antibiotic treatment, type 1 diabetes (Jones et 
al., 2014; Sanz et al., 2015). If the dysbiosis of gut microbiota represent the cause or the 
consequence of a certain pathological condition has not been definitively clarified. 
Dysbiosis conditions have been observed at different taxonomic levels, from phyla to species, 
e.g. from a low Bacteroidetes and Firmicutes ratio, to a low F. prausnitzii level in obesity 
(Turnbaugh et al., 2009; Walters et al., 2014). However, in a broad taxonomic group, for 
example, a genus, different species can be associated to a healthy or a pathological state 
(Arboleya et al., 2016). In general, it has been proposed that complex phenotypes are associated 
with a dysbiotic microbiota, rather than a single disease-causing microbe (Jones et al., 2014). 
Another common trait in metabolic disorders/pathologies connected to a dysbiosis condition is 
represented by the modulation of intestinal permeability, that has been reported in several 
studies. For example, increased intestinal permeability has been observed in subjects affected by 
Type 1 diabetes (Vaarala et al., 2008) and obesity (Teixeira et al., 2012), in association with gut 
microbiota aberrations and to an inflammatory status. 
 
Perspectives in restoring a healthy condition through the diet 
Knowledge of the role that the gut microbiota plays in diseases and pathological condition is 
necessary, and it could be used to develop intervention strategies to prevent and/or treat 
imbalances that contribute to autoimmune and metabolic disorders (Sanz et al., 2015; Brahe et 
al., 2016). In fact, given the impact of diet on the composition and activity of gut microbiota, a 
specific dietary intervention could be useful in the modulation of a “dysbiotic” microbiota 
towards a “healthier” state. 
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With regard to the intestinal compartment, positive effects of a probiotic/prebiotic, or, in general, 
of an intervention could rely on the decrease of pathogen or pathobiont microorganisms (Sgouras 
et al., 2004; Honda et al., 2011), increase in bacterial diversity (Karlsson et al., 2010), increase 
of beneficial resident bacterial groups, for example Bifidobacterium species (Bosscher et al., 
2009), or butyrate producer species, e.g. Faecalibacterium prausnitzii (Miquel et al., 2014), and 
on reduction of gut permeability thanks to increased butyrate production (Brown et al., 2011) or 
other mechanisms, e.g. influence on the tight junctions (Ahrné and Hagslätt). The strategy of 
improving health status through the use of probiotics, prebiotics, or functional foods have being 
explored in an increasing number of clinical trial dealing with metabolic syndrome or 
pathological conditions, with some positive microbiological and clinical outcomes (Iannitti and 
Palmieri, 2010; McFarland, 2014; Delzenne et al., 2013, Jones et al., 2014). For example, in the 
contest of obesity, treatment with different types of dietary fibres including prebiotics have been 
shown to modulate gut composition and improve insulin sensitivity, low-grade chronic 
inflammation, and lipid metabolism (Brahe et al., 2016). 
For investigating the impact of a dietary intervention on the gut microbiota, human trials 
represent the gold standard. However, clinical trials are expensive and difficult to control, mainly 
because of the fact that, often, participants differ markedly in their dietary behaviour and 
lifestyle (Graf et al., 2015). Thus, an initial assessment performed through the utilisation of in 
vitro and animal models can provide preliminary useful information (Williams et al., 2015). In 
vitro gut models represent a quick, easy and cost-effective tool of studying gut microbiota. 
Different categories of systems are available, and in general they also present some limitations, 
mainly related to the fact that in vitro models lack epithelial and immune cells, and feedback 
mechanisms by the host (Venema and Van den Abbeele, 2013). However, the use of such 
systems can allow to obtain mechanistic insight in understanding human colon microbiota, in 
terms of composition and metabolism in response to tested substrates, e.g. probiotics, prebiotics 
(Venema and Van den Abbeele, 2013; Williams et al., 2015). Obtained knowledge can be then 
used for the planning of a clinical trial, that will finally assess the impact of the nutritional 
treatment at the systemic level. 
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2. Thesis outline and objectives 
 
This thesis is focused on the development of a novel whole grain functional pasta enriched with 
a spore-forming probiotic strain, Bacillus coagulans GBI-30, 6086 (BC30), and β-glucans from 
barley, from the first steps of the design and production, till the evaluation of its properties and 
potential effects on gut microbiota, and in general, on the consumer. The thesis is structured in 
three sections, the first one dealing with the development and characterisation of the functional 
pasta product, with specific reference to microbiological aspects related to the probiotic strain, 
while the second and the third part regard the investigation of the impact of the functional pasta 
on gut microbiota in two case contest, pre-diabetes/diabetes and overweight/obesity, 
respectively. Finally, overall concluding remarks are presented. 
In Chapter 1, beside providing synthetic information on the production and characterisation of 
the overall pasta product, a specific relevance is given to the assessment of the stability of the 
probiotic strain during the pasta manufacturing and cooking processes; in fact, a probiotic 
bacterium has to be present at sufficiently high amounts in a dietary supplement or food, in order 
to guarantee certain doses during ingestion. Moreover, the stability during the transit trough the 
gastrointestinal tract (GI) represents another crucial point, since only if the probiotic strain is 
able to reach the colon alive it could exert its properties on the host. Thus, the survival of B. 
coagulans BC30 while passing through the GI tract is investigated in Chapter 2. 
Once that a new product has been developed, the most interesting question raises about which 
are the effects that it can induce in the host. Type 1 diabetes and obesity are two conditions in 
which alterations in gut microbiota have been reported. Since diet represents one of the most 
important factors involved in the modulation of gut microbiota, the restoration of a balanced 
microbiota condition through the use of specific dietary products is an interesting, not invasive 
strategy that is receiving much attention and appears as promising. In the contest of diabetes, a 
case-control study involving children at risk for type 1 diabetes (T1D) and healthy children has 
been firstly performed for investigating possible differences in microbiota composition, as 
described in Chapter 3. From these children, a small group has been individuated for a second 
study, reported in Chapter 4, that is specifically aimed at revealing the effects of the functional 
pasta on gut microbiota. This research is conducted using an in vitro model of the proximal 
colon, TIM-2, inoculated with fecal microbiota from the former children. In this study, not only 
the functional pasta is investigated, but also the functional ingredients B. coagulans BC30 and β-
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glucans are objects of study, in order to unravel their contribution in the pasta-related effects, and 
also expanding available knowledge about these specific products. Finally, following the 
preliminary in vitro step, the effects of the ingestion of the functional pasta on resident gut 
microbiota are assessed in humana, in a clinical trial involving overweight/obese adults, 
illustrated in Chapter 5. Moreover, in the perspective of disclosing the impact of the new 
functional product on the host, microbiological data are correlated with clinical results, in an 
integrated view. 
Results 
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Chapter I 
 
Development of a novel functional pasta containing β-glucans and a 
stable probiotic strain, Bacillus coagulans GBI-30, 6086 
 
 
1.1. Introduction 
During the last decade, consumer requirements in the field of food production have changed 
considerably. Thus, foods are no more intended to only satisfy hunger and to provide the 
necessary nutrients, but also to prevent nutrition-related diseases and to improve physical and 
mental well-being. In this frame, the functional foods represent one of the most interesting areas 
of research and innovation in the food industry. 
Cereals can be considered important sources of functional ingredients as they contain, especially 
in the outer layers of kernels, substances (i.e. polyphenols) with protective activities related to 
the reduction in the incidence of coronary heart disease, diabetes and cancer (Hemery et al., 
2007). Most of the bioactive compounds are linked to fibre and are present in bran, while most of 
vitamins E and B, minerals and sterols are present in the germ. However, the production of 
foodstuff from whole grain must guarantee to the consumer the absence of mycotoxins and 
pesticide residues. A good compromise between food security and preservation of the main 
health compounds of wheat is represented by the application of the debranning process prior to 
milling, for which new processes have been developed (Hemery et al., 2007; Fares et al., 2010). 
To enhance the healthy properties of semolina, barley flour is often added to increase the soluble 
fibre, mainly the β-glucans content. Due to their chemical and physical properties, β-glucans, 
which can form high-viscosity solutions, could aid in reduction of blood cholesterol levels and 
lower glycemic response (Tosh, 2013), as also recently recognized by EFSA (EFSA, 2011). 
Probiotics are “live microorganisms that, when administered in adequate amounts, confer a 
health benefit on the host” (FAO/WHO, 2002; Hill et al., 2014). Many different microorganisms 
have been used as probiotics, mostly strains of the bacterial genera Lactobacillus and 
Bifidobacterium, but also strains of Escherichia coli, Saccharomyces boulardii or Bacillus 
coagulans, together with other spore-forming bacilli (Cutting, 2011). For their spore-forming 
nature, these latter organisms possess improved viability and stability compared to other 
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probiotic bacterial strains, e.g. the ability to withstand high temperature processes, such as 
baking and boiling, thus representing an ideal choice for the development of functional cereal-
based products. Indeed, the endospores of the genus Bacillus are a very stable duration form and 
show high stability during the processing and storage of the food product (Bader et al., 2012). 
Further, in many food products, germination of the spores does not occur and thus the quality of 
the product is not affected because of their inactive metabolism. 
Some commercial probiotic formulations containing B. coagulans are actually available, 
including B. coagulans GBI-30, 6086 (marketed as GanedenBC30, thereafter referred as BC30), 
that has been also incorporated into foods, thanks to the fact that spores can survive 
manufacturing processes, including mild heat-treatments used to sterilise food (Cutting, 2011). 
This spore-forming strain has obtained the Generally Recognized As Safe (GRAS) status in 2012 
from the U.S. Food and Drug Administration (FDA), following assessment of toxicological 
studies (Endres et al., 2011). Moreover, the species B. coagulans is included in the list of 
Qualified Presumption of Safety (QPS) biological agents that can be added to food (EFSA, 
2007). Bacillus coagulans BC30 has been reported to improve the symptoms related to 
gastrointestinal disorders, such as irritable bowel syndrome and intestinal gas, and rheumatoid 
arthritis (Jurenka, 2012), and it has been shown to enhance the immunological response in 
common viral infections of the respiratory tract (Kimmel et al., 2010). Furthermore, evidences 
from animal models show that B. coagulans BC30 acts as a coadjuvant in the response towards 
pathogens in colitis (Fitzpatrick et al., 2012). 
The present study is aimed at the design and development of a novel functional pasta product, 
not yet present on the global market, formulated with durum wheat flour naturally enriched in 
phenolic acids, and added with B. coagulans BC30 and barley β-glucans. A second pasta obtained 
from the same flour, but without addition of the two functional ingredients represents the 
respective control. In particular, the microbiological focus of the present study consists in the 
evaluation of the fate of the probiotic strain during pasta-making and cooking processes, using 
culture-dependent and culture-independent approaches. Therefore, information about the 
preparation and characterisation of the newly developed products will be briefly provided, in 
order to have a more comprehensive overview. 
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1.2. Material and methods 
Preparation of durum wheat flours and pasta manufacturing 
An Italian durum wheat (Triticum durum L.) cultivar (Vendetta) was grown in Foggia during 
2010-2011 and used to evaluate on a small-scale the process for obtaining a flour enriched in 
phenolic compounds and fibre. The following year (2011/2012), the cultivation of Vendetta was 
carried out to start the industrial process (25 q). The durum wheat was milled by Antico Molino 
Rosso SRL (Buttapietra, VR, Italy), conducted in a first step by a debrannig process and 
subsequently by stone milling. The milled grain was divided into two batches. The first batch 
(12.5 q), consisting of durum wheat Vendetta hulled up to 4.5% and stone milled (control flour); 
the second batch (12.5 q), consisting of the durum wheat flour described above (78.5%) mixed 
and homogenized with 18% of enriched barley flour (11% β-glucans) (Agro Alimentare Sud, 
Melfi, Potenza, Italy), and 3.5% of vital gluten powder (Sedamyl S.p.A., Saluzzo, Cuneo, Italy). 
A small quantity of the second batch (500 kg) was added with 1% of a freeze-dried preparation 
of the probiotic culture described below (functional flour). 
Two different shapes of pasta were produced on a small scale for preliminary analyses, and in 
particular: spaghetti with BC30 added, obtained at different drying temperatures (50°C and 
90°C), manufactured at the Agricultural Research Council (CRA) (Rome, Italy), and fusilli with 
BC30 added, obtained at a low drying temperature (50°C), manufactured at the industrial plant 
Rustichella d’Abruzzo S.p.A. 
Two novel pasta, one derived from the control flour (control pasta), and one derived from the 
functional flour (functional pasta) were then produced at the plant Rustichella d'Abruzzo S.p.A. 
The durum wheat flours were mixed with water to obtain a total dough water content of 41-42%, 
and, after mixing, the product was extruded into the shape of penna rigata pasta of 1.12 mm of 
thickness, 38-42 mm of length and 9 mm of diameter. Pasta products were dried at about 50°C. 
 
Characterisation of pasta samples 
Determination of total dietary fiber and β-glucans content, protein content, yellow pigment 
content, phenolic acids, and antioxidant activity were performed on the durum wheat flours and 
pasta samples (uncooked and cooked). Available carbohydrate, fat and ash contents were 
analysed with respect to uncooked and cooked pasta products. Cooking characteristics of pasta 
samples were determined, i.e. cooking time, pasta firmness, and texture parameters. The 
glycemic index of the pasta products was also evaluated. All detailed information about these 
analyses are available in the study of Fares and colleagues (2015). 
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Microbiological analyses 
The strain B. coagulans BC30, a patented probiotic bacterium widely marketed as a dietary 
supplement or incorporated in functional foods was selected to be used as the probiotic 
ingredient in the pasta-making process. The freeze-dried probiotic preparation was obtained from 
Sochim International S.p.A. (Cornaredo, Milan, Italy) and contained a declared concentration of 
10.3 log CFU/g. 
Preliminary analyses on different shapes of pasta, i.e. spaghetti with BC30 added, obtained at 
drying temperatures of 50°C and 90°C, and fusilli with BC30 added, obtained at a drying 
temperature of 50°C, were performed to assess the viability of the probiotic strain. 
To evaluate the survival of the probiotic strain during the cooking process, pasta (fusilli) (10 g) 
was cooked in 100 mL of boiling tap water, for different cooking times (5, 7, 9 and 11 min). The 
effect of the addition of NaCl to the cooking water was also evaluated, as well as the dispersion 
of B. coagulans cells in the cooking water. 
Regarding samples from the production chain of the novel functional pasta, the freeze-dried 
BC30 preparation, the durum wheat flour added with barley flour (semolina), semolina with 1% 
of BC30 added, the uncooked and cooked functional pasta, and the cooking water were analysed. 
The control pasta was analysed, too. 
Enumeration of B. coagulans BC30 was carried out by conventional plating following the 
recommendations of USP's Food Chemicals Codex (FCC) (2014). Regarding pasta sample 
preparation, dried samples were ground to homogeneity using a household blender, while cooked 
samples were homogenized with a Ultra-Turrax T25 (Janke and Kunkel, IKA-Labortechnik, 
Staufen, Germany); then, 1 g of sample was weighed out and suspended in 199 mL of sterile 
peptone (0.1%) water. Appropriate decimal dilutions were pour plated in duplicate in Glucose 
Yeast Extract (GYE) agar, before and after a heat-treatment (75°C for 30 min) step, and 
incubated aerobically at 37°C for 48 h; this last part of the procedure was followed for each 
sample analysed. The experiments were performed as biological replicates. 
Furthermore, enumeration of the probiotic strain in the functional and control pasta was 
conducted by a qPCR assay. Initially, serial dilutions of the freeze-dried B. coagulans BC30 
dissolved in sterile peptone water were used to generate a standard curve. The cells were counted 
by plating and subjected to DNA extraction and qPCR analysis as described below. 
DNA was extracted using the protocol of Marmur (1961) with some modifications. In particular, 
cells were harvested from 2 mL of the serial dilutions and lysed with 10 mg/mL lysozime in 
Tris-EDTA pH 8 for 60 min at 37°C; moreover the DNA treatment with 20 µg/mL proteinase K 
Chapter I 
19 
 
was performed for 30 min at 37°C. DNA concentration was determined using a NanoDropLite 
spectrophotometer (Thermo Scientific, DE, USA). 
Quantitative PCR was performed in the Light Cycler Nano System (Roche, Mannheim, 
Germany). The primers BG-For and BG-Rev were designed on the 16S rDNA gene and their 
specificity for B. coagulans was assessed in silico and on a collection of Bacillus spp. strains. 
The qPCR reactions were performed in a total volume of 20 μL containing Fast Start Essential 
DNA Green Master and PCR grade water (Roche, Mannheim, Germany), 0.5 μM of forward and 
reverse primers, and 5 μL of genomic DNA. The amplification program consisted of 1 cycle of 
95°C for 10 min, followed by 45 cycles of 95°C for 15 sec, 66°C for 15 sec, and 72°C for 16 sec. 
The qPCR experiments were performed as biological replicates and technical triplicates. 
The efficiency (E) of the qPCR reactions was calculated using LinRegPCR version 2012.3 
according to Ruijter et al. (2009). 
Isolation of DNA from pasta samples was performed starting from 2 mL of a suspension of 
homogenised pasta in sterile peptone water, and following the protocol of Cocolin et al. (2000) 
using 425-600 μm-diameter glass beads (Sigma, Milan, Italy). After cell disruption, an additional 
step with CTAB 2X (1% PVP, 2% cetyltrimethylammonium bromide, 100 mMTris-HCl pH 8.0, 
20 mM EDTA pH 8.0, 1.4 M NaCl) was performed at 65°C for 5 min and followed by a 
purification step with chloroform/isoamylic alcohol. 
Quantification of the probiotic strain in the pasta samples was calculated based upon comparison 
of the corresponding threshold cycle (Ct) values with the standard curve. 
Results are presented as means ± standard deviation (SD). The significance of the B. coagulans 
BC30 count results was evaluated using Student’s t-test. Differences were considered significant 
at p < 0.05. 
 
1.3. Results and discussion 
Preliminary analyses for assessing the viability of the probiotic strain during pasta-making 
and cooking processes 
The viability of the probiotic strain B. coagulans BC30 has been firstly assessed in a series of 
preliminary analyses, performed with different experimental pasta. These analyses were 
performed with plate counts. 
First, analyses of the viability of the probiotic strain were conducted with reference to two 
different drying processes (Figure 1.1). In particular, a process at a low drying temperature, i.e. 
50°C for 18 hours, and a process at a high drying temperature, i.e. 90°C for 4 and a half hours, 
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were tested. In this case a “long” pasta format, spaghetti, produced on a small scale, was 
analysed, dried and cooked. Cooking times of 7 and 10 minutes were tested for the analyses. 
 
 
 
Figure 1.1. Quantification of the probiotic strain B. coagulans BC30, in the uncooked (a) and cooked (b) 
experimental spaghetti pasta, following a low temperature (50°C) or a high temperature (90°C) drying 
processes. Regarding cooked pasta, analyses with two different cooking times (7 or 10 minutes), and 
performed by plating immediately after cooking, or after a subsequent heat treatment are presented. 
 *: p < 0.05. 
 
Plate count analyses were performed on the uncooked pasta after grinding, and after the heat 
treatment. Results obtained before the thermal treatment provided information about amounts of 
vegetative cells and spores, while from the results obtained following the heat treatment the 
amount of spores were retrieved, in according to previous works (Maathuis et al., 2010; Ghelardi 
et al., 2015). In the uncooked product, dried with both processes, vegetative cells and spores 
were observed to be approximately in a 1:1 proportion (Figure 1.1a). However, a significant 
reduction of the microbial loads in the pasta dried at the higher temperature was observed. As a 
consequence, also the amount of probiotic cells that survived the cooking process was 
considerably lower in the pasta produced with the high temperature process (Figure 1.1b). Also 
for the analyses of cooked pasta, samples were plated immediately or after a following thermal 
treatment. In this case, considering that vegetative cells are expected to die during the cooking 
processes, results obtained immediately after cooking suggested that a quote of spore germinated 
proximately after the cooking process. Pasta dried at the low temperature exhibited the same 
amounts of spores (before or after the thermal treatment), independently from the cooking time. 
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Pasta dried at the high temperature exhibited a decrease in the amounts of spores, that appeared 
more marked in the case of 10 minutes cooking, as expectable. Moreover, in this case, average 
amount of spores counted after cooking corresponded to the amount of spores counted after the 
subsequent heat treatment, indicating that, probably, 10 minutes represented a sufficiently long 
period to induce germination of all present spores (Figure 1.1b). 
Further analyses were then conducted to specifically evaluate the impact of different cooking 
times on the viability of the probiotic strain. In this case, analyses were performed on the 
experimental fusilli, a “short” pasta format, dried at 50°C, and that was cooked for 5, 7, 9 or 11 
minutes. These analyses indicated that the cooking process caused a reduction of the bacterial 
counts that depended on the cooking time of the functional pasta. Indeed, similar cell numbers 
were observed applying cooking time of 5 min (6.9 ± 0.1 log CFU/g) and 7 min (6.8 ± 0.3 log 
CFU/g), while 9 and 11 min led to a significant (p < 0.05) decrease in the counts (6.4 ± 0.3 log 
CFU/g and 6.3 ± 0.1 log CFU/g, respectively). The addition of 1% NaCl to the cooking water did 
not have a negative effect on the viability of the probiotic strain (data not shown). A certain 
quote of probiotic cells were released from the pasta matrix in the water during cooking; 
however this quote did not represent a relevant amount (2-3 log CFU/g of pasta). 
Results of these preliminary analyses showed that the probiotic strain withstood the pasta-
manufacturing and cooking processes. In particular, the drying process at low temperature could 
guarantee a high viability of the probiotic strain, while the higher drying temperature had a 
detrimental effect. Moreover, a short cooking time (5 or 7 minutes) guaranteed a higher survival 
of the bacterial strain, suggesting that a pasta with an appropriate thickness, that can be cooked 
in few minutes, could represent an optimal solution to deliver the spore-forming probiotic strain. 
Considering these findings, the functional experimental pasta was produced on a large scale, in 
the format of penne rigate, which have a cooking time of approximately 6-7 minutes. Therefore, 
subsequent analyses were performed using cooking time of 5 and 7 min, and by adding NaCl to 
the water in order to better simulate the domestic cooking process. 
 
Analyses of the novel functional and control pasta 
Regarding the functional pasta produced at the industrial level, samples derived from the 
different steps of the pasta-making and cooking processes were analysed, i.e. the freeze-dried 
BC30 preparation, the durum wheat flour added with the barley flour (semolina), the semolina 
with 1% of BC30 added, the uncooked and cooked pasta, and the cooking water. Plate count 
analyses were performed on each sample without and with the thermal treatment, as reported in 
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Materials and Methods section. Quantification of the freeze-dried B. coagulans BC30 preparation 
showed that before and after the thermal treatment the same number of cells were counted 
(Figure1.2a); thus, the found BC30 amount was considered to be 100% of spores, and it 
corresponded to the expected cell concentrations, i.e. approximately 10.2 log CFU/g (Figure 
1.2b). 
 
 
 
 
Figure 1.2. Quantification of the probiotic strain B. coagulans BC30, in the freeze-dried BC30 preparation, 
in the semolina with 1% of BC30, in the dried and cooked penne rigate pasta, after 5 or 7 minutes 
cooking, and in the cooking water (BC30 amounts in the cooking water are expressed in CFU/ g of pasta).  
Results are expressed as a) values obtained prior or after the heat treatment and as b) estimations of 
vegetative cells and spores amounts. *: p < 0.05. Statistically significant differences were indicated for 
comparisons among semolina with 1% BC30 added and dried and cooked pasta samples. 
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Observed colonies were small (1-5 mm in diameter for surface colonies, 0.5-1 mm for colonies 
inside the agar), white to cream coloured; surface colonies were round and convex with smooth 
edges, while colonies inside the medium appeared as small points (Figure 1.3), as reported in 
USP, 2014. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. B. coagulans BC30, as observed from plating analyses (a) and at the optical microscope (b). 
 
Parallel to the quantification of the probiotic product, also the durum wheat flour added with 
barley flour (semolina) used for the production of the functional pasta was analysed, in order to 
evaluate the presence of environmental contaminants belonging to the genus Bacillus. Plate 
count analyses showed a spore load of approximately 4 log CFU/g, indicating that the flour was 
contaminated with environmental spore-forming bacilli, in agreement with previous evidences 
(Fangio et al., 2010; Sorokulova, 2013). 
B. coagulans BC30 was then quantified in the semolina added with 1% of the probiotic strain. 
Also in this case, the same count values were obtained before and after the thermal treatment 
(Figure 1.2a), thus confirming the presence of 100% spores (Figure 1.2b). In particular 8.1 log 
CFU/g were found in the mix, in agreement with the amount added. In this contest, several 
samples deriving from different bags in which the product was collected were analysed, in order 
to evaluate the homogeneity of the dispersion of the probiotic strain in the flour. Results were 
highly reproducible, thus demonstrating the effectiveness of the mixing process. 
Analyses of the uncooked functional pasta samples were carried out for monitoring the viability 
of the probiotic strain following the food production process, and indicated that B. coagulans 
BC30 was present at a concentration above 7.0 log CFU/g (total of vegetative cells and spores) 
(Figure 1.2a). Thus, the general stability of the probiotic strain during the pasta-making process 
was confirmed, even if a significant reduction was observed with respect to the semolina with 
a. b. 
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BC30 added. This was probably due to the difficulty in retrieving the bacterial cells from the 
hard, compact matrix of the dried pasta. Moreover, in the dried pasta, a high level of presumed 
vegetative cells was observed, that could be caused by a germination process occurred during the 
step of water addition to semolina. However, further studies would be necessary to clarify this 
aspect. 
Regarding the analyses of the cooked functional pasta samples, results on the penne rigate 
confirmed previous preliminary data on the fusilli. The cooked pasta included more than 6.0 log 
CFU/g and no differences in BC30 amounts between cooking for 5 or 7 minutes were found 
(Figure 1.2a and Figure 1.2b). However, a significant difference between the dried pasta and the 
pasta cooked for 7 minutes was found (Figure 1.2a and Figure 1.2b), indicating that a certain 
reduction in BC30 amounts occurred during 7 minutes cooking. Finally, a release of about 4.0 log 
CFU/g of pasta was observed in the cooking water (Figure 1.2a and Figure 1.2b), corresponding 
to approximately 3.0 log CFU/ml of water. In the case of the cooked samples (pasta and water), 
results obtained from plating prior to the heat treatment could represent a quote of spores that 
germinated just after the cooking process, as previously observed for the spaghetti. 
Also with regard to the control pasta, plate count analyses were performed to assess the presence 
of spore-forming bacteria. Results on dried pasta samples showed values of about 3.5 log CFU/g 
spores, confirming the presence of environmental contaminants belonging to the genus Bacillus. 
However, these bacteria were not revealed anymore in the cooked product, thus indicating that 
they did not survive the cooking process. 
To fulfill the requirements of a robust quality management, a qPCR assay based on 16S rRNA 
gene for accurate identification and quantification of B. coagulans BC30 was developed. 
The newly designed primers BG-For (5’-AAAAGCTTGCTTTTAAAAGGTTAGCG-3’) and BG-
Rev (5’-GTTCGAACGGCACTTGTTCT-3’) provided an amplicon of 400 bp that was 
demonstrated to be specific for this species. Indeed, using the BLAST algorithm, used primers 
were confirmed to target B. coagulans sequences. Thus, the selected 16S rRNA gene region 
appears to be a suitable target for the identification of the probiotic strain. Further, no 
amplification was observed when purified DNA from other spore-forming bacterial species was 
used, supporting the specificity of this novel PCR procedure. 
To correlate amplification curves and CT values with colony forming units and the actual number 
of cells present in one sample, a standard curve was produced from DNA extracted from 10-fold 
dilutions of the freeze-dried BC30 product, as described in the Materials and Methods section. A 
linear response was observed over a range of five order of magnitude (R2= 0.990), and the limit 
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of detection was 3.0 log CFU per assays. The efficiency of the qPCR reaction was 1.88, 
according to Ruijter et al. (2009). From the standard curve, the level of B. coagulans was 
calculated using the equation log CFU = (Ct – 41.36)/ -4.79. 
One of the key advantages of this assay is its rapidity, as it allows specific detection of B. 
coagulans within a day without any prior cultivation. In contrast, culture-dependent techniques, 
such as conventional colony PCR plus sequencing needs up to 96 hours to identify the isolated 
bacteria at the species level. 
B. coagulans enumeration by qPCR was performed on dried pasta samples and on 5 minutes and 
7 minutes cooked pasta samples, providing values of 7.5 ± 0.5 log CFU/g, 7.2 ± 0.2 log CFU/g, 
and 7.3 ± 0.2 log CFU/g, respectively. The qPCR data were slightly higher compared to the 
results from plate counts probably due to the presence of dead cells or ungerminated spores, 
which contributed to the signal in the molecular analysis. However, B. coagulans BC30 total 
levels resulted above 7.0 log CFU/g with both techniques, supporting the fact that the industrial 
pasta-making process had no strong detrimental effect on the viability of the probiotic bacteria. 
The cooking process caused a small reduction of B. coagulans BC30 concentration, but no 
difference between samples cooked for 5 or 7 min was observed, consistently with plate 
analyses. Regarding the control pasta, contaminants observed through plate count analyses were 
not detected by the qPCR assay, indicating that they probably belonged to other Bacillus species, 
different than B. coagulans. 
 
Another test was performed by cooking the pasta (for 7 minutes), storing it into the fridge 
overnight, and warming it up into the microwave oven the following day, in order to simulate 
what can be commonly done by a consumer, and to verify the viability of the probiotic strain in 
this condition. Results showed that this procedure did not affect the viability of the probiotic 
strain. In fact the same level of the probiotic strain, i.e. 6.2 log CFU/g of pasta, was found after 
plating the sample after the overnight conservation and the following warming up, or 
immediately after pasta cooking. 
 
Stability of the probiotic strain during functional pasta storage 
The stability of the probiotic strain during long-term storage of the functional pasta was 
evaluated for fusilli and penne rigate pasta samples. Analyses were performed on samples stored 
at room temperature (approximately 20°C-22°C), for several months. Quantifications were 
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performed on cooked pasta, since this represent the most interesting data defining the actual 
amount of bacteria that can be ingested. 
 
 
Figure 1.4. Quantification of the probiotic strain B. coagulans BC30, in the fusilli and in the penne rigate 
cooked samples, after storage from several months. Cooking was performed for 7 minutes. 
 
Results showed that for both pasta, the amount of the probiotic strain was kept at high levels, i.e. 
more than 6.0 log CFU/g of pasta, for several months, till to half a year (Figure 1.4). 
Another study in literature assessed the viability of a B. coagulans strain added to different foods 
after storage for several months, i.e., 1, 2, 3, 6 and 12 months (Majeed et al., 2016). Also in this 
work, the viability of the probiotic strain was shown to be extremely high, both with storage in 
frozen conditions (e.g. waffles samples) or at room temperature (e.g. chocolate fudge frosting). 
 
General characterisation of durum wheat flour and pasta samples 
The flour samples were characterised by a high protein content (PC) of approximately 18%. 
Since PC has a crucial role in determining the cooking performances of pasta products (Del 
Nobile et al., 2005), a great relevance was assigned to this result, obtained through the 
debranning process. Moreover, as a result of the cooking process, in both control and functional 
penne rigate samples, PC increased. Furthermore, obtained wheat flours resulted enriched in 
phenolic acids, further demonstrating the effectiveness of the debranning process prior to milling 
(Fares et al., 2010). 
The addition of β-glucans from barley significantly increased the amount of total dietary fibre 
(TDF) in the functional flour, in agreement with the amount of β-glucans added. According with 
previous findings (Fares et al., 2008; Fares et al., 2010), fibre and β-glucans content was 
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positively affected by cooking, and in the two cooked product the amounts of TDF were 
comparable. The main event responsible for these observed increases of TDF is the gelatinisation 
and retro-degradation of the starch during cooking, which changes part of it into resistant starch 
and leads to an increase in the TDF (Vasanthan et al., 2002). β-glucans were found at a final 
concentration of 2.3% in the dried functional pasta, and of 2.6% in the cooked one. 
Regarding the glycemic index (GI) evaluation, all GI values resulted medium, with no 
statistically significant differences between analysed pasta, indicating that the addition of the 
functional ingredients did not affect the glycemic response. 
Detailed information on all characterisation performed on flours and uncooked and cooked pasta 
are reported in Table S1.1, S1.2, and S1.3. 
 
2.4. Concluding remarks 
A new functional pasta obtained from a durum wheat flour rich in phenolic acids, and with added 
B. coagulans BC30 and β-glucans from barley was developed. This new pasta product combined 
the health potential of cereals that are further strengthened by the presence of a probiotic strain, 
in a stable, storable product, that could represent a high-quality food for its nutritional appeal as 
well as the potential beneficial properties. 
Regarding the probiotic strain B. coagulans BC30, preliminary analyses provided indications 
about resistance of the strain at two different pasta drying processes, and led to define the 
optimal pasta cooking time in order to maintain a high viability. Then, the functional pasta 
produced on the industrial scale was analysed, and the viability of the probiotic strain during the 
manufacturing process and in the subsequent cooking step was demonstrated using both culture-
dependent and culture-independent methods. Thus, considering that the cooked functional pasta 
included more than 106 CFU of the probiotic strain per gram, for an average portion of 70-100 g 
of pasta consumed during a meal, a minimum dose of approximately 108 CFU of probiotic 
bacterium B. coagulans BC30 would be introduced with the diet. Given the high stability of the 
spore-forming bacterium, it is supposed that the probiotic strain could also be able to withstand 
the transit through the stomach to the intestine, as previously demonstrated in an in vitro study 
(Maathuis et al., 2010), thus being potentially able to exert its positive properties. 
 
 
This study was supported by the Italian Ministry for Development in the framework of the project 
“Pass-World - pasta e salute nel mondo - Industria 2015” [MI01_00138]. 
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Supplementary material 
Table S1.1. Functional properties of the control and functional durum wheat flours, obtained by Vendetta variety. 
Data are means of three determinations ± standard deviation. Different letters in the same row indicate statistical differences by LSD test (p < 0.05). 
Abbreviations: PC = protein content; YPC = yellow pigment content; TDF = total dietary fibre. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PC YPC TDF β-glucans Phenolic acids Antioxidant activity 
Durum wheat flour 
samples (%) (%) (%) (%) (µg/g) (µmoli trolox /g) 
     Free Bound Free Bound 
Control flour 18.18±0.19 a 3.77±0.01 a 12.63±0.07 b 0.36±0.01 b 2.73±0.38 a 389.4±14.71 a 1.36±0.21 a 12.94±0.27 a 
Functional flour 17.72±0.03 a 3.78±0.03 a 13.61±0.13 a 2.64±0.03 a 2.04±0.07 b 364.8 ±5.66 a 1.41±0.13 a 13.46±0.94 a 
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Table S1.2. Functional properties of the uncooked and cooked control and functional pasta samples. 
 PC YPC TDF β-glucans Phenolic acids Antioxidant activity 
Pasta samples (%) (%) (%) (%) (µg/g) (µmoli trolox /g) 
     Free Bound Free Bound 
Uncooked         
Control 19.22±0.01 b 3.63±0.03 a 12.52±0.03 d 0.37±0.01 e 2.62±0.40 b 499.97±23.58 a 0.79±0.01 b 12.70±0.09 ab 
Functional 16.84±0.04 f 3.26±0.03 c 13.63±0.33 c 2.30±0.01 d 2.46±0.13 b 421.14±8.38 bc 1.19±0.02 a 11.44±0.15 c 
Cooked         
Control 19.81±0.16 a 2.74±0.03 d 13.57±0.15 c 0.42±0.00 e 2.32±0.04 b 504.99±22.64 a 0.77±0.06 b 13.44±0.21 a 
Functional 17.29±0.00 e 2.37±0.01 f 13.80±0.05 c 2.61±0.04 a 2.08±0.07 b 401.74±4.63 c 0.72±0.22 b 12.90±0.49 ab 
Data are means of three determinations ± standard deviation. Different letters in the same row indicate statistical differences by LSD test (p < 0.05). 
Abbreviations: PC = protein content; YPC = yellow pigment content; TDF = total dietary fibre. 
 
 
 
 
 
Table S1.3. Proximate composition of uncooked pasta samples, cooking behaviour and glycemic index of cooked pasta samples. 
Pasta samples ACC(%) Fat (%) Ash (%) CT (min) WCP (%) Firmness GI 
Control pasta 63.2 ± 1.8 a 2.67 ± 0.07 a 1.43 ± 0.01 b 7 100% 770 ± 29.0 a 67.5 ± 5.3 a 
Functional pasta 61.5 ± 1.2 a 2.37 ± 0.05 a 1.51 ± 0.01 a 7 100% 782 ± 30.2 a 59.7 ± 6.0 a 
Data are means of three determinations ± standard deviation.  
Different letters in the same row indicate statistical differences by LSD test (p < 0.05). 
Abbreviations: ACC = available carbohydrate content; CT = cooking time; WCP = weight cooked pasta; GI = glycemix index. 
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Chapter II 
 
Survival of the probiotic strain Bacillus coagulans GBI-30, 6086 to 
the transit into the gastrointestinal tract 
 
 
2.1. Introduction 
Probiotics are frequently administered to improve gut functionality or restore a gut microbiota 
balance (Iannitti and Palmieri, 2010). In this perspective, one of the main requirements for a 
probiotic strain is to survive during the transit through the different compartment of the 
gastrointestinal (GI) tract (Papadimitriou et al., 2015). 
After ingestion, probiotic bacteria have to face a hostile environment; in particular, they have to 
survive the low pH of the stomach, below 3, and high levels of pepsin, which could lead to cell 
inactivation and death. Moving forward through the GI tract, pH rise to values above 6, but the 
presence of bile, pancreatin and lipase constitute another critical point. If survived to these 
conditions, once reached the colon, ingested bacteria are capable to transiently integrate the gut 
microbiota (Derrien and van Hylckama Vlieg, 2015). 
In order to assess the survival of probiotics to the transit through the GI tract, quantification of 
the ingested strain in the fecal samples is usually performed, both with the use of culture-
dependent or molecular approaches. Analyses of the fecal samples allow to the define the so 
called “persistence”, that results from the balance among the dose of the ingested strain, the 
extent of cell death and replication of surviving cells (Derrien and van Hylckama Vlieg, 2015). 
Spore-forming probiotic bacteria present improved stability and resistance than conventional 
probiotics. Because of these properties, Bacillus species have received an increasing attention as 
probiotics, and they are being extensively used (Cutting, 2011). 
Regarding the species B. coagulans, few information about the resistance to low pH values and 
to the other adverse conditions present in the intestinal environment are available, and they 
indicate that these properties are strain dependent (De Vecchi and Drago, 2006). The survival of 
the probiotic strain Bacillus coagulans GBI-30, 6086 (thereafter BC30) was investigated in an in 
vitro study (Maathuis et al., 2010), and then confirmed in an in humana trial (Nyangale et al., 
2015). In the first study, survival and activity of the strain BC30 in the first portion of the GI tract 
were assessed through the use of an in vitro model, representative of the stomach and small 
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intestine. Results showed that the 70% of spores survived, thus demonstrating the resistance of 
the probiotic strain to the acid gastric compartment and to bile salts presence (Maathuis et al., 
2010). Furthermore, B. coagulans BC30 was detected in the fecal samples of subjects that 
assumed the probiotic strain, in a human trial (Nyangale et al., 2015). 
The aim of the present study was the investigation of the stability of the probiotic strain B. 
coagulans BC30, included in a new functional pasta, during the transit through the GI tract. The 
presence of the probiotic strain was assessed in the fecal samples of twenty subjects who 
ingested the functional pasta in a 12-week trial. A parallel group of 19 subjects which consumed 
a control pasta with no added B. coagulans BC30 was analysed. Cultivation and molecular 
analyses were performed to this aim. 
 
2.2. Materials and Methods 
Study design 
The study design was a randomized, parallel, 12 week trial. Thirty-nine healthy subjects (16 
males and 23 females, aged 29-74 years old, BMI > 25 kg/m2) participated to the study. An 
exclusion criterium was the use of food supplements, i.e. prebiotics and probiotics, and antibiotic 
use in the previous three months. Recruited subjects were assigned in a random order to one of 
two treatments: a) a functional pasta obtained from whole wheat flour and supplemented with β-
glucans from barley and the probiotic strain B. coagulans BC30. Subjects assigned to this 
treatment were named as “treated” group; b) a control pasta produced with the same 
technological process and from the same whole wheat flour, but without addition of β-glucans 
and the probiotic strain. Subjects assigned to this treatment were named as “control” group. 
Detailed characteristics of the functional and control pasta are reported in Chapter 1. Further 
information on the clinical trial are reported in Chapter 5. 
 
Control and functional pasta 
The functional pasta, and in particular the cooked product, contained a microbial load above 6 
log CFU/g of the probiotic strain B. coagulans BC30, as previously reported (Chapter 1). Instead, 
the cooked control pasta did not contain bacteria of the genus Bacillus. 
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Collection of fecal samples 
At the baseline of the study and every 4 weeks, for a total of 4 times, fresh fecal samples were 
collected at the Department of Food and Drug (University of Parma), and stored at 4°C in 
RNAlater (Sigma-Aldrich, Saint Louis, MO, USA). For 5 subjects, fecal samples were collected 
also few days after the end of the intervention period. For molecular analyses, all samples were 
further subdivided in 200 mg aliquots and stored at -20°C till processing. 
 
Microbiological analysis on fecal samples 
Viable Bacillus spore count 
One gram of each fecal sample was mixed with 9 ml sterile peptone (0.1%, w/v) water and 
mixed with vortex until the sample was thoroughly homogenized. Appropriate dilutions were 
heat-treated (75°C for 30 min) in a water bath, immediately cooled and pour plated in duplicate 
in Glucose Yeast Extract (GYE) agar (USP, 2014). Plates were incubated aerobically at 37°C for 
48 h, after which the B. coagulans colonies were identified on the basis of their characteristic 
morphology and then counted and recorded. Plate count analyses were performed at the baseline 
of the intervention period (T0), and after 1, 2 or 3 months (T1, T2 and T3). 
 
DNA extraction procedures 
Extraction of DNA from 200 mg fecal sample was performed following the protocol of QIAamp 
DNA stool Mini Kit (Qiagen, Hilden, Germany), as described by the manufacturer with a lysis 
temperature of 95°C. DNA concentration and quality were measured using a NanoDrop Lite 
UV-Vis Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). 
 
Quantitative PCR analyses 
A quantitative real-time PCR (qPCR) assay was used for the detection of B. coagulans BC30 in 
fecal samples. Enumeration of the probiotic strain was conducted using primers reported in 
Table 2.1. In particular, these primers, GBI-30F and GBI-30R, were newly designed, basing on 
comparative analyses on available B. coagulans genomes. These primers recognized a region 
located in a sequence (ID JPSK01000058.1, NCBI) coding for an hypothetical protein, and their 
specificity was assessed on a collection of B. coagulans strains. 
Quantitative PCR assays were performed with a LightCycler Nano System (Roche, Mannheim, 
Germany), using the FastStart DNA Master SYBR Green kit (Roche, Mannheim, Germany), in a 
final volume of 20 μL, containing 5 μL of each fecal DNA preparation, 0.25 μM of each primer, 
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MasterMix buffer 1 × and PCR grade water. No-template controls were included in each assay. 
The thermal cycling conditions used for B. coagulans BC30 consisted in one cycle of 95°C for 10 
min, followed by 45 cycles with denaturation at 95°C for 15 s, primer annealing at 55°C for 15 
seconds, and extension at 72°C for 15 seconds. 
A standard curve was constructed by inoculating a pool of fecal samples which did not contained 
the probiotic strain with 10-fold serial dilutions of freeze-dried B. coagulans BC30. Serial 
dilutions of the inoculated fecal pool were pour plated in GYE agar. BC30 amounts were plotted 
against the cycle number at which the fluorescence signal increased above the threshold value 
(CT value). qPCR amplification efficiency was obtained using the equation E = 10(-1/slope). Cell 
numbers of bacteria in fecal samples were calculated by comparing the threshold cycle values 
with the standard curve, and expressed as CFU per gram of feces. All PCR analyses were carried 
out in technical triplicate, and presented data are the mean values obtained. 
 
Table 2.1. Primer sequences and specifications for qPCR assays (annealing temperature and extension 
time). 
Target Primer Sequence (5’-3’) Lenght (bp) 
Ta 
(°C) 
Extension 
time (sec) Reference 
B. coagulans 
BC30 
GBI-30F 
GBI-30R 
TCAAAACTCGCATGAAATCG 
TTCCATCCGAAAGCAAATTC 188 55 15 This study 
 
 
2.3. Results and discussion 
Plate count analyses 
Plating analyses were performed on the fecal samples from the group of subjects who ingested 
the functional pasta enriched with the probiotic strain (treated group), and results were compared 
with those obtained from the subjects who ingested the pasta without the probiotic strain (control 
group). 
For both groups of samples, a heat treatment step at 75°C for 30 min was carried out in order to 
select the heat-resistant spore-forming bacteria. This approach represented a valid strategy to 
focus on the bacterial population of interest. 
At the baseline of the study, observations of the plates obtained from both groups of subjects 
revealed very heterogeneous colony characteristics (Figure 2.1), for morphology (rough or 
smooth), opacity (matt or gloss), and colour (white, yellow, pink or reddish). Colonies with 
different morphology and colour were observed under an optical microscope, that revealed 
 different types of bacilli, short and stubby or long, found singularly or in pairs
constituted the aerobic spore-
Bacilli class, that represent one
anaerobic Clostridia (Hong et al.
relatively low levels, up to 104
 
Figure 2.1. Examples of growth observed from fecal samples of the subjects, belonging to the control or 
treated groups, at the baseline of the intervention period.
 
For subjects who ingested the control pasta, observed morphologies and colony characteristics 
continued to be extremely heterogeneous among subjects, during the intervention study. 
for the control and treated group at the baseline of the trial, and f
trial (T1, T2, T3), the probiotic strain was not detected in the fecal samples. 
subjects who ingested the functional pasta, s
they showed the presence of 
the baseline of the study, at high amounts (above 10
Plates from the analyses of fecal samples o
T2, T3) showed round, smooth, wh
shown in Figure 2.2. 
 
Figure 2.2. Examples of growth observed from fecal samples of subjects who ingested the functional 
pasta (treated group) during the intervention period.
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From a quantitative point of view, the amounts of B. coagulans in the faecal samples of subjects 
who consumed the functional pasta varied between 105 and 107 CFU/g during the whole period 
of intake of the product, as shown in Figure 2.3. These results showed that the probiotic strain 
survived to the transit through the GI tract. Moreover, during a constant and prolonged 
consumption of the functional pasta, B. coagulans BC30 become the predominant component of 
the spore-forming fecal microbiota (Figure 2.2). In fact, it overcome the growth of the highly 
different colonies observed at the baseline of the intervention (Figure 2.1). 
 
Figure 2.3. Quantification of B. coagulans BC30 in the fecal samples of the subjects who ingested the 
functional pasta, through plate count analysis, before the beginning of the treatment and after 4, 8 and 12 
weeks. 
 
qPCR analyses 
The study of the persistence of the strain was carried out through quantitative PCR to complete 
and confirm results obtained from culture-dependent analyses. These analyses were conducted at 
the baseline (T0) and at the end (T3) of the trial, for the control and treated groups of subjects. 
Quantification of the probiotic strain was performed through the use of a standard curve 
presenting the equation y=-3.69x+51.67, and obtained with the newly designed primers GBI-30F 
and GBI-30R, that presented an efficiency of 1.87. The limit of detection of the method was 103 
CFU per assay, which corresponded to 105 CFU/g of feces. 
Regarding analyses of the control group, the presence of BC30 was not detected at the end of the 
trial, confirming the fact that these subjects ingested a product that did not contain the probiotic 
strain. The analyses of the samples of the treated group at time 0 confirmed that BC30 was not 
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present in the fecal samples, except for the two subjects (2 and 39) who also showed the 
presence of the probiotic strain at the baseline of the intervention period, through plate count 
analyses. These two subjects reported later that they ingested the functional pasta few days 
before the baseline time (T0). Analyses of samples of the treated group, at time 3, confirmed that 
the probiotic strain was found at high concentration at the end of the clinical trial, in the range of 
105-108 CFU/g of fecal sample. 
Comparing results obtained from plate count and qPCR analyses it was possible to observe that 
values obtained with qPCR analyses were generally higher than those obtained from plate 
analyses (Figure 2.4). 
Figure 2.4. Quantification of B. coagulans BC30 in the fecal samples of the subjects who ingested the 
functional pasta, through plate count analysis (in light grey) and qPCR (in dark grey), at the end of the 
intervention study (T3). 
 
These results were in agreement with previous evidences from literature dealing with 
quantification of probiotics in fecal samples; in these studies it was reported that molecular 
methods (e.g. qPCR) led to quantification values one or two orders of magnitude greater than 
those obtained through classical microbiology methods (Ahlroos and Tynkkynen, 2009). The 
reason of this may be related to the presence in the fecal samples of non-viable or viable but non-
culturable cells (VBNC), that could not grow in plate assays, but whose DNA is detected with 
molecular techniques. In the case of the present study, dead or damaged vegetative cells 
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following the heat treatment applied to analyse the fecal samples could represent a remarkable 
quote of non-viable cells that was not revealed in plate count analyses. 
 
Analyses of the follow-up samples 
Some days after the end of the period of intake of the functional pasta, fecal samples from few 
subjects (32, 36, 37, 39 and 46) were analysed  to verify the persistence of the strain after the end 
of the consumption of the product (follow-up). The aim of this part of the work was to estimate 
BC30 transit time in the GI tract, namely the period in which the strain was found in fecal 
samples from the end of the consumption period (Hong et al., 2005a). 
Once that ingestion of the functional pasta was stopped, plate count analyses revealed the 
presence of colonies with different morphology than BC30, probably due to the growth of the 
other spore-forming bacteria. In fact, in the samples of the follow-up, the strain may have been 
present in lower amounts compared to the previous sampling time, and its growth in the plate 
could have been inhibited by the presence of these other colonies. Another attempt was 
performed by incubating the plates in anaerobic conditions, where it was possible to observe the 
growth of typical colonies of strain BC30. Thus, anaerobiosis inhibited the growth of other spore-
forming bacteria, allowing the detection of the probiotic strain, that could grow since it is a 
facultative anaerobe. 
The quantification of the strain BC30 in the samples of the five subjects is represented in Figure 
2.5. In particular, samples were collected after 4 days (2 subjects, 36 and 39), 5, 8 and 9 days 
(one subject for each time, with code 46, 37 and 32, respectively). 
 
Figure 2.5. Quantification of B. coagulans BC30 in the fecal samples of the subjects who ingested the 
functional pasta, through plate count analysis, during the follow-up period. 
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BC30 counts decrease from a value above 106 CFU/g (average value of the whole group of 
subjects who consumed the functional pasta) at the end of the trial, to a value of 104 CFU/g after 
four days. After five days, BC30 level was reduced by a further logarithmic unit, reaching 103 
CFU/g, and after eight days a further reduction was observed, with levels around 102-103 CFU/g. 
After nine days the strain was no longer found in fecal samples. 
The presence of the strain BC30 in the fecal samples of the follow-up period was assessed also 
through qPCR. Given the low values obtained from plate count analyses, below the limit of 
detection of the qPCR method (105 CFU/g), DNA isolation was performed not directly from the 
fecal samples, as it was done for all the other samples, but from the colonies grown on plates. 
Thus, all colonies were harvested for DNA extraction and qPCR analyses were performed in 
order to detect the strain, also if present in low proportions and/or even in the case where BC30 
growth was partially masked by other colonies. In these assays, a quantification was not 
performed, but a qualitative information was retrieved, i.e. the presence/absence of the melting 
peak characteristic of BC30 amplified fragment. 
Analyses were done for subjects 36, 37, 39 and 46. Subjects 32 was not considered since strain 
BC30 did not shown any growth in plate analyses. The results indicated the presence of the BC30 
related melting peak for all samples analysed, excluded subjects 37, which showed no 
amplification products. The fecal sample from this subject was collected eight days after the end 
of the consumption of the functional pasta, and it provided the lowest count value among the 
samples of the follow-up. 
In conclusion, results from this part of the study showed that the strain BC30 transiently 
colonised the GI tract of the subjects who consumed the functional pasta, with a residence time 
of approximately 8 days. In literature, it is reported that probiotic ingested strains are still 
detected after few days, but rarely after one week (Derrien and van Hylckama Vlieg, 2015). For 
example, a similar time to that observed for BC30 was reported for B. stearothermophilus, that 
showed a residence time in the GI tract of 8-10 days (Hong et al., 2005a). On the contrary, in 
another study, B. polyfermenticus was found in fecal samples within 4 weeks from the end of the 
ingestion (Park et al., 2002). In the first case, the strain simply transited through the GI tract, 
while in the second study the strain was able to persist in the gut for longer time, probably thanks 
to specific adhesion properties (Hong et al. 2005a). 
The dose of orally ingested strains from fermented foods and probiotics ranges between 108 and 
1012 CFU per day (Derrien and van Hylckama Vlieg, 2015). In the present study, for 70-100 g of 
functional pasta consumed from the subjects, a minimum dose of 108 CFU of B. coagulans have 
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been ingested daily, for 12 weeks. Results from the present study showed that the probiotic strain 
survived to the transit through the GI tract and was found at high levels in the fecal samples of 
the subjects, with an average value on the whole group of subjects above 106 CFU/g of fecal 
samples, after one (T1), two (T2) and three (T3) months of functional pasta intake (Figure 2.6). 
Since plate count analyses were performed after the thermal treatment, in order to select the 
population of interest in the total fecal microbiota, the fore mentioned values were related to the 
spore content in the fecal samples. The data demonstrated that the probiotic strain transited intact 
in the GI tract. 
 
Figure 2.6. Average B. coagulans BC30 levels in the fecal samples of the subjects who ingested the 
functional pasta, through plate count analysis (in light grey) and qPCR (in dark grey). *: p < 0.05. 
 
This finding confirmed the stability and resistance of spore-forming probiotics belonging to the 
genus Bacillus (Cutting et al. 2011), and reported for the strain B. coagulans BC30 from in vitro 
(Maathuis et al., 2010) and in vivo (Nyangale et al., 2015) evidences. 
However, regarding administration of dormant bacterial probiotics, the discussion is opened 
about how they can exert a beneficial effect on the gastrointestinal microbiota (Ghelardi et al., 
2015). In fact, only following spore germination into vegetative cells a probiotic can exert its 
effects, e.g. manifesting immunomodulatory properties, secerning antimicrobials or other 
metabolites (Tam et al., 2006). Studies in animal models showed that Bacillus spores, from 
different Bacillus species, e.g. B. subtilis, B. licheniformis, B. polyfermenticus, can germinate in 
the small intestine, grow, proliferate and then re-sporulate (Casula and Cutting, 2002; Tam et al., 
2006; Leser et al., 2008; Jung et al., 2012). Regarding human studies, few information is 
available. In a recent research, the persistence of a mix of Bacillus clausii strains following oral 
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administration has been evaluated in a human trial (Ghelardi et al., 2015). Bacillus clausii is a 
species used in pharmaceutical preparations for the treatment or prophylaxis of intestinal 
dysbiosis, that presented several properties e.g. antimicrobial and immunomodulatory activity, 
involvement in immune responses, cell growth and differentiation, cell adhesion, signal 
transcription and transduction, secretion of vitamins (Ghelardi et al., 2015). In the study, the 
authors highlighted that most of these positive functions could only be carried out if the probiotic 
strain survives, germinates and grows in the gut. The results of the study indicated that the 
probiotic mix could germinate, since the strains were found in the fecal samples of the subjects 
after 12 days, after a single dose administration. In fact, considering that the average transit time 
into the colon is about 2 days (Graff et al., 2001), such a longer transit time would probably have 
implied the germination of the spores. 
With respect to the probiotic strain BC30, an in vitro study dealing with the topic of germination 
of the spores is available in literature (Maathuis et al., 2010). In this research, when a dose of 
2×109 spores of B. coagulans BC30 were introduced into the gastric compartment, the 70% of the 
spores survived and, moreover, germinated cells were found to be 13.9%. Since in the study the 
spores were administrated without any growth medium, the authors suggested that, probably, in 
conditions more similar to those of the GI, germination could have been more pronounced. 
Regarding the present study, two evidences could support the hypothesis of the germination of 
the probiotic strain. First, a statistically significant difference was found between BC30 levels at 
the end of the trial (T3), observed trough plate counts and qPCR analyses (6.3 log CFU/g versus 
6.7 log CFU/g) (Figure 2.6). If plate count analyses provided a value related to the number of 
viable spores, results from qPCR reflected the amount of the entire population (spores and 
vegetative cells), since no thermal treatment was done prior DNA isolation from the fecal 
samples. Thus, the differences between the two values could be due to the contribution of 
vegetative cells, derived from germination of the spores and proliferation. Secondly, the spores 
of B. coagulans BC30 were counted after 8 days from the end of the treatment with the functional 
pasta, so after a period longer than the gastrointestinal transit time, estimated to be from a 
minimum of 14 hours to a maximum of 32 hours (Derrien and van Hylckama Vlieg, 2015). This 
could indicate that BC30 could have germinated into the GI tract, according to what reported 
from Ghelardi and colleagues (2015). Regarding this second point, the evidence obtained from 
the present study was less robust than the one from the former study, for several reason. In the 
study from Ghelardi and colleagues, the mix of B. clausii strains was administered in a single 
dose, while in the present study the subjects assumed the functional pasta continuously for 12-
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week; this could physiologically led to a quite long time needed to work off all the spores. 
Moreover, in the present study, the analyses of the follow-up period were performed on a very 
small number of subjects. Finally, BC30 amounts found in the follow-up period (104 after 4 days) 
were considerably lower than levels observed during the treatment. 
In any case, taking these findings and considerations together, germination of the probiotic strain 
BC30 could be hypothesised in the investigated subjects, but further studies will be necessary to 
clarify these aspects. 
 
2.4. Concluding remarks 
This study evaluated the survival of the probiotic strain B. coagulans BC30 following the transit 
through the GI tract. In particular, the strain was administered as included in a functional pasta, 
and the evaluation of its persistence was performed based on classical and molecular analyses of 
fecal samples of the subjects who participated to the intervention trial. 
Results from the study indicated that strain BC30 survived to the transit through the GI tract and 
its spores were found at a high concentration (above 106 CFU/g) in the fecal samples. Thus, the 
functional pasta investigated in this study represented a good daily vehicle of the probiotic strain, 
also considering that pasta constitutes a must product of the Mediterranean diet. 
The probiotic strain was found to transiently colonize the GI tract of the subjects. In fact, it was 
found in the fecal samples 8 days after the end of the intervention period with the functional 
pasta. Consequently, to guarantee high levels of the probiotic strain in the gut, a constant 
consumption of the functional food is necessary.  
Differences in BC30 levels obtained trough plate count analyses after a thermal treatment (viable 
spore count) and qPCR (quantification of spores and vegetative cells) were significant and could 
be related to a quote of vegetative cells that germinated, grew and proliferated. Moreover, the 
presence of the probiotic strain in the fecal samples some days after the end of the intervention 
treatment could represent another evidence supporting the hypothesis of the germination of the 
probiotic strain in the GI tract. However, given the small number of subjects monitored during 
the follow up period, further studies will be necessary to clarify the aspect of germination. 
 
 
 
This study was supported by the Italian Ministry for Development in the framework of the project 
“Pass-World - pasta e salute nel mondo - Industria 2015” [MI01_00138]. 
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Chapter III 
 
A case-control study for assessing gut microbiota composition and 
intestinal permeability in Italian children at risk for type 1 diabetes 
and healthy children 
 
 
3.1. Introduction 
Type 1 diabetes (T1D), an autoimmune disease caused by immune cell-mediated destruction of 
insulin-secreting pancreatic beta cells, is preceded by the presence of genetic, immunological 
and/or metabolic markers, in the absence of clear clinical symptoms. Immunological markers are 
indicative of pancreatic organ-specific autoimmunity, which can be demonstrated months or 
years before the clinical onset of T1D (Atkinson et al., 2014). 
Evidences from both rodent model (Roesch et al., 2009) and human studies (Vaarala et al., 2008; 
Bach and Chatenoud, 2012) suggest that the composition of gut microbiota has a significant 
impact on the immune system development and function. To date, only a few studies explored 
microbiota composition in children with T1D (Giongo et al., 2011; Murri et al., 2013; Soyucen 
et al., 2014; Mejía-León et al., 2014) or in subjects with pancreatic organ-specific autoimmunity 
(de Goffau et al., 2013; Davis-Richardson et al., 2014; Endesfelder et al., 2014; Kostic et al., 
2015), therefore evidences for the role of gut microorganisms in the onset and progression of 
T1D are still limited. Interestingly, most studies agree in reporting a reduced microbial diversity 
in subjects with overt or pre-T1D than in controls and, remarkably, microbiota composition in 
T1D or pre-T1D subjects was found different from that of control subjects (de Goffau et al, 
2013; Davis-Richardson et al., 2014; Kostic et al., 2015). However, a typical T1D-associated 
microbiota has not been identified, as relevant microbial genera were different among studies, 
possibly due to the different geographical origin of subjects (Kemppainen et al., 2015). 
A recent study (Brown et al., 2011), based on whole metagenome sequencing, depicted a 
functional model to explain the relationship between intestinal dysbiosis and increased 
permeability (commonly called leaky gut). In this model, the fate of lactate is crucial in 
determining gut health: the presence of bacteria able to convert lactate to butyrate results in 
increased mucin synthesis and strengthened tight junctions, that are related to improved gut 
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integrity. On the contrary, conversion to short chain fatty acids (SCFA) different than butyrate 
reduces mucin and tight junctions with consequent increase of gut permeability and, eventually, 
onset of T1D. Those microbial activities have been associated to a small number of bacterial 
genera, namely Lactobacillus, Bifidobacterium, Faecalibacterium, Subdoligranulum, Alistipes, 
Bacteroides and Veillonella, in order of possible action in the lactate production/consumption 
chain (Brown et al., 2011). 
Pancreatic organ-specific autoimmunity in children at risk for T1D (pre-T1D) is associated with 
increased intestinal permeability, a condition that precedes the clinical onset of the disease (Bosi 
et al., 2006). However, the mechanisms originating leaky gut in these subjects are not well 
known. In pre-T1D subjects, the presence of an aberrant gut microbiota may result in immune 
dysregulation responsible for the increase of intestinal permeability and destruction of pancreatic 
beta cells, thus influencing the onset of the pathology, in the so called “perfect storm” (Vaarala 
et al., 2008). 
Therefore, the aim of this study was to test, for the first time in an Italian sample of children, the 
hypotheses that: i.) the gut microbiota composition of children with beta cell autoimmunity at 
risk for T1D, analysed using PCR-DGGE and 16S rRNA gene sequencing profiling, is different 
from that of autoantibody negative children, with particular reference to lactate-
producing/consuming bacteria; ii.) the intestinal permeability of children with beta cell 
autoimmunity at risk for T1D is higher than in controls; and iii.) there is a possible relationship 
between these two phenomena. 
 
3.2. Methods 
Study participants and design 
This case-control study comprised 10 children at risk for T1D (Group: Cases), positive for at 
least one diabetes associated autoantibody (glutamic acid decarboxylase autoantibodies, GADA; 
insulin autoantibodies, IAA; insulinoma-2-associated autoantibodies, IA-2A), independently of 
HLA-DQ genotype, and 10 healthy children (Group: Controls). Regarding children at risk for 
T1D, four have a first degree relative with T1D, while six have been screened for pancreatic 
autoimmunity and HLA owing to hyperglycemic episodes. Inclusion criteria were age (range: 6-
16 years), normal weight (BMI <85th percentile for age and gender, with Italian BMI percentile 
tables as reference (Cacciari et al., 2006), residence in Veneto region (North East Italy), 
exclusion criteria were chronic diseases, dieting, eating disorders, overweight or obesity, chronic 
use of drugs, presence of active infections, use of antibiotics, probiotics, prebiotics or any other 
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medical treatment influencing intestinal microbiota during the 3 months before the start of the 
study. The protocol was in accordance with the 1975 Declaration of Helsinki as revised in 2008 
and has been approved by the Institutional Ethics Committee of Verona (Italy). 
During the days before the tests, no attempt was made to influence the usual diet of each child. A 
fecal sample from children was collected using stool collection vials and immediately stored in 
home refrigerator (4°C) until delivered, within 12 hours, to the study centre and stored at -20°C 
till bacterial DNA isolation. 
 
Gut microbiota analyses 
PCR amplification, DGGE analysis and molecular bacterial identification 
Polymerase Chain Reaction followed by Denaturing Gradient Gel Electrophoresis (PCR-DGGE) 
consists of a PCR amplification of total DNA isolated from a specific matrix (e.g., stool samples) 
and a subsequent separation of the obtained mixture of amplicons in a denaturing gradient; this 
results in a profile, where bands are resolved on the basis of their melting temperature/sequence, 
which can be identified through band sequencing (Muyzer et al., 1993). 
Isolation of total DNA from stool samples was carried out using the QIAamp® DNA Stool Kit 
(Qiagen, Venlo, The Netherlands). PCR fragments of 200 bp representing total fecal bacteria 
were amplified with the universal primers HDA1-GC and HDA2 as reported before (Walter et 
al., 2000) (Table 3.1). Moreover, specific bacterial genera (Lactobacillus, Bifidobacterium, 
Bacteroides-Prevotella-Alistipes, Clostridium, Faecalibacterium and Veillonella) were targeted 
using primer sets with a reduced amplification specificity (Table 3.1). 
Reaction conditions used were identical to those for HDA1-GC and HDA2, except for the 
annealing temperature (Table 3.1) and longer amplicons obtained were used as templates for 
nested PCRs performed with the universal primers. DGGE analysis of PCR amplicons was 
carried out using the Dcode Universal Mutation Detection System (Bio-Rad, Richmond, CA, 
USA) as described previously (Marzotto et al., 2006). The linear denaturing gradients of urea 
and formamide used for separation of amplicons are reported in Table 3.1. 
DGGE patterns were analysed with the software package UVI band Map (UVItec, Cambridge, 
United Kingdom). Similarities between DGGE profiles were determined using the Dice 
coefficient and the unweighted-pair group method with the arithmetic average (UPGMA) 
clustering algorithm. The number of bands of each individual in every DGGE profile was 
considered as an indicator of diversity of the fecal microbiota. 
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Table 3.1. Sets of primers used in this study with the corresponding annealing temperature in PCR 
reaction, and gradients used for the DGGE gels. 
Target Primer Sequence Lenght (bp) 
Ta 
(°C) 
Gradient Reference 
Total 
Microbiota 
HDA1-GC 
HDA2 
ACTCCTACGGGAGGCAGCAGT-(GC) 
GTATTACCGCGGCTGCTGGCAC 
200 56 30-60% Walter et al., 
2000 
Walter et al., 
2000 
Bacteroides - 
Prevotella - 
Alistipes 
Bac303F 
Bac708R 
GAAGGTCCCCCACATTG 
CAATCGGAGTTCTTCGTG 
418 58 30-55% Bernhard and 
Field, 2000 
Bernhard and 
Field, 2000 
Bifidobacterium Bif164mod 
Bif662 
GGGTGGTAATACCGGATG 
CCACCGTTACACCGGGAA 
520 58 45-60% Satokari et al., 
2001 
Satokari et al., 
2001 
Clostridium 
cluster XI 
HDA1-mod 
CXI-R2 
ACTCCTACGGGAGGCAG 
GAGCCGTAGCCTTTCACT 
280 58 30-60% This study 
Song et al., 
2004 
Clostridium 
cluster XIV 
HDA1-mod 
CXIV-R2 
ACTCCTACGGGAGGCAG 
CTACGCWCCCTTTACAC 
250 48 30-60% This study 
Song et al., 
2004 
Faecalibacterium HDA1 
Fprau645R 
ACTCCTACGGGAGGCAGCAGT 
AATTCCGCCTACCTCTGCACT 
315 64 30-60% Walter et al., 
2000 
Ramirez-
Farias et al., 
2009 
Lactobacillus Lac1 
Lac2 
AGCAGTAGGGAATCTTCCA 
ATTYCACCGCTACACATG 
340 61 30-55% Walter et al., 
2001 
Walter et al., 
2001 
Veillonella Vpar-longF 
HDA2 
ATCAACCTGCCCTTCAGAGGG 
GTATTACCGCGGCTGCTGGCAC 
390 64 30-60% This study 
Walter et al., 
2001 
 
Selected unknown DGGE bands, present in more than 50% of the subjects in one of the two 
groups, were excised from the denaturing gels, re-amplified with the universal primers without 
the GC-clamp and cloned with the cloning kit pGEMT-easy vector system (Promega, Madison, 
WI, USA). Recombinant plasmids were sequenced at the GATC biotech centre (Koln, 
Germany). Analyses to determine the closest relatives of the partial 16S rRNA gene sequences 
retrieved were conducted in EzTaxon database (Kim et al., 2012). 
 
16S rRNA gene profiling 
Genomic DNA isolation from samples was done using standard molecular biology kits from 
ZYMO Research provided by Baseclear (Leiden, the Netherlands). PCR amplification of the 16S 
rRNA gene (V3-V4 region), barcoding and library preparation were performed by BaseClear. 
Short paired-end sequence reads were generated using the Illumina MiSeq system and converted 
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into FASTQ files using the BCL2FASTQ pipeline version 1.8.3. Quality trimming was applied 
based on Phred quality scores. Subsequently sequences were analyzed using the QIIME-pipeline. 
The dendrogram was constructed by calculating the Bray-Curtis distance between each sample, 
after which neighbor joining was used for clustering. For comparative analyses of the samples at 
the species level, the threshold of 0.1% on the total composition was fixed, i.e species found at 
lower values were not considered. 
 
Intestinal permeability test 
Gut permeability was investigated with lactulose/mannitol test (LA/MA test). This consists in the 
administration of an oral dose of two probes, lactulose and mannitol, and in the measurement of 
their intestinal uptake by evaluating their urinary excretion in the following 5 hours. The amount 
of sugars was administered according to the age of children. After an overnight fast and 
collection of a basal urine sample, children ingested 100 ml of water containing 5 g lactulose and 
2.5 g mannitol (double doses for children over 10 years). Urine were collected during the next 5 
hours in a container, with the addition of chlorhexidine as a preservative. At the end of the test 
the total volume of urine was measured and a 10 ml sample was stored at -20°C until the assay. 
Lactulose and mannitol concentrations in urine were measured using a HPLC method (Marsilio 
et al., 1998). Results were expressed as a percentage of the administered lactulose and mannitol 
excreted in urine and as a lactulose:mannitol ratio (LMR). 
 
Biochemical analyses 
HbA1c was measured using high-performance liquid chromatography with variant II cation 
exchange column (Bio-Rad, Richmond, CA, USA). HLA-DQA1 and DQB1 genotyping was 
performed by sequence specific PCR using AllSet+ Gold High-Resolution Kit (Life 
Technologies, Carlsbad, CA, USA). 
 
Data analysis 
All results were shown as mean and standard deviation of the mean (SD). Student t-test was used 
to compare means. Frequency comparisons were performed by χ2 test. The Spearman’s rho 
correlation coefficient was calculated to estimate correlations between variables (intestinal 
permeability, HbA1c% and presence of bacterial groups), and these analyses were performed 
using SPSS 20.0 software for windows (SPSS Inc., Chicago, IL;USA). A p-value <0.05 was 
considered statistically significant. 
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Intestinal permeability test, biochemical analyses and data analyses were performed at the 
Regional Center for Pediatric Diabetes, Department of Surgical Sciences, Dentistry, Gynecology 
and Pediatrics, University of Verona. 
 
3.3. Results 
Gut microbiota analyses 
PCR-DGGE analyses 
Fecal bacteria were investigated targeting (i) the overall composition with universal primers 
(Figure 3.1), and (ii) the composition of specific bacterial groups related to lactate metabolism, 
namely Lactobacillus, Bifidobacterium, Bacteroides-Prevotella-Alistipes, Clostridium, 
Faecalibacterium and Veillonella. 
 
 
Figure 3.1. Profiles obtained from PCR-DGGE analyses of the total microbiota, for the Controls (C, on 
the left), and Cases/Pre-diabetics (P, on the right), obtained from the amplification with universal primers 
HDA1-GC/HDA2. 
PCR-DGGE profiles obtained from universal primers displayed very high complexity (average 
number of bands/profile = 40.2 ± 3.5) and great individual variability but a clear differentiation 
between Cases and Controls profiles was not possible, as shown in the similarity dendrogram 
(Figure 3.2) where the two groups are intermixed. 
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Figure 3.2. Dendrogram obtained from the profiles of the total microbiota of Controls (C) and Cases/Pre-
diabetics (P), obtained through PCR-DGGE analyses. 
 
The group-specific DGGE profiles showed a lower complexity than the universal ones (average 
number of bands/ profile = 11.8 ± 2.5). Again, a clear-cut differentiation between Cases and 
Controls was not possible. Most representative bands were excised from gels, cloned and 
sequenced to be identified: 3 from Lactobacillus-targeting PCR, 4 from Bifidobacterium, 3 from 
Bacteroides/Prevotella/Alistipes, 5 from Clostridium, 2 from Faecalibacterium and 3 from 
Prevotella, for a total of 20 bands (Table 3). 
Chapter III 
50 
 
Table 3.2. Putative bacterial groups identified by sequencing of the DGGE bands amplified from fecal 
DNA of children at risk for T1D (Cases) and healthy children (Controls), using the group-specific 
primers. Significant differences between the two groups established at p<0.05 by using the χ2 test are 
evidenced in bold. 
ID Closest relative Identity Cases (pre-T1D) Controls p-value 
L1 Gemella sanguinis 98,50% 80% (8) 30% (3) 0,0246  
L2 Eubacterium eligens 99,43% 100% (10) 90% (9) 0,3049 
L3 Dialister invisus 99,00% 90% (9) 0% (0) 0,0001 
B1 Bifidobacterium longum subsp. infantis 99,44% 100% (10) 80% (8) 0,1360 
B2 Bifidobacterium longum subsp. longum 98,31% 60% (6) 0% (0) 0,0034 
B3 Bifidobacterium sp. 99,45% 70% (7) 40% (4) 0,1775 
B4 Bifidobacterium sp. 98,91% 70% (7) 80% (8) 0,6056 
Ba1 Bacteroides dorei 99,49% 80% (8) 90% (9) 0,5312 
Ba2 Prevotella copri 95,90% 60% (6) 50% (5) 0,6531 
Ba3 Bacteroides uniformis 99,49% 80% (8) 80% (8) 1 
XI1 Lachnospiraceae sp. 99,43% 80% (8) 40% (4) 0,0679 
XI2 Lachnospiraceae sp. 99,43% 90% (9) 90% (9) 1 
XI3 Lachnospiraceae sp. 99,43% 100% (10) 100% (10) 1 
XIV1 Lachnospiraceae sp. 98,29% 90% (9) 100% (10) 0,2437 
XIV2 Barnesiella intestinihominis 99,49% 100% (10) 90% (9) 0,3049 
F1 Lactobacillu rogosae 99,43% 100% (10) 100% (10) 1 
F2 Eubacterium eligens 98,29% 100% (10) 90% (9) 0,3049 
V1 Alistipes shahii 98,97% 70% (7) 60% (6) 0,6392 
V2 Veillonella atypica 99,50% 80% (8) 80% (8) 1 
V3 Alistipes shahii 98,46% 80% (8) 80% (8) 1 
 
It must be pointed out that sequencing of such a short sequence could not always be considered 
reliable for identification at the species level, but only at the taxonomic level of the genus. 
Remarkably, three bands, identified as Gemella sanguinis (L1), Dialister invisus (L3) and 
Bifidobacterium longum (B2), were present in more than 50% of Cases and only in a few healthy 
subjects, if any. This could indicate the presence of microbial markers possibly associated to the 
onset of T1D. 
 
16S rRNA gene profiling 
Analyses of fecal microbiota of the children at risk for T1D and healthy children were performed 
also through 16S rRNA gene sequencing, with the aim of extending the analyses to the overall 
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fecal communities, thus confirming biomarkers found with PCR-DGGE analyses and possibly 
expanding the number of candidate biomarkers. 
On the overall communities, these analyses confirmed what obtained from similarity analyses of 
the PCR-DGGE profiles. The two groups, Cases and Controls, resulted intermixed, with no 
individuation of separated clusters as observed from the dendrogram and PCoA plot (Figure 3.3, 
Figure 3.4). 
 
Figure 3.3. Dendrogram obtained from the analyses of the total microbiota of Controls (C) and 
Cases/Pre-diabetics (P), obtained through 16S rRNA gene profiling. 
 
 
 
Figure 3.4. Weighted PCoA three-dimensional plot representing microbiota composition of Controls (in 
red) and Cases (in blue), obtained with UniFrac metric. 
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A consensus list of classified species among Cases and Controls was created, consisting in a total 
number of 91. The same frequency test applied to the bands found through PCR-DGGE analyses 
was applied to the species of the consensus list. In Table 3.3 species found in the two groups are 
listed basing on increasing p-value (only species with a difference in the frequencies between the 
two groups of at least 3 are reported in the table). Moreover, an analysis for comparing 
abundances in the species of the consensus list in the two groups was performed (data not 
shown). 
 
Table 3.3. Species differentially present in Cases and Controls. Significant differences between the two 
groups established at p<0.05 by using the χ2 test are evidenced in bold. Species indicated with (a) showed a 
p-value close to 0.05. 
 
 
Two species were found to be differentially present in the two groups, basing on frequencies 
(presence or absence in the subjects of a group) namely Ruminococcus callidus in Controls and 
Eubacterium eligens in Cases. However, these two species were present in a restricted number of 
subjects in a group (below of equal to 50% of the subjects for each group, Cases and Controls). 
Thus, these species were not added to previous found markers. Two Bifidobacterium species, B. 
bifidum and B. pseudocatenulatum were found with a higher frequencies in the Controls. Even if 
the p-value was slightly above the 0.05 they were not considered as indicative of a certain state 
(healthy or pre-pathologic), as previous found markers. 
No species characterised the Controls or Cases in terms of significantly different abundances. 
Species Cases (pre-T1D) Controls p-value 
Ruminococcus callidus  0% (0) 50% (5) 0.0098 
Eubacterium eligens  40% (4) 0% (0) 0.0253 
Bifidobacterium bifidum  10% (1) 50% (5)    0.0510(a) 
Bifidobacterium pseudocatenulatum  50% (5) 90% (9)    0.0510(a) 
Blautia faecis  70% (7) 100% (10) 0.0603 
Eubacterium hallii  70% (7) 100% (10) 0.0603 
Bacteroides vulgatus  80% (8) 40% (4) 0.0679 
Bacteroides ovatus  40% (4) 10% (1) 0.1213 
Terrisporobacter glycolicus  10% (1) 40% (4) 0.1213 
Clostridium celatum  30% (3) 60% (6) 0.1775 
Dialister invisus  70% (7) 40% (4) 0.1775 
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Regarding biomarkers found with PCR-DGGE analyses, they were not found in association to 
T1D in the present 16S rRNA sequencing analyses. Gemella sanguinis was not found in the 
samples of pre-diabetic or healthy children, considering the fixed threshold (0.1%). The other 
two species were found in different frequencies in Cases and Controls (in 7 Cases and 4 Controls 
for Dialister invisus and in 10 Cases and 8 Controls for Bifidobacterium longum) than those 
found with PCR-DGGE. 
 
Intestinal permeability and biochemical measurement 
Lactulose urinary excretion results significantly higher in Cases than in Controls (0.313±0.127 
vs 0.216±0.072 %; p=0.043), while mannitol excretion showed no significant differences 
between the two groups. The lactulose:mannitol excretion ratio (LMR) was also significantly 
higher in Cases than in Controls (0.024±0.009 vs 0.017±0.005; p=0.042), with three subjects 
above the limit of 0.025, suggestive of altered permeability (Table S3.1). In children with 
pancreatic autoimmunity we found a significant positive correlation between LMR and HbA1c 
levels (rho= 0.718, p= 0.019). 
 
Correlation between intestinal permeability and aberrant microbiota 
In order to investigate the potential connection between gut integrity and microbiota alteration, 
the data obtained by PCR-DGGE were compared to those concerning the progression of the 
disease and the permeability of the gut. Subjects showing the highest number of autoantibodies 
(Case #1 and #7) were the same with the highest intestinal permeability and almost all of the 
three microbial markers, whereas those with a lower extent of autoimmunity had a normal 
intestinal permeability and reduced microbial markers (Case #5 and #10) (Table S3.1). 
Moreover, since PCR-DGGE is a semi-quantitative method, the detection of a band is related to 
the relative abundance of the corresponding microorganism in the sample, at least 1% of the total 
DNA (Muyzer et al., 1993). Normalisation of DNA concentration in the different samples was 
performed; therefore we can assume that the relative abundance of the three biomarkers 
(Dialister invisus, Gemella sanguinis and Bifidobacterium longum) is higher in Cases than in 
Controls. In this context, a significant correlation between presence of the three microbial 
markers, in PCR-DGGE, and intestinal permeability, provided by LA/MA test, was found 
(Figure 3.5) (rho=0.542; p= 0.011). 
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Figure 3.5. Linear correlation between the presence of the microbial markers in PCR-DGGE and 
intestinal permeability, provided by LA/MA test. White circles = Controls ; grey circles = Cases with 1 or 
0 HLA aplotype at risk for diabetes and 1 or 2 autoantibodies; black circles = Cases with 2 HLA 
aplotypes at risk for diabetes and at least 2 autoantibodies. 
 
3.4. Discussion 
To the best of our knowledge, this is the first study conducted in subjects with pre-T1D in which 
gut microbiota composition and intestinal permeability were contemporaneously investigated. 
Moreover, for the first time, Italian children at risk for T1D were investigated for their 
microbiota composition. The results of this study showed that: i.) the gut microbiota composition 
of pre-T1D children is different, in some components, from that of autoantibody negative 
children and ii.) intestinal permeability of children with beta cell autoimmunity at risk for T1D is 
higher than in Controls. 
Regarding analysis of gut microbiota composition, PCR-DGGE was chosen since it allows a 
rapid semi-quantitative detection of specific microbial groups, which could be rapidly compared 
across multiple samples with a low cost and no requirement for specific bioinformatic skills. 
This technique is one of the most well-established tools for the analysis of complex bacterial 
communities (Muyzer et al., 1993; Ercolini, 2004; Fraher et al., 2012), it has been recently re-
evaluated (Foerster et al., 2014; Ferrocino et al., 2015), and applied also to the analysis of T1D 
subjects (Murri et al., 2013). In this context, considering the overall composition of the 
microbiota, our results showed that a clear-cut differentiation between Cases and Controls was 
not possible; this is in agreement with a previous study reporting analysis with PCR-DGGE 
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(Murri et al., 2013), and it is probably due to the marked individual variability. However, 
investigating the microbial populations related to lactate metabolism (lactate-
producers/consumers), three species were found statistically associated with beta cell 
autoimmunity: Dialister invisus, Gemella sanguinis, and Bifidobacterium longum. These 
markers are different from the species described before as associated to the pre-T1D or T1D 
group (de Goffau et al., 2013; Davis-Richardson et al., 2014). This could be due to the different 
techniques applied but, also, to environmental factors, such as differences in geographical origin, 
eating habits, age or degree of disease progression (i.e. presence of genetic, immunologic or 
metabolic markers) (Kemppainen et al., 2015). Indeed, literature data refer mainly to Finnish 
subjects, with a very high genetic risk and aged 0 to 2 years. The impact of such environmental 
factors on the gut microbiota makes it extremely difficult to recognise common characteristics, 
universally valid for the description of a pathologic state (Endesfelder et al., 2014). The 
identification of potential biomarkers appears possible only within a sufficiently homogeneous 
population (e.g., in terms of geographical and clinical aspects); thus the three markers we found 
could be characteristic of our specific Italian group of subjects. 
From a biological viewpoint, Dialister and Gemella belong to the category of the so-called 
pathobionts, i.e. normal inhabitants of the gut in low concentrations (symbionts) that could 
determine undesired/pathogenic effects where their concentration increase (Chow et al., 2011; 
Anders et al., 2013). Moreover, in case of altered intestinal permeability, they could also enter 
the blood stream, possibly inducing complications. On the contrary, Bifidobacterium longum 
belongs to a genus, Bifidobacterium, generally considered beneficial to the health of the host, 
which includes also numerous probiotic strains (Gomes et al., 2014). However, an increase in the 
level of this genus has already been reported in association with T1D (Brown et al., 2011), and 
future investigations on the relevance of this category for T1D development could be important.  
Interestingly, microorganisms found support the functional model suggested in the literature 
(Brown et al., 2011) as the main products of their metabolism are the SCFA acetate and 
propionate; these two metabolites, unlike butyrate, cannot stimulate the biosynthesis of mucin 
and the assembly of the tight junctions, hypothetically leading to an increase of intestinal 
permeability and finally promoting the autoimmunity reactions (Brown et al., 2011). 
Moreover, 16S rRNA gene profiling analyses were performed on samples from the same 
subjects, in order to extend the analyses to the overall fecal communities, thus confirming 
previous find biomarkers and possibly expanding the range of candidate biomarkers. These 
analyses on one hand confirmed the fact that there was not a clear differentiation in the profiles 
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of Cases and Control, considering the overall composition of the microbiota. On the other hand, 
at the species level, the three biomarkers individuated through PCR-DGGE were not confirmed. 
The choice of the analysis technique could have an impact on results, and moreover, any bias 
introduced in the technical pipeline can potentially contribute to relevant differences (Thomas et 
al., 2015). In this specific case, several points could be responsible of the different findings 
obtained with the two techniques about the three microbial species. First, DNA for PCR-DGGE 
and for 16S sequencing was extracted from two different aliquots of a same fecal sample, and, 
moreover, using different isolation kits. Also, it is known from literature that different primers 
for 16S rRNA gene could result in a different richness of amplified species, based on targeted 
hypervariable regions (Huse et al., 2012). In the case of the present study, the V2-V3 region was 
amplified for PCR-DGGE analyses while the V3-V4 region was amplified in 16S profiling. 
Moreover, another important point is that in PCR-DGGE analyses a first PCR step was 
performed with group specific primers, that selected a certain population, further amplified with 
universal primers; this procedure could have impacted the proportion of the species in the 
samples, that eventually resulted different to those observed in 16S profiling. In conclusion, 16S 
profiling analyses did not reveal any new biomarkers, so G. sanguinis, D. invisus and B. longum 
remained the species which characterised the pre-diabetic microbiota. 
The second main finding of the study, i.e. intestinal permeability of children with beta cell 
autoimmunity at risk for T1D is higher than in Controls, is in agreement with previous studies 
conducted in animal models and in individuals affected by T1D as well as in subjects with pre-
T1D. Signs of enteropathy were shown to be present in BioBreeding diabetes-prone rats soon 
after weaning and preceding insulitis, suggesting that increased intestinal permeability may be 
necessary for the development of pancreatic autoimmune response (Graham et al., 2004; Neu et 
al., 2005). This hypothesis was supported also in humans, where intestinal permeability, along 
with structural mucosal alteration, was found significantly higher in non-celiac subjects with 
T1D (Secondulfo et al., 2004). Finally, Bosi and co-workers (2006) showed an increased 
permeability to lactulose not only in long term or new onset T1D but also in first-degree relatives 
of T1D patients positives for two or more autoantibodies, demonstrating that an intestinal 
damage precedes the clinical onset of T1D. Nevertheless, it was not clear if autoimmune reaction 
could develop as a consequence of increased permeability to abnormally adsorbed dietary 
antigens or, rather, mucosal integrity could be compromised as an effect of inflammation 
associated to an immune mediated process. 
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Considering microbial species found and observed increased permeability in pre-T1D children, 
we evaluated the possible association between gut microbiota and gut integrity, comparing 
microbiological results with the clinical data related to the intestinal permeability. A significant 
correlation between the relative abundance of the three microbial markers, evaluated by PCR-
DGGE, and the increased intestinal permeability in children at risk of developing T1D was 
observed (Figure 3.5) (rho=0,542; p=0,011). 
In our study, also children with positivity to just one autoantibody, suggestive of a lower risk for 
diabetes onset, were included. Moreover, it is interesting to note that subjects showing the 
highest number of autoantibodies (Case #1 and #7) were the same with the highest intestinal 
permeability and almost all of the three microbial markers, whereas those with a lower extent of 
autoimmunity had a normal intestinal permeability and reduced microbial markers (Figure 3.5). 
Interestingly, the former had T1D onset a few months after participating in this study. 
These preliminary findings seem to support the hypothesis that increased permeability parallels 
the autoimmune process rather than being a consequence of the metabolic disorder, and that gut 
microbiota could have a certain influence in the development of the pathological state. 
Nevertheless, the exact role of gut bacteria in the development of the pathological state remains 
to be defined, since gut microbiota impairment could be either the cause or a consequence of 
leaky gut. 
The potential strengths of this study are: i.) all children participating in the study were living in 
the same area (Veneto region, North East Italy), eliminating the potential impact of geographic 
differences on microbiota composition; ii.) all children had their intestinal permeability and 
microbiota composition contemporaneously assessed. 
The study has also some potential limitations: i.) the sample size is relatively small. This is 
explained by the fact that only 25-30% of children, first degree relatives of patients with T1D 
followed in the Center for Pediatric Diabetes, accept to participate in screening programs to 
identify at risk subjects. The main reason is that, up to now, there are not effective therapies for 
stopping the autoimmune process leading to T1D and this discourages families to participate in 
the screening program. ii.) PCR-DGGE selected for microbial analyses, even though advantages 
like being inexpensive, its repeatability, the easy interpretation of the results, the ability to 
highlight the predominant species present in the microbial community and the ability to 
modulate the depth of the analysis by carefully selecting the primers, according to their 
specificity (Fraher et al., 2012), has a limited degree of discrimination at the specie level. 
However, in the specific case of this study, differences in microbiota components individuated 
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with PCR-DGGE were not confirmed using a most powerful analyses tool, as 16S rRNA gene 
profiling. These divergent results, obtained analyzing the same samples, underlined the need of 
applying more uniform protocols and approaches, also to allow the comparison of results from 
different studies. 
 
3.5. Concluding remarks 
In conclusion, Italian children with beta cell autoimmunity at risk for T1D have a different 
intestinal microbiota composition and a higher intestinal permeability than healthy children. 
Taking into consideration the evidence of microbiota variability among populations, an external 
validity of the results of this study is possible. Future studies are necessary to assess the potential 
effect of microbiota modifications on the process leading to increased permeability and/or 
autoimmune mechanisms promoting diabetes onset in order to develop possible therapeutic 
treatments. 
On the basis of the evidences that several disorders are linked to the intestinal microbiota, 
suppression of dysbiosis could represent an important clinical goal. Even though much 
fundamental research remains to be done, several promising potential therapeutic options have 
been proposed (Walker and Lawley, 2013). In particular for T1D, an intervention on the 
microbiota in the pre-pathological phase has the ambitious goal of delaying the diabetes onset or, 
at least, of improving the intestinal conditions of the subjects. The use of specific antibiotics or 
the application of a fecal transplant are two of the principal methods used to restore a healthy 
microbiota. Therefore, the most applicable method seems to be the modulation of the diet, also 
introducing a probiotic. In fact, probiotics are single (or defined mixtures of) microorganisms 
which probably exert their beneficial action through mechanisms of interaction/inhibition with 
gut microbiota, as well as stimulating the immune response (Corr et al., 2009; Reid et al., 2011). 
Several studies are already available on this topic (Bron et al., 2011) and the results on the actual 
effectiveness of probiotics on the treatment of T1D seem promising (Gomes et al., 2014; 
Dolpady et al., 2016). A better knowledge of gut microbial composition associated with the 
development of T1D is necessary to be able to choose the best treatment. 
 
 
 
The study was sponsored by the Department of Surgical Sciences, Dentistry, Gynecology, and 
Pediatrics and by the Department of Biotechnology, University of Verona.  
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Supplementary material 
Table S3.1. Summary of Cases characteristics: HLA genotypes, autoantibodies positivity, HbA1c%, 
lactulose:mannitol excretion ratio (LMR), and eventual T1D onset. HLA alleles associated with increased 
risk to T1D are in bold, whereas in italic are showed alleles with decreased risk. Values considered as 
pathological for LMR and calprotectin are in bold. Asterisk in Case 8 HbA1c indicates that value is not 
fully informative due to glucose-6-phosphate dehydrogenase deficiency. 
Cases 
(pre-T1D) 
T1D first-
degree 
relatives 
HLA  DQA1-DQB1 
(A1B1/A1B1) 
Autoantibody 
positive 
HbA1c % 
(mmol/mol) LMR 
T1D diagnosis 
(days after 
test) 
1 Yes 0301-0302 / 0501-0201 GAD, IA2, IAA 6,0 (42) 0,035 64 
2 No 0301-0302 / 0501-0201 GAD, IA2 5,4 (36) 0,022 - 
3 No 0102-0604 / 0201-0202 GAD 5,3 (34) 0,020 - 
4 No 0501-0201 / 0501-0201 GAD 5,8 (40) 0,023 - 
5 No 0303-0301 / 0303-0302 IAA 5,6 (38) 0,010 - 
6 Yes 0201-0202 / 03011-0302 IAA 5,8 (40) 0,027 - 
7 Yes 0301-0302 / 0501-0201 GAD, IA2, IAA 6,3 (45) 0,043 181 
8 No 0401-0402 / 0501-0201 GAD, IA2 5,4 (36)* 0,017 15 
9 Yes 0201-0202 / 0201-0303 GAD 5,3 (34) 0,020 - 
10 No 0101-0501 / 0301-0302 IAA 5,2 (33) 0,018 - 
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Chapter IV 
 
An in vitro study to investigate the effects of a new functional pasta 
and its ingredients on gut microbiota from children with different 
susceptibility to type 1 diabetes 
 
 
4.1. Introduction 
Diet is one of the key elements involved in the modulation of gut microbial composition (Scott et 
al., 2013). Diet can be intended at different levels, from dietary patterns (e.g. Western diet versus 
vegetarian diets), to specific foods (e.g. whole grain products) or certain food constituents (e.g. 
dietary fibres, fat or proteins (Graf et al., 2015), which have impact on the composition and 
activity of gut microbiota. Diet has an important role in the maintenance of a healthy condition 
or in specific disorders or pathologies (Conlon and Bird, 2015). To this aim, the development of 
functional foods, that include prebiotics or probiotics aimed to improve the health status through 
the modulation of gut microbiota, is a recent emerging area (Bosscher et al., 2009). 
In order to study the effects and properties of a new functional food on gut microbiota, and 
before the in humana trial step, a previous in vitro evaluation step could be useful to obtained 
preliminary information (Williams et al., 2015). The TNO in vitro model of the colon (TIM-2) 
(Minekus et al., 1999) is a system that accurately mimics the conditions in the human large 
intestine, being maintained under well defined controlled parameters (temperature, pH, 
anaerobiosis), and it can be inoculated with fecal material from subjects of interest. It represents 
a powerful tool to study the effects of the administration of different substrates on the gut 
microbiota, under standardised conditions (Venema et al., 2000). 
Analyses of microbiota composition trough 16S gene DNA profiling is a common strategy to 
investigate modulations in microbial communities (Fraher et al., 2012). Moreover, analyses of 
produced metabolites can give complementary information about the effect of the administration 
of a given treatment on gut microbiota In particular, short chain fatty acids (SCFA) derived from 
undigested carbohydrates that are fermented by the microbiota in the large intestine. SCFA, i.e. 
acetate, propionate and butyrate, can exert different effects on the host (Den Besten et al., 2013) 
and, for example, among key functions, they represent a source of energy for the host (Bergman, 
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1990). In particular, butyrate is considered the energy source for the colonic epithelial cells (Roy 
et al., 2006) and it is considered a beneficial metabolite thanks to its role in modulating the 
intestinal barrier and to its anti-inflammatory properties (Pryde et al., 2002; Brown et al., 2011). 
In a previous study, a novel whole grain functional pasta, enriched in a probiotic bacterium 
Bacillus coagulans GBI-30, 6086 (thereafter BC30) and β-glucans from barley was developed 
(Fares et al., 2015). The effects of the ingestion of the functional pasta on the gut microbiota is 
not known, yet. However, some information about the effects of the functional ingredients, B. 
coagulans BC30 and β-glucans, are available. β-glucans are reported to have prebiotic properties, 
leading to the stimulation of specific bacterial genera (e.g. Lactobacillus, Bifidobacterium) as 
reported in in vitro studies (Hughes et al., 2008; Kedia et al., 2009) or in humana (Mårtensson et 
al., 2005; Mitsou et al., 2010). On the contrary, the effects of the probiotic strain on gut 
microbiota has been evaluated in few studies (Honda et al., 2011; Nyangale et al., 2014; 
Nyangale et al., 2015). Furthermore, also the whole dietary fibre included in the functional pasta 
could be active in the modulation of resident microbiota (Portune et al., 2017). 
Type 1 diabetes (T1D) is an autoimmune disorders that causes the destruction of pancreatic β-
cells; in T1D a dysbiosis condition has been reported in association to the development of the 
pathology. Differences in microbiota composition among children with the pathology and 
healthy children were reported in several case-control studies (Giongo et al., 2011; Murri et al., 
2013), and, moreover, differences were reported also for children in the condition of pre-diabetes 
(de Goffau et al., 2013; Davis-Richardson et al., 2014; Maffeis et al., 2016). Regarding the use 
of intervention studies aimed at modulating gut microbiota in T1D subjects, few studies are 
available. In particular, the role of probiotics in T1D condition has been studied in animal 
models (Gomes et al., 2014), but not in humana. Moreover, no data about the use of prebiotics 
for the modulation of gut microbiota in children with T1D is available, but a study protocol has 
been recently published to assess the effect of prebiotic intake on gut microbiota, intestinal 
permeability and glycemic control in children with T1D (Ho et al., 2016). 
Here, an in vitro study with the TIM-2 model was carried out to evaluate the effects of the new 
functional pasta and its functional ingredients on the gut microbiota coming from children with 
different susceptibility to T1D, i.e. healthy, pre-diabetic and diabetic children. The functional 
ingredients investigated were the probiotic strain B. coagulans BC30 and β-glucans, tested 
separately or in combination; then, the functional pasta containing both the functional 
ingredients, the pasta enriched with only B. coagulans BC30, and a control pasta without the two 
considered ingredients were examined. The investigation of gut microbiota was performed 
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through 16S rRNA gene profiling for determining composition, and gas chromatography for 
determining short chain fatty acid (SCFA) production, respectively. In particular, to reveal 
relationship between dietary interventions and gut microbiota modulation, bacterial diversity 
within and among samples, and inference of the metabolic capabilities associated with the 
bacterial microbiome of the three groups of children following each of the tested treatments were 
investigated. Finally, results from microbiota composition analyses and metabolites were 
merged. 
 
4.2. Materials and Methods 
Intervention meals and SIEM control 
A standard ileal efflux medium (SIEM) was used as a control. The composition of this medium 
was partially modified from previous descriptions (Gibson et al., 1988; Maathuis et al., 2009). 
Briefly, it contains TBCO [mixture of Tween 80 (33.4 g/L), casein (46.5 g/L), bactopeptone 
(46.5 g/L), and ox bile (0.8 g/L)], CHO [mixture of pectin (5.9 g/L), xylan (5.9 g/L), 
arabinogalactan (5.9 g/L), amylopectin (5.9 g/L) and starch (49.6 g/L)]. 
To this standard medium, the specific ingredients of interest were added and in particular: a 
freeze-dried preparation of Bacillus coagulans GBI-30, 6086 (BC30) (Ganeden, Mayfield 
Heights, OH, USA), in a dose of 1010 CFU/day, β-glucans (purity > 94%) (Megazyme, Bray, 
Ireland) in a dose of 4 g/day, the combination of BC30 and β-glucans (1010 CFU/day and 4 g/day, 
respectively), a simulated pasta enriched with the probiotic strain, obtained from the control 
pasta (about 27 g/day) to which the probiotic strain (1010 CFU/day) was added, the whole grain 
control pasta (about 27 g/day), the functional pasta (Fares et al., 2015) (about 27 g/day). Pasta 
samples were previously cooked in water with 1% NaCl added, and subsequently homogenised 
with a domestic blender. Regarding the meal with the functional pasta, it was diluted with water 
(50:50) in order to avoid problems due to the high viscosity of the medium, and the same was 
done also on an aliquot of the meal containing the control pasta. Finally, these two diluted meals 
included an amount of pasta of about 13.5 g/day. 
 
Microbiota origin and preparation of fecal homogenates 
Two healthy children, two children at risk for T1D diabetes and two children with T1D were 
recruited at the Regional Center for Pediatric Diabetes, Department of Surgical Sciences, 
Dentistry, Gynecology and Pediatrics, University of Verona. They participated to the previous 
study described in Chapter 3 (Maffeis et al., 2016), and in particular they represented Controls 
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C1 and C2, and Cases P1, P3, P6 and P7 of that research. In particular, Cases P1 and P7 
manifested T1D onset some months after the study. All children had not used antibiotics, 
prebiotics, or probiotics for at least 3 months prior to the donation. 
Fresh fecal samples were collected by parents in a closed box with an anaerobic strip 
(AnaeroGen, Oxoid, Cambridge, UK), and delivered to the laboratory where they were snap-
frozen in liquid nitrogen and stored at -80°C. After thawing, microbiota for each couple of 
children (healthy, pre-diabetic and diabetic) was pooled in an anaerobic cabinet. In particular, 
fecal donations were diluted in a ratio 1:1 in a physiological saline preparation/dialysate (content 
per litre: 2.5 g K2HPO4·3H2O, 4.5 g NaCl, 0.005 g FeSO4·7H2O, 0.05 g ox-bile), glycerol was 
added (10% w/w) as a cryoprotective agent, and this mix was homogenized with a Turrax (IKA 
Ultra turrax T25 digital, Staufen, Germany). Aliquots of the fecal homogenates were snap-frozen 
in liquid nitrogen and stored at -80°C till use. Before being introduced into the system, the 
homogenate was thawed through 1 h immersion in a 37°C water bath. 
 
TIM-2 experiments 
The TIM-2 system (Figure 4.1) has been previously described in details (Maathuis et al., 2009). 
Briefly, the system was kept in anaerobic condition by flushing with nitrogen (Figure 4.1f), 
maintained at 37°C, monitored by a temperature sensor (Figure 4.1j), and the pH was kept at 5.8 
through automatic titration with 2M NaOH (Figure 4.1c). A luminal content of approximately 
120 ml was maintained constant and monitored through a level sensor (Figure 4.1e), and 
peristaltic movements were performed regularly (Figure 4.1a). All parameters were computer-
controlled. 
A dialysate system consisting of a semi-permeable hollow membrane ran through the lumen, in 
order to remove water and fermentation products from the lumen (Figure 4.1d). A dialysate 
solution was flushed through this membrane at a speed of 1.5 ml/min, and it consisted in the 
physiological saline preparation described in the microbiota section, plus MgSO4·H2O (0.5 g/L), 
CaCl2·2H2O (0.45 g/L), cysteine hydrochloride (0.4 g/L), and 0.1% of a vitamine solution 
containing menadione (1 mg/L), D-biotin (2 mg/L), vitamin B12 (0.5 mg/L), pantothenate (10 
mg/L), nicotinamide (5 mg/L), p-aminobenzoic acid (5 mg/L), and thiamine (4 mg/L). 
At the beginning of each experiment, about 60 ml of fecal homogenate were inoculated in the 
system together with 60 ml of dialysate, in order to obtain a final volume of approximately 120 
ml. After the inoculation of the microbiota, the previously described SIEM medium was 
administered to the system for the following 16-hours (adaptation period). After that, the 
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microbiota was deprived of any medium for 2 hours (starvation) in order to let it consume the 
substrates received previously. After this starvation period, the meal of interest was 
administrated to the microbiota, during the following 72 hours. 
 
Figure 4.1. Schematic representation of TIM-2 model (from Hatanaka et al., 2012). a) peristaltic 
compartments containing faecal homogenate, b) pH sensor,  c) NaOH secretion, d) dialysate system, e) 
level sensor, f) nitrogen inlet, g) sampling port, h) gas outlet, i) test compound/SIEM feeding syringe, j) 
temperature sensor. 
 
The tested meals or the control SIEM medium were gradually introduced into the system through 
a feeding syringe (Figure 4.1i). In particular 60 ml of the SIEM medium were introduced in the 
system in the 16-hours adaptation period, while 270 ml of the control SIEM or of a certain tested 
meal were introduced in the following 72-hours, at a rate of 0.067 ml/min.  
Samples from the lumen (Figure 4.1g) and dialysate (Figure 4.1d) were collected at the end of 
the starvation period (time 0 hours), and after 24, 48 and 72 hours from the beginning of the 
treatment with the meal of interest (time 24 hours, time 48 hours and time 72 hours, 
respectively). Samples were analysed for SCFA production at each time point, while they were 
analysed for microbiota composition at time 0 hours and time 72 hours. 
 
SCFA analyses 
SCFA were analysed on a TRACE GC Ultra Gas Chromatograph system coupled with a FID 
detector (Interscience, Breda, the Netherlands), as described in details by Ladirat and colleagues 
(2014). Brieﬂy, 50 l of samples or standards were mixed with 50 l of 0.15 M oxalic acid; after 
30 min, 150 l water was added and 1 l of the sample was analysed. 
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Microbiota analysis 
Genomic DNA isolation from TIM-2 samples was done using standard molecular biology kits 
from ZYMO Research provided by Baseclear (Leiden, the Netherlands). PCR amplification of 
the 16S rRNA gene (V3-V4 region), barcoding and library preparation were performed by 
BaseClear. Short paired-end sequence reads were generated using the Illumina MiSeq system 
and converted into FASTQ files using the BCL2FASTQ pipeline version 1.8.3. Quality trimming 
was applied based on Phred quality scores. Subsequently sequences were analyzed using the 
QIIME-pipeline.  
 
Data analyses and presentation 
All experiments were performed in duplicate (n=2); in fact, it was previously shown that the 
number of replicates can be confined to two, since the experiments are highly reproducible, 
thanks to the fact that conditions are strictly controlled through the computer-connected system, 
and to the use of a standardized microbiota (Venema et al., 2000). Results are presented as 
average of duplicates. Regarding microbiota composition, for comparative analyses of the 
samples at the genus and species levels, thresholds of 1% and 0.1% with respect to the total 
composition were used, respectively. Modulation was calculated and expressed as the difference 
between the abundances of a given microbial group, at time 72 hours and time 0 hours (Δ 72h-
0h), further normalised for the difference (Δ 72h-0h) of the control meal; in particular Δ 72h-0h 
of the control meal was subtracted to Δ 72h-0h of the treatment of interest. Regarding SCFA 
production, the concentration of metabolites at time 0 hour was set to zero. In comparing relative 
SCFA production (acetate, propionate or butyrate in a same experiment) a difference equal or 
above 25 mmol was set as a threshold to define the predominance of a metabolite with respect to 
another. In merging microbiota composition and SCFA production, the increases in SCFA (Δ 
72h-0h) were compared with increases in composition (Δ 72h-0h); in this specific case, increases 
in composition were not further normalised for the control meal. 
 
4.3. Results and discussion 
Microbiota composition 
Analyses at the beginning of the in vitro interventions 
A first investigation was performed on the microbiota from the three groups of children (healthy, 
pre-diabetic and diabetic children) at the beginning of the in vitro experiments (time 0 hours), i.e. 
after the 16 hour-adaptation period and the 2 hour starvation period in the TIM-2 model. 
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Analyses were initially performed at the genus level, and expressed, for each of the three groups, 
as average of the profiles obtained in the replicates (Figure 4.2). 
 
Figure 4.2. Average compositions at the genus level of the microbiota from healthy (H; n=16), pre-
diabetic (P; n=15) and diabetic (D; n=18) children at the beginning of the in vitro fermentations (time 0 
hours). 
 
Results at this time point showed that the microbiota of the three groups of children exhibited 
differences in the composition, in terms of presence and/or abundances of different genera. 
Bacteroides and Bifidobacterium were present in the microbiota from the healthy children 
(healthy microbiota) at low ratios (9% and 20% of the total microbiota, respectively), and they 
were higher in microbiota from pre-diabetic children (pre-diabetic microbiota) (12% and 35%) 
and further more in the microbiota from diabetic children (diabetic microbiota) (24% and 41%), 
compared to the healthy microbiota. On the contrary, the genus Gemmiger was present in high 
proportion in the healthy microbiota (28%) and in low proportion in the diabetic microbiota 
(6%). Also Faecalibacterium was found at high levels in the healthy microbiota (18%) and it 
was lower in pre-diabetic (11%) and diabetic microbiota (5%). Differences in average 
abundances of the genus Collinsella were also observed (10% in the healthy microbiota, 18% in 
the pre-diabetic microbiota, 7% in the diabetic microbiota). Moreover, Ruminococcus was 
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present in healthy and pre-diabetic microbiota (4% and 7%), Dorea in pre-diabetic microbiota 
(5%) and Clostridium (6%) and Eubacterium (9%) in the diabetic microbiota. 
At the species level, different microorganisms appeared to be statistically associated with one of 
the microbiota from the three children groups. Among these, four microorganisms were 
markedly associated to the healthy or pre-diabetic or diabetic microbiota. In particular, 
Gemmiger formicilis and Faecalibacterium prausnitzii resulted associated to the healthy 
microbiota, while Bacteroides vulgatus and Bifidobacterium adolescentis appeared 
characteristics of both the pre-diabetic and diabetic microbiota. Faecalibacterium prausnitzii is 
notably recognized as a microorganism associated with a healthy condition (Miquel et al., 2014); 
moreover, both G. formicilis and F. prausnitzii are butyrate producers (Gossling and Moore, 
1975; Duncan et al., 2002); thus, the fact that these two species, that present beneficial 
characteristics, were found in the microbiota from healthy children, was in agreement with what 
expected. Bacteroides vulgatus, that resulted at higher levels in pre-diabetic and diabetic 
microbiota, was already reported as associated to pathologic conditions (Finegold et al., 2010). 
Interestingly, also B. adolescentis, belonging to a genus traditionally considered as beneficial, 
was found at high levels in pre-diabetic and diabetic microbiota. However, B. adolescentis was 
reported as associated to other diseases, such as allergies, IBS, asthma (Sánchez et al., 2010; 
Arboleya et al., 2016). 
 
Analyses after the 72 h in vitro interventions 
Firstly, modulations due to the tested treatments were analysed in each of the three microbiota 
(healthy, pre-diabetic and diabetic), after normalisation with respect to the effects observed for 
the control meal. 
In the healthy microbiota, eighteen genera resulted modulated after the interventions with the 
different treatments (Figure 4.3). 
Different bacterial groups were decreased, compared to the SIEM control, after treatment with 
every intervention tested. In particular, Bacteroides, Collinsella and Gemmiger showed marked 
decreases, while Dialister and Oscillospira exhibited a decrease of less than 5%. 
In the perspective of unravelling a direct relationship diet-microbiota, the focus was mainly on 
bacterial groups that resulted increased after treatment with a specific diet. Thus, 13 genera were 
individuated as positively modulated in the healthy microbiota, which are reported in Table 4.1a. 
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Most remarkable modulations (increases above 5%) were related to the genera Bifidobacterium, 
Blautia, Eubacterium, Faecalibacterium, Fusicatenibacter, Lactobacillus, Prevotella and 
Ruminococcus. 
 
 
Figure 4.3. Modulations of microbial genera after 72 hour-fermentations with the different dietary 
treatments, on the microbiota from healthy children. 
 
Regarding these most relevant modulations, a massive increase in Bifidobacterium was shown 
after administration of pasta with BC30 added and control pasta, and a remarkable increase was 
also observed after treatment with BC30, and β-glucans. The second most relevant increase was 
observed for Prevotella, that markedly responded to the interventions with the diluted control 
and functional pasta.  
Blautia increased after administration of β-glucans, while Eubacterium increased after the 
combination of BC30 and β-glucans, and the functional pasta. Faecalibacterium was positively 
modulated by BC30 and the diluted functional pasta, and Fusicatenibacter was increased after 
treatment with BC30, BC30+β-glucans and the diluted functional pasta. Interestingly, 
Lactobacillus increased after administration of BC30+pasta. Finally, an increase in Ruminococcus 
was observed after treatment with the diluted control pasta. 
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These experiments with TIM-2 model allowed to explore the effects of the administration of the 
functional pasta and to compare them with the effects due to its functional ingredients, in order 
to investigated the contribution of each ingredient in the final effect observed for the functional 
pasta. In the healthy microbiota the diluted functional pasta caused remarkable increases in 
Eubacterium, Faecalibacterium, Fusicatenibacter, and Prevotella. Considering 
Fusicatenibacter, which increased after BC30, BC30+β-glucans and the diluted functional pasta 
treatments, but not after β-glucans or high concentrations of starch, it was possible to suppose 
that the increase in this genus could be attributed to the probiotic strain. In the same way, the 
increase in Eubacterium in the functional pasta, and in the combination of BC30+β-glucans 
appeared to be attributed mostly to the probiotic strain, as it was observed also with respect to  
the increase in Faecalibacterium. Thus, in the healthy microbiota the probiotic strain appeared to 
promote the growth of Fusicatenibacter, Faecalibacterium and Eubacterium. In particular, 
increases in Faecalibacterium and Eubacterium could represent beneficial effects of the 
functional pasta. Finally, the growth of Prevotella after administration of the functional pasta 
could be attributed to the diluted starch, and also to the two functional ingredients. 
Regarding pre-diabetic microbiota, sixteen genera were observed to be modulated by the tested 
treatments (Figure 4.4). Some of the groups were modulated in the same way for each 
treatments, i.e. Collinsella, and Gemmiger were always decreased. The 14 genera that resulted 
increased after the treatments with the nutritional intervention were reported in Table 4.1b. 
Most important modulations involved genera Bacteroides, Bifidobacterium, Blautia, 
Eubacterium, Lactobacillus, Prevotella and Ruminococcus. 
Again, the most relevant modulation was that related to genus Bifidobacterium, markedly 
increased after treatment with the highest doses of starch (control pasta and pasta added with 
BC30), followed by treatments with the diluted functional pasta and with BC30+β-glucans. 
Another modulation particularly pronounced was the increase of Lactobacillus after 
administration of BC30+pasta, as already observed in a minor extent in the healthy microbiota.  
Bacteroides resulted mainly increased after treatment with β-glucans and the diluted functional 
pasta. Blautia levels increased primarily after administration of BC30, β-glucans, and BC30+β-
glucans, while Eubacterium increased after treatment with β-glucans, and BC30+β-glucans. 
Prevotella and Ruminococcus levels resulted increased after intervention with BC30 and the 
diluted control pasta, and Ruminococcus, resulted increase also due to the functional pasta. 
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Figure 4.4. Modulations of microbial genera after 72 hour-fermentations with the different dietary 
treatments, on the microbiota from pre-diabetic children. 
 
The intervention with the functional pasta led to increases in the genera Bacteroides, 
Bifidobacterium, and Ruminococcus. With the intent to relate effects of the functional pasta with 
effects of its ingredients, increase in Bacteroides appeared to be mainly attributed to β-glucans. 
The strong increase in Bifidobacterium could be caused by the starch, even if a minor 
bifidogenic potential was presented also by the two functional ingredients. Increase in 
Ruminococcus levels could be attributed both to the probiotic strain and the diluted starch. 
Regarding diabetic microbiota, 19 genera appeared to be modulated after treatment with the 
different interventions (Figure 4.5), five of which decreased, namely Coprococcus, Dialister, 
Faecalibacterium, Lachnoclostridium and Oscillospira. 
The 14 increased genera were reported in Table 4.1c. Also in the case of diabetic microbiota, the 
most modulated genus was Bifidobacterium, which markedly increased after administration of 
all tested interventions, and in particular of the control pasta and the pasta added with the 
probiotic strain. Also Collinsella was positively modulated by almost every treatment, with the 
highest increase observed after administration of BC30+pasta. 
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Figure 4.5. Modulations of microbial genera after 72 hour-fermentations with the different dietary 
treatments, on the microbiota from diabetic children. 
 
Lactobacillus was increased also in this case after treatment with the pasta with probiotic strain 
added, together with Anaerococcus. Bacteroides and Clostridium were increased after treatment 
with the diluted functional pasta. Other minor modulations involved increases in Blautia, 
following β-glucans intervention, Eubacterium, after BC30+β-glucans administration,  
Gemmiger, with BC30 and the diluted control pasta, Roseburia, with BC30.  
In diabetic microbiota, the treatment with the functional pasta led to increases in Bacteroides, 
Bifidobacterium, Clostridium and Collinsella. Increases in Bacteroides and Clostridium did not 
appear to be directly related to one of the pasta components. Referring to Bifidobacterium, each 
ingredient of the pasta, i.e. the probiotic strain, the β-glucans and the starch, had a strong 
bifidogenic effect. Also for Collinsella, from the same family Actinobacteria, each component 
appeared to contribute to the increase observed for the functional pasta. 
 
Results of in vitro fermentations gave a broad range of information regarding modulation of 
specific microbial groups following the different nutritional intervention. In many cases a 
specific treatment led to different responses in the microbiota of the three groups, i.e. different 
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patterns of microbial genera were increased in a specific microbiota (healthy, pre-diabetic, and 
diabetic), but not in another. For example, Fusicatenibacter increased after administration of the 
probiotic strain in the healthy microbiota, but not in the pre-diabetic or in the diabetic ones. This 
can be due to differences in the composition of the three microbiota at the baseline of the 
experiments, which led to alternative cross-feeding. 
 
With respect to the microorganism that appeared related the healthy microbiota (i.e. Gemmiger 
formicilis and Faecalibacterium prausnitzii) and to the pre-diabetic and diabetic ones 
(Bacteroides vulgatus and Bifidobacterium adolescentis) at the beginning of the in vitro 
experiments, a positive output of a treatment could be the increase in a biomarker characteristic 
of the healthy state or a decrease in a biomarker considered as associated to a pre-pathological or 
pathological conditions. G. formicilis resulted decreased following almost every treatment in the 
healthy, pre-diabetic and diabetic microbiota. The exceptions were represented by the probiotic 
strain BC30 and the diluted control pasta, that led to an increase in this microbial species in the 
diabetic group. Regarding F. prausnitzii, in the healthy microbiota it resulted increased following 
intervention with the probiotic strain BC30 and the functional pasta, while in the pre-diabetic 
microbiota, an increase in this species was observed after administration of the functional pasta. 
In diabetic microbiota F. prausnitzii did not increase following any of the treatment. 
Regarding the species that at the beginning of the in vitro study resulted associated to the pre-
diabetic and diabetic microbiota, treatments leading to a decrease in B. vulgatus, that could 
represent a positive effect, were the control pasta in the healthy and diabetic microbiota, and the 
probiotic strain in the diabetic microbiota; in pre-diabetic microbiota all treatments led to an 
increase in this species (data not shown). Finally, regarding B. adolescentis, most of the 
treatment caused an increase in this species. Among these, treatments with the highest doses of 
starch, and most of all the control pasta caused the major increases. The pasta enriched with the 
probiotic strain led to a different effect in the pre-diabetic and diabetic microbiota; this aspect 
will be further discussed later. Overall, these results indicated that some treatments (e.g. the 
probiotic strain, the functional pasta), more than others (e.g. β-glucans, BC30+β-glucans) could 
promote the growth of the markers of the healthy condition or the decrease of the markers related 
to the pre-pathological/ pathological status. However, in most cases results were microbiota-
dependent.  
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Table 4.1. Modulations of microbial genera following the different in vitro interventions; a) microbiota from healthy children, b) microbiota from pre-diabetic 
children, c) microbiota from diabetic children. 
 
 a. 
HEALTHY Anaerostipes Bifidobacterium Blautia Eubacterium Faecalibacterium Fusicatenibacter Lactobacillus Lactococcus Pediococcus Prevotella Roseburia Ruminococcus Weissella 
BC30   ↑ 17.9% (↑) 1.0% (↑) 1.3% ↑ 7.4% ↑ 10.5%   (↑) 1.2%   ↑ 9.9%   (↑) 1.9%   
β-glucans   ↑ 12.7% ↑ 13.9%         (↑) 2.6%   ↑ 7.2% (↑) 2.9%   (↑) 2.7% 
BC30+  
β-glucans   (↑) 3.1% (↑) 1.8% ↑ 10.4%   ↑ 11.6%     (↑) 2.9% ↑ 8.8% (↑) 1.6%   (↑) 1.2% 
BC30+pasta (↑) 1.0% ↑↑↑ 60.6%   (↑) 1.0%     ↑ 9.0%             
Control pasta (↑) 2.5% ↑↑↑ 68.5%           (↑) 3.5%           
Dil. 
functional 
pasta 
      ↑ 5.6% ↑ 9.5% ↑ 11.4%       ↑↑ 22.7%   (↑) 1.5%   
Dil.  
control pasta           (↑) 1.0%       ↑↑↑ 61.3%   ↑ 10.5%   
 
 b. 
PRE- 
DIABETIC Bacteroides Bifidobacterium Blautia Catenibacterium Dorea Eubacterium Faecalibacterium Fusicatenibacter Lactobacillus Lactococcus Pediococcus Prevotella Roseburia Ruminococcus 
BC30 ↑ 5.1% (↑) 4.0% ↑ 15.4%   (↑) 1.4%             ↑↑ 22.5% (↑) 2.7% ↑ 7.5% 
β-glucans ↑ 14.7% ↑ 9.2% ↑ 17.3% (↑) 1.9% (↑) 2.4% ↑ 10.5%                 
BC30+  
β-glucans (↑) 3.8% ↑ 19.1% ↑↑ 23.3% (↑) 3.7%   ↑ 14.8%         (↑) 1.1%       
BC30+pasta ↑ 9.0% ↑↑ 48.8%     (↑) 3.8%       ↑↑ 32.6% (↑) 3.4%         
Control pasta   ↑↑ 51.3%       ↑ 5.0%   (↑) 2.3%             
Dil. functional 
pasta ↑ 17.7% ↑↑ 32.2% (↑) 4.2%   (↑) 2.8%   (↑) 2.7%             ↑ 7.8% 
Dil. control 
pasta ↑ 6.5%   (↑) 1.0%     (↑) 2.0%           ↑ 11.7%   ↑ 17.1% 
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 c. 
DIABETIC Anaerococcus Bacteroides Bifidobacterium Blautia Clostridium Collinsella Eubacterium Fusicatenibacter Gemmiger Lactobacillus Lactococcus Pediococcus Roseburia Ruminococcus 
BC30     ↑↑ 30.8%     ↑ 13.9%     ↑ 4.9%       ↑ 7.4%   
β-glucans     ↑↑ 48.0% ↑ 6.8%   ↑ 8.9%           (↑) 4.3%     
BC30+  
β-glucans     ↑ 17.6%     ↑ 11.6% ↑ 4.9%               
BC30+pasta (↑) 4.5%   ↑↑↑ 65.0%     ↑↑ 24.3%       ↑ 7.4% (↑) 1.8%       
Control pasta     ↑↑↑ 90.7%                       
Dil. functional 
pasta   ↑ 14.8% ↑↑ 46.6%   ↑ 5.5% ↑ 4.9%                 
Dil. control 
pasta     ↑↑ 39.1%     ↑ 13.5%   (↑) 1.3% ↑ 7.3%         (↑) 1.4% 
Modulations for a specific microbial group are indicated in the table if the difference in abundance (Time 72h-Time 0h), normalised to the control meal, is close 
to or > 1%. 
(↑) increase corresponding to a value <5%. 
↑ increase corresponding to a value between 5% and 20%. 
↑↑ increase corresponding to a value between 20% and 60%. 
↑↑↑ increase corresponding to a value > 60%.  
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Shared effects of the ingredients and pasta on certain bacterial groups in the different 
microbiota 
As reported previously, many of the tested diets led to modulations that were microbiota-
dependent. On the contrary, interestingly, some of the nutritional interventions led to 
modulations of specific microbial groups, that were shared in the healthy, pre-diabetic and 
diabetic microbiota or in two of them. In particular, modulations shared in the three microbiota 
resulted the most interesting, because particularly informative of the effects of a certain dietary 
intervention. 
Bacillus coagulans BC30 appeared to have a bifidogenic effect, that was much more pronounced 
on healthy (17.9%) and diabetic microbiota (30.8%) than the pre-diabetic one (4.0%) (Figure 
4.6a). In healthy and pre-diabetic microbiota, BC30 markedly increased Prevotella levels (9.9% 
and 22.5%, respectively), and to a minor extent, Ruminococcus levels (1.9% and 7.5%, 
respectively). Finally, increases of Roseburia were observable after administration of the 
probiotic strain to the pre-diabetic and diabetic groups (2.7% and 7.4%). β-glucans, also, had a 
marked effect on Bifidobacterium, on the healthy, pre-diabetic and diabetic microbiota (12.7%, 
9.2% and 48.0%) (Figure 4.6b). Moreover, a shared effect on the three microbiota was observed 
regarding increases of Blautia (13.9%, 17.3%, 6.8%). When Bacillus coagulans BC30 and β-
glucans were administered together, increases in Bifidobacterium were observed for the three 
microbiota (3.1%, 19.1% and 17.6%) , together with increases in Eubacterium (10.4%, 14.8% 
and 4.9%) (Figure 4.6c). Increases of Blautia and Pediococcus were observed in healthy and pre-
diabetic group (1.8% and 23.3% for Blautia, 2.9% and 1.1% for Pediococcus). 
Thus, after the intervention with the two functional ingredients, BC30 and β-glucans, 
administered separately or in combination, an increase in Bifidobacterium was observed in the 
three microbiota. If a bifidogenic effect was already known for β-glucans, in vitro (Hughes et al., 
2008; Kedia et al., 2009) and in humana (Mårtensson et al., 2005; Mitsou et al., 2010), this 
effect was not reported for the probiotic strain BC30 in previous studies (Honda et al., 2011; 
Nyangale et al. 2015). Regarding the increase in Blautia observed after administration of β-
glucans, a previous in humana study showed an increase in this genus following ingestion of a 
whole grain barley flakes containing a high amount of β-glucans (14.1%) (Martínez et al., 
2013a). Another interesting trend observed in the three microbiota was the increase in 
Eubacterium spp., and in particular in Eubacterium rectale, after the administration of BC30+β-
glucans. In the healthy microbiota, increases in Eubacterium appeared to be due mainly to the 
probiotic strain, while in the pre-diabetic microbiota the effect could be attributed to the β-
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glucans; in the diabetic microbiota no direct connection with one of the two functional 
ingredients was observed. An increase in E. rectale after combined administration of the 
probiotic strain BC30 and a probiotic (i.e. FOS o GOS) has been previously reported in literature 
(Nyangale et al., 2014). 
The pasta with added BC30 led to a marked increase of Bifidobacterium (60.6%, 48.8% and 
65.0%), and interestingly also Lactobacillus was increased after this nutritional treatment in the 
three microbiota (9.0%, 32.6% and 7.4%). Lactococcus resulted increased in pre-diabetic and 
diabetic microbiota (3.4% and 1.8%) (Figure 4.7a). Also the control pasta, as previously reported 
had a strong bifidogenic effect in the three microbiota (68.5%, 51.3% and 90.7%). (Figure 4.7b). 
Thus, the most relevant modulation after administration of the pasta added with the probiotic 
strain and the control pasta (i.e. treatment with the highest doses of starch) was the marked 
growth in Bifidobacterium. Increases in Bifidobacterium population after administration of starch 
was previously reported in literature (Liu et al., 2015). Moreover, the enormous increase in 
Bifidobacterium observed with these diets could have been amplified from the fact that 
investigated pasta were whole grain products. Examples of bifidogenic effect of whole grain 
cereal products from wheat (Costabile et al., 2008), or other cereal, e.g. maize (Carvalho-Wells 
et al., 2010) have been reported in literature; in these studies the bifidogenic effects obtained 
from WG products were more pronounced to that observed with the control, i.e. non-whole grain 
cereals. At the species level, evidences from literature reported that a certain species, B. 
adolescentis, is reported to increase following administration of starch, in particular R2 and R4 
type starch (Martínez et al., 2010; Venkataraman et al., 2016). In the present study, increases in 
B. adolescentis were observed after administration of the pasta enriched with the probiotic strain 
in the healthy microbiota, and of the control pasta in the healthy, pre-diabetic and diabetic 
microbiota. However, this species was not the only species involved in the massive increased 
observed for Bifidobacterium genus, as further explained in the following paragraph. 
At the end of the in vitro interventions Bifidobacterium represented the dominant population 
(>50% of the total population) (data not shown). It has to be considered that such a high increase 
in this microbial genus may be less pronounced in vivo, due to the fact that  the children would 
have a varied diet; thus, the bifidogenic effect of these meals could be exaggerated in TIM-2. 
Another very interesting aspect was the increase in Lactobacillus spp. in the three microbiota, 
following administration of the pasta added with the probiotic strain. Since this effect was not 
observed after treatment with the control pasta, it appeared to be related to the presence of the 
probiotic strain; in any case, Lactobacillus was not increased after treatment with BC30 alone, so 
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probably, the stimulation of this genus was due to the synergistic effect of the starch and the 
probiotic strain. This aspect will be further discussed in the following paragraph. 
Different modulations were obtained for the functional pasta. An increase in Bacteroides was 
observed for the pre-diabetic and diabetic microbiota (17.7% and 14.8%) as well as an increase 
in Bifidobacterium was observed for the same microbiota (32.2% and 46.6%). Faecalibacterium 
was increased in healthy and pre-diabetic groups (9.5% and 2.7%) and the same was for 
Ruminococcus (1.5% and 7.8%) (Figure 4.7c). 
The diluted control pasta, which presented a lower dose of starch with respect to the control 
pasta, had an effect on healthy and pre-diabetic microbiota on Prevotella (61.3% and 11.7%) and 
Ruminococcus (10.5% and 17.1%); Ruminococcus levels were also slightly increased in the 
diabetic microbiota (1.4%) (Figure 4.7d). In particular, the species Ruminococcus bromii was 
responsible of the increase observed for Ruminococcus genus after administration of starch. This 
result was consistent with previous findings that indicated R. bromii as a key species in the 
degradation of resistant starch type 3 in the human colon (Walker et al., 2011; Ze et al., 2012). 
Increases in this microbial genus or species were not observed after the administration of higher 
doses of starch, i.e pasta enriched with the probiotic strain and control pasta, probably because of 
the massive increase in Bifidobacterium spp. 
In conclusion, in the analysed microbiota, interventions with tested treatments resulted in 
modulations of microbial taxa that are consistent with previous literature about specific diet-
microbial group relationship. Furthermore, in general, certain tested treatments led to positive 
modulations of bacterial groups that are considered as beneficial at the gut microbiota level, in 
term of healthy promoting organisms (i.e. Bifidobacterium and Lactobacillus spp.), and 
producers of beneficial metabolites, as butyrate (i.e. Eubacterium rectale, Roseburia and F. 
prausnitzii).
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Figure 4.6. Modulations of microbial genera after 72 hour-fermentations with a) the probiotic strain BC30 b) the β-glucans and c) the probiotic strain BC30 +β-
glucans, on the microbiota from healthy (in green), pre-diabetic (in yellow) and diabetic (in red) children. 
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Figure 4.7. Modulations of microbial genera after 72 hour-fermentations with a) the pasta enriched with the probiotic strain BC30, b) the control  pasta, c) the 
functional pasta and d) the diluted control pasta, on the microbiota from healthy (in green), pre-diabetic (in yellow) and diabetic (in red) children. 
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Analyses at the species level for Bifidobacterium genus following treatment with the highest 
concentration of starch 
Given the differences in Bifidobacterium abundances at time 0 hours in the healthy, pre-diabetic 
and diabetic microbiota, and in particular considering that B. adolescentis was observed to be 
characteristic of the pre-diabetic and diabetic group, it was interesting to investigate 
Bifidobacterium at the species level following treatments that caused the most marked increase 
in this microbial genus (control pasta and pasta added with BC30) in order to understand which 
species were stimulated from the treatments. 
 
 
 
Figure 4.8. Bifidobacterium species at the beginning (time 0 hours) and at the end (time 72 hours) of the 
intervention with the probiotic pasta and the control pasta, on the microbiota from healthy (H), pre-
diabetic (P) and diabetic (D) children.  
 
Analyses at the beginning (time 0 hours) and at the end (time 72 hours) of the nutritional 
treatments with these two pastas showed that four species were mainly involved in the massive 
increase of this microbial group, namely B. adolescentis, B. animalis, B. pseudocatenulatum, B. 
pseudolongum (Figure 4.8). 
Among these four species, most interesting results were related to B. adolescentis and B. 
animalis. Regarding B. adolescentis, considering the hypothesis of this species as a putative 
marker of a pre-pathological/pathological condition, its increase would not be beneficial. 
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Administration of the control pasta led to an increase in this species in each of the three 
microbiota, and an increase was observed also after treatment with the pasta added with BC30, 
but just in the healthy group. On the contrary, interestingly, in the pre-diabetic and diabetic 
groups B. adolescentis resulted decreased after the intervention with the probiotic pasta. Thus, a 
treatment with the probiotic pasta, that could reduce this microbial species would be potentially 
advisable. 
B. animalis was increased after intervention with pasta with BC30 added, especially in control 
and diabetic microbiota, while it was not present in the three microbiota after treatment with the 
control pasta. Consequently, its growth would appear related to BC30 administration; however 
this species did not increase after administration of the other meals containing BC30 (the 
probiotic strain itself, the combination of BC30+β-glucans, the diluted functional pasta). Thus, 
probably, the increase in B. animalis was due to a synergistic effect of BC30 and the pasta (high 
concentration of starch). Growth of B. animalis has been reported after administration of a 
probiotic mixture (Lactobacillus and Bifidobacterium strain) together with a prebiotic, i.e. inulin, 
in rats presenting colitis (Schultz et al., 2004). Moreover, it has been reported that B. animalis 
could promote growth of Lactobacillus species in in vitro fermentations, through production of 
exopolysaccharides (Salazar et al., 2009). This could explain the increase in Lactobacillus 
observed after administration of the pasta added with the probiotic strain (Figure 4.7a). 
Finally, B. pseudolongum increased after intervention with the probiotic pasta, in a marked trend 
for the pre-diabetic and diabetic group, and after treatment with the control pasta in the pre-
diabetic group. B. pseudocatenulatum markedly increased after administration of the control 
pasta in the healthy and diabetic microbiota, while it remained at a low level in the pre-diabetic 
group; treatment with the probiotic pasta decreased this species in each of the three microbiota. 
 
SCFA production 
Production of acetate, propionate and butyrate was measured by gas chromatography on samples 
collected during in vitro fermentations, and results on samples collected at the end of 
fermentation (time 72 hours) are presented. 
Interventions with the different ingredients caused different relative proportions among SCFA 
(% of total SCFA) and amounts, and this was observed for any of the three microbiota, healthy 
(Figure 4.9a, b), pre-diabetic (4.10a, b) and diabetic. (fig 4.11a, b). 
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a.              b. 
  
Figure 4.9. Acetate, propionate and butyrate production in the microbiota from healthy children after 72 
hours of fermentation with the different dietary treatments, expressed as percentages of total SCFA 
production (a), and absolute amounts (b). 
 
a.        b. 
Figure 4.10. Acetate, propionate and butyrate production in the microbiota from pre-diabetic children 
after 72 hours of fermentation with the different dietary treatments, expressed as percentages of total 
SCFA production (a), and absolute amounts (b). 
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In the healthy group (Figure 4.9), butyrate was markedly the dominant produced metabolite 
(about 50% or more of total SCFA production) following administration of the combination of 
BC30 and β-glucans, and of the diluted functional and control pasta. On the contrary, acetate was 
the main product obtained following fermentation with the pasta added with the probiotic strain 
and, most of all, with the control pasta. 
Also in the pre-diabetic group (Figure 4.10), butyrate was the metabolite produced in highest 
proportions following administration the combination of BC30 and β-glucans, and of the diluted 
functional and control pasta. Moreover, also β-glucans led to a similar production. In the pre-
diabetic microbiota, acetate was the main product of fermentation with the pasta added with the 
probiotic strain, while the control pasta led to a comparable production of acetate and butyrate. 
Finally, in the diabetic group (Figure 4.11), butyrate was the metabolite produced in the highest 
ratios after administration of β-glucans, the combination of BC30 and β-glucans, and of the 
diluted functional and control pasta. Acetate was the main product of fermentations with the 
pasta added with the probiotic strain and the control pasta. 
 
a.        b. 
 
Figure 4.11. Acetate, propionate and butyrate production in the microbiota from diabetic children after 72 
hours of fermentation with the different dietary treatments, expressed as percentages of total SCFA 
production (a), and absolute amounts (b). 
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Obtained results showed that, in general, the relative proportions of SCFA observed after 
treatment with a specific diet appeared comparable in the three microbiota (Figure. 4.12). The 
ratio observed for the control meal at the end of the fermentations was considered as a reference 
and was 37:24:39, with acetate and butyrate present in equal proportions. Acetate and butyrate 
were the main products of all fermentations, while propionate was in the lowest relative ratio, 
after any dietary treatment, in the three microbiota. In particular, butyrate was the principal 
metabolite at the end of the treatment with most of diets, with highest proportions obtained after 
treatment with the combination of BC30 and β-glucans, the diluted functional and control pastas, 
in the three microbiota. Treatment with β-glucans also caused a high butyrate production in pre-
diabetic and diabetic microbiota. On the contrary, acetate was the major metabolite revealed after 
treatment with the pasta enriched in the probiotic strain and the control pasta, i.e. the meals at the 
highest concentration of starch. An exception was represented by the control pasta treatment, 
which led to an equal production of acetate and butyrate in the pre-diabetic microbiota. 
Figure 4.12. Ratios among acetate, propionate and butyrate (expressed as percentages of total SCFA 
production), in the microbiota from healthy, pre-diabetic and diabetic children, after 72 hours of 
fermentation with the different dietary treatments. 
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Considering absolute amounts, the highest production of total SCFA was observed after the 
interventions that included the highest dose of starch (control pasta and pasta added with BC30), 
in control, pre-diabetic and diabetic microbiota (Figure 4.13a). Moreover, in the pre-diabetic 
microbiota, also and β-glucans led to similarly high average values (more than 300 mmol). The 
fact that a high dose of starch caused the highest amount of SCFA produced is consistent with 
literature, since starch is considered to provide the largest proportion of energy at the colon level 
(Duncan et al., 2003). 
a.                  b.  
  
c.       d. 
  
 
Figure 4.13. SCFA production after 72 hours of fermentations with the different dietary treatments, in the 
microbiota from healthy (H), pre-diabetic (P) and diabetic (D) children. In particular: a) total SCFA, b) 
acetate, c) butyrate and d) propionate production. 
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Beside leading to the highest production of total SCFA, administration of the two pasta led to the 
highest production of acetate, in term of average amounts (> 150 mmol), in each of the three 
microbiota (Figure 4.13b). Maximum production was observed in the healthy microbiota after 
treatment with the control pasta (287 mmol). 
Referred to butyrate, common trends for a specific meal on the three different microbiota were 
not found (Figure 4.13c). Considering absolute amounts, in the healthy group butyrate 
production was at the highest levels after treatment with the pasta added with BC30, and high 
values were obtained also with the control pasta and the diluted functional pasta. It was also 
interesting to note that, in the healthy group, the probiotic strain or the β-glucans, when 
administered separately, led to a production comparable to the one obtained with the control 
meal (84-89 mmol), while, when contemporarily present, they remarkably increased butyrate 
production (118 mmol). 
In the pre-diabetic group, the β-glucans, the combination of the probiotic strain and β-glucans, 
and the control pasta, led to the highest average butyrate production. In this case, a high butyrate 
level following combined administration of the probiotic strain and the β-glucans was 
comparable to what obtained after treatment of the β-glucans alone. Thus, it appeared that in the 
pre-diabetic microbiota the prebiotic component mainly contributed to the production of 
butyrate, when the two functional ingredients were tested together.  
Finally, for the diabetic group, almost every treatment (excluded the control pasta) led to a high 
butyrate production, with the maximum average value obtained for the diluted control pasta. 
Regarding propionate production, the highest absolute amounts were produced after treatment 
with the control meal, in healthy (56 mmol) and diabetic (52 mmol) microbiota. For pre-diabetic 
microbiota, slightly lowest level of propionate were produced (41 mmol), and they were similar 
to those obtained following administration with the probiotic strain and β-glucans (Figure 4.13d). 
 
In the contest of T1D, conditions leading to the highest production of butyrate would represent, 
in principle, the best output at which aiming, since butyrate is considered a beneficial metabolite 
that contributes to colon health, through the improvement of gut integrity (Brown et al., 2011). 
In particular, a high butyrate production could be considered as both absolute amounts or 
proportions in the ratio with acetate and propionate. Results showed that not in all cases a high 
butyrate absolute amount matched with a condition in which butyrate was at the highest 
proporton (Figure 4.12 and Figure 4.13c). Thus, the highest yield in butyrate production can be 
considered the one that is based on both parameter. In this perspective, the functional pasta 
Chapter IV 
87 
 
provided the highest yield in butyrate in healthy and diabetic conditions, while BC30+β-glucans 
gave the highest yield in pre-diabetic microbiota. 
On the contrary, treatments leading to a high production of acetate, that overcome butyrate and 
propionate production, as the diets at a high concentration of starch in the present study (i.e. the 
probiotic pasta and the control pasta) could been considered as not so beneficial. In particular, in 
diabetes contest, it was recently proposed that acetate could act as a promoter for the metabolic 
syndrome (Perry et al., 2016); thus, diets leading to a high production of acetate could not be 
proper for pre-diabetic and diabetic children. As a comment regarding dietary fibres, even 
considering their beneficial properties, there is a lack of studies investigating their effects in 
children and adolescents (Edwards et al., 2015), and a study related to diabetes in an animal 
model reported that a cereal diet could act as a promoter for T1D (Patrick et al., 2013). 
Of course, these comments about positive or negative effects of the tested treatments from a 
clinical point of view are speculative, and still far to be considered for the planning of an in 
humana trial in T1D. For example, the small size of the pools in the present study, i.e. couples of 
children, represented a limit of the work. For this reason, further investigations on microbiota 
from large number of donors will be necessary. 
 
Merging microbial composition and SCFA following dietary interventions 
As previously reported, a marked increase in Bifidobacterium was observed following the 
administration of the pasta enriched with the probiotic strain and the control pasta. Moreover, 
after the same two treatments, that included the highest concentration of starch, acetate 
production was at the highest levels. This was observed considering both acetate proportions 
(Figure 4.12) and absolute amounts (Figure 4.13b). Since Bifidobacterium spp. mainly produce 
acetate and lactate with their carbohydrate degradation metabolism (De Vuyst et al., 2014), the 
two findings appeared to be connected one to each other. Only in one case, i.e. treatment with the 
control pasta in the pre-diabetic group, acetate was not the principal metabolitet; in fact, acetate 
and butyrate amounts were at a similar level in this condition (Figure 4.12). Interestingly, 
observing microbiota composition in this specific condition, a high abundance in Eubacterium, 
and specifically in E. rectale (15.6%) one of the most abundant butyrate producers in human gut 
(Louis et al., 2010) was detected, and this could explain the high butyrate level observed. 
Considering butyrate production, different treatments in the three microbiota led to highest 
amounts (Figure 4.13c). In healthy microbiota, the pasta added with the probiotic strain, the 
control pasta and the diluted functional pasta were related to highest production in term of 
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amounts, as could be expected from the presence of starch and the previously reported high 
butyrate production from starch (Kovatcheva-Datchary et al., 2009; Venkataraman et al., 2016). 
High levels of butyrate observed after treatment with the control pasta could be due to increases 
in Anaerostipes (2.53%); and in particular in Anaerostipes hadrus, a butyrate producing species 
(Allen-Vercoe et al., 2012). It has been reported that strains of A. hadrus can utilise acetate to 
produce butyrate (Allen-Vercoe et al., 2012). Moreover, cross-feeding between species of the 
genus Bifidobacterium and acetate-converting butyrate producers have been already reported 
after probiotic administration (Falony et al., 2006). Thus, a cross-feeding mechanism could be 
responsible of the observed high butyrate production also in the present study and explained the 
bifidogenic/butyrogenic effect observed. Basing on the same logic, butyrate production after 
intervention with the pasta enriched with the probiotic strain could be related to an increase in 
Anaerostipes and Eubacterium (both increased of approximately 1%), while increases observed 
following administration of the diluted functional pasta could be supported by the increase in 
Eubacterium (5.6%) and Roseburia (3.8%). This last treatment also caused the highest 
proportion of butyrate (Figure 4.12) in the ratio with acetate and propionate, thus representing 
the treatment leading the best butyrate yield. Regarding the other two treatments leading to the 
highest proportion of butyrate, high proportion following BC30+β-glucans administration could 
be related to an increased in Eubacterium (10.4%) and Roseburia (6.4%), while Roseburia could 
be potentially responsible of the butyrogenic effect following the diluted control pasta 
administration (2.3%). Considering butyrate production following BC30+β-glucans 
administration, in the healthy microbiota, it was reported in the previous paragraph that the 
probiotic strain or the β-glucans, when administered separately, did not increase butyrate 
production more than the control meal (84-89 mmol), while when contemporarily present, they 
remarkably increased butyrate production (118 mmol). This observed synergistic effect could be 
connected, from a compositional point of view, to the genus Eubacterium; in fact, this microbial 
group, that includes some of the most important butyrate producers, was not increased after the 
separated treatments with the two functional ingredients, but it markedly increased after their 
combined administration (10.4%). 
In the pre-diabetic group, the β-glucans, the combination of the probiotic strain and β-glucans, 
and the control pasta led to the highest butyrate amounts (Figure 4.13c). Composition data 
appeared to explain this evidence; in fact, following beta-glucans and BC30+β-glucans 
administration, three butyrate-producing genera were increased, i.e. Eubacterium (21.2% and 
25.5%, respectively), Catenibacter, another genus including species that produce butyrate 
Chapter IV 
89 
 
(Kageyama and Benno, 2000) (1.9% and 3.7%, respectively) and Roseburia (1.7% and 2.6%, 
respectively). Increases in butyrate amount after treatment with the control pasta could be related 
to Eubacterium (15.6%). In conditions with high butyrate proportion (diluted functional and 
control pasta) (Figure 4.12) Eubacterium appeared increased (9.0% and 12.7%, respectively). 
BC30+β-glucans also lead to a high proportion of butyrate, and thus, considering the fact that 
they led to a high absolute amount, it represented the treatment with the best butyrate yield. 
Finally, in the diabetic group, the highest butyrate production, intended as maximum average 
value, was obtained with the treatment with the diluted control pasta (Figure 4.13c), and it could 
be due explained on the basis of an increase in Eubacterium (5.7%), Gemmiger (7.3%) and 
Roseburia (5.3%), all genera known to contain butyrate producers (Louis et al., 2010; Gossling 
and Moore, 1975; Duncan et al., 2006). With this treatment also butyrate proportion was high 
(Figure 4.12), so the functional pasta represent the best treatment in terms of butyrate yield. 
Regarding proportion, high butyrate was observed also after administration of β-glucans, 
probably due to the increase of Eubacterium (7.5%) and Roseburia (4.2%), of the combination of 
BC30 and β-glucans, due to the increase of Eubacterium (12,8%), and of the diluted control pasta, 
due to the increase of Eubacterium (3.7%), Gemmiger (13.5%) and Roseburia (3.7%). 
Regarding propionate production, the highest levels were reached after treatment with the control 
meal, in particular in healthy and diabetic microbiota (Figure 4.13d). High propionate levels 
could be related to Bacteroides population (Macy et al., 1978). In fact, this genus remained 
stable during treatment with the control meal, for the healthy (13% at time 0h and time 72h) and 
diabetic group (26% at time 0 hours and 32% at time 72 hours) (data not shown). 
 
4.4. Concluding remarks 
In this study the effects of different diets on gut microbiota from three groups of children with 
different susceptibility to T1D were investigated, through the use of an in vitro model of the 
colon, TIM-2. This system represents an excellent tool to investigate specific diet-microbiota 
interactions, through analyses of microbiota composition and produced metabolites. 
Results from the composition analyses showed that a specific diet produced different responses 
in the three microbiota, i.e. modulations of different bacterial genera or species. However, even 
considering the microbiota-dependent differences in the response to a nutritional treatment, 
interestingly, for certain treatments, it was possible to observe increases of bacterial groups that 
were modulated with the same trend in the three microbiota, thus obtaining information about 
specific diet-microbiota relationships. For example, diets with a high concentration of starch had 
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a strong bifidogenic effect, or  administration of the pasta enriched with the probiotic strain BC30 
specifically increased Lactobacillus populations. 
Regarding metabolite profiles, highest total SCFA production was obtained with meals at highest 
concentrations of starch; in most cases, with these treatments, acetate was the principal produced 
metabolite. Treatments that led to the highest yield in butyrate, intended as both absolute 
amounts and proportions, were the diluted functional pasta in the healthy and diabetic 
microbiota, and BC30+β-glucans, in the pre-diabetic microbiota. 
The merging between results of microbial composition and metabolites generally fitted well one 
to each other. For example, the high increase in Bifidobacterium populations, following 
treatments including the highest dose of starch, corresponded to a high production of acetate, 
consistently to Bifidobacterium metabolism. 
In general, while microbiota composition analyses revealed more punctual differences in the 
response to a diet among the three microbiota, pointing out patterns of specific microbial groups, 
production of metabolites appeared to be more similar among the three microbiota; thus, a 
certain diet lead to a similar SCFA production in the three microbiota, despite differences in 
microbiota composition, probably due to functional redundancy (Louis et al., 2010). 
Evidences from the present study provided preliminary information about the effects of tested 
diets on gut microbiota; further studies will be necessary to confirm these findings, for example 
increasing the number of microbiota donors, also in the perspective of planning an intervention 
study in humana. 
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Chapter V 
 
Evaluation of the effects of a new functional pasta on gut microbiota 
of overweight and obese subjects 
 
 
5.1. Introduction 
Obesity represents one of the most important health issues of our time (Clarke et al., 2012). 
According to the World Health Organization (WHO), in 2014, more than 1.9 billion adults were 
overweight; of these, over 600 million were obese (WHO, 2016). In percentages, this 
corresponds to 39% of overweight adults worldwide, and 13% of obese subjects. 
Obesity is a multifactorial condition, in which modern eating habits coupled with sedentary 
lifestyles are the most important ones. However, other risk factors are emerging, and in 
particular, the involvement of gut microbiota is receiving a lot of attention (Brahe et al., 2016). 
Studies in both animal models and in humana showed that there are differences in composition 
of microbiota between lean or obese individuals (Clarke et al., 2012). At the phylum level, a 
lower ratio between Bacteroidetes and Firmicutes was found in obese subjects, compared to the 
healthy controls (Ley et al., 2006; Turnbaugh et al., 2009). However, following studies reported 
contrasting results (Schwiertz et al., 2010; Duncan et al., 2007), so the usefulness of this 
biomarker has been discussed. At lower taxonomic levels, e.g. genus or species, differences 
among lean and overweight/obese subjects are reported in several studies (e.g. Kong et al., 2014; 
Schwiertz et al., 2010), but it is difficult to point out common features, intended as bacterial taxa 
characteristic of the lean or obese conditions, shared among different studies; this can be due to 
the choice of the methodology used or to clinical factors related to the investigated subjects 
(Finucane et al., 2014). In the study of Walters and colleagues (2014), Faecalibacterium 
prausnitzii was reported to be decreased in obese subjects analysed in several studies, thus 
representing a consistent biomarker. 
Basing on the differences observed among lean and overweight/obese subjects, and considering 
the impact of the diet in shaping the gut microbiota (Graf et al., 2015), intervention studies based 
on the use of probiotic, prebiotics or other bioactive ingredients represent a strategy to modulate 
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gut microbiota towards an healthy state, thus contributing to the general status of the individual 
(Brahe et al., 2016). 
Epidemiological evidences indicate that a high consumption of whole grain cereals is associate 
to a reduced risk of chronic disease, e.g. cardiovascular disease, type 2 diabetes, obesity (Cooper 
et al., 2015). Mechanisms lying behind these positive effects are not clear, but the higher fibre 
content and the presence of phytochemical compounds that characterize whole grain products 
could have a role in this protective effect (Tuohy et al., 2012). 
Moreover, at the gut microbiota level, whole grain cereal can promote the growth of specific 
microbial groups. For example, whole grain cereals are able to increase Bifidobacterium 
amounts, as reported in in humana studies (Costabile et al., 2008; Christensen et al., 2013). 
Marked effects of high-fibre content are recently been related to species of the genus Prevotella 
(Kovatcheva-Datchary et al., 2015). 
β-glucans are known to have beneficial properties in lowering glucose and cholesterol levels, as 
recently recognized by EFSA (EFSA, 2011), thanks to their viscosity that reduce intestinal 
motility. At gut microbiota level, β-glucans are known to be able to increase Bifidobacterium and 
Lactobacillus levels, as observed from in vitro (Hughes et al. 2008; Kedia et al., 2009) and in 
vivo studies (Mårtensson et al., 2005; Mitsou et al., 2010). 
Probiotics represent another strategy for modulating gut microbiota composition and activities 
(Nova et al., 2016). The probiotic strain Bacillus coagulans GBI-30, 6086 (thereafter BC30) is a 
commercial probiotic strain reported to improve immunological parameters, intestinal 
functionality and physical performances (Kimmel et al., 2010; Dolin, 2009; Jäger et al., 2016). 
However, few studies are available about the impact of this probiotic strain on the gut microbiota 
(Honda et al., 2011; Nyangale et al., 2014; Nyangale et al., 2015). In particular, B. coagulans 
BC30 was reported to increase F. prausnitzii level in a human trial (Nyangale et al., 2015). 
Moreover, it was observed to increase the level of a recently described species, Fusicatenibacter 
saccharivorans (Takada et al., 2013), in another in vitro research (Chapter IV). 
The aim of this study was to investigate the effects of a whole grain functional pasta enriched in 
β-glucans and in the probiotic strain B. coagulans BC30 on the gut microbiota of 
overweight/obese subjects, in a 12-week parallel trial. Firstly, the overall modulation of 
microbiota composition following administration of the functional pasta was monitored through 
PCR-DGGE analyses. Then, four microbial taxa specifically related to the different ingredients 
of the functional pasta, i.e. the genera Prevotella and Bifidobacterium, and the species 
Faecalibacterium prausnitzii and Fusicatenibacter saccharivorans, were assessed through 
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qPCR; results were compared with those obtained following consumption of a whole grain 
control pasta, that did not include β-glucans and the probiotic strain. 
 
5.2. Materials and Methods 
Study design 
The study design is a randomized, parallel, 12 week trial. Thirty-nine healthy subjects (16 males 
and 23 females, aged 29-74 years old, BMI > 25 kg/m2) participated to the study. Subjects were 
habitual consumers of pasta (≥ 70 g/day), and poorly consumers of whole grain products, fruit 
and vegetables. Exclusion criteria were habitual use of medications which can influence glucidic 
and lipidic profiles, inflammatory status, blood pressure, and intestinal functions, and use of food 
supplements, i.e. prebiotics and probiotics; antibiotic use in the previous three months; presence 
of metabolic, intestinal and immune pathologies; pregnancy and breast-feeding conditions. 
Recruited subjects were assigned in a random order to one of two treatments: a) a functional 
pasta obtained from whole wheat flour and supplemented with β-glucans from barley and the 
probiotic strain B. coagulans BC30. Subjects assigned to this treatment were named as “treated” 
group; b) a control pasta produced with the same technological process and from the same whole 
wheat flour, but without addition of β-glucans and the probiotic strain. Subjects assigned to this 
treatment were named as “control” group. Detailed characteristics of the functional and control 
pasta are reported in Chapter 1. 
Subjects were asked to maintain their usual eating habits and their usual level of physical activity 
throughout the study, and to replace the daily portion of pasta they habitually consumed with one 
of the test products. 
 
Control and functional pasta 
The functional pasta, and in particular the cooked product, contained a microbial load above 6 
log CFU/g of the probiotic strain B. coagulans BC30, as previously reported (Chapter 1). Instead, 
the cooked control pasta did not contain bacteria of the genus Bacillus. 
 
Collection of fecal samples 
At the baseline of the study and every 4 weeks, for a total of 4 times, fresh fecal samples were 
collected at the Department of Food and Drug (University of Parma), and stored at 4°C in 
RNAlater (Sigma-Aldrich, Saint Louis, MO, USA). For molecular analyses, they were further 
subdivided in 200 mg aliquots and stored at -20°C till processing. 
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Microbiological analysis on fecal samples 
DNA extraction procedures 
Extraction of DNA from 200 mg fecal sample was performed following the protocol of QIAamp 
DNA stool Mini Kit (Qiagen, Hilden, Germany), as described by the manufacturer with a lysis 
temperature of 95°C. DNA concentration and quality were measured using a NanoDrop Lite 
UV-Vis Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). 
 
PCR amplification and DGGE analysis 
PCR fragments representing total fecal microbiota were amplified with the universal primers 
HDA1-GC and HDA2 (Walter et al., 2000); PCR fragments representing species of the genus 
Bifidobacterium were amplified with the primers Bif164 and Bif662 (Satokari et al., 2001). The 
amplification products of bifidobacteria were further amplified by a nested PCR reaction using 
primers HDA1-GC and HDA2. PCR amplifications were conducted in the conditions reported by 
Fasoli et al. (2003). 
PCR amplicons were separated by denaturing gradient gel electrophoresis (DGGE) using the D-
Code Universal Mutation Detection System (Bio-Rad Laboratories, Richmond, CA, USA), 
basically as described previously (Fasoli et al., 2003; Marzotto et al., 2006). The denaturing 
gradients of urea and formamide used for discrimination of amplicons from total microbiota and 
bifidobacteria were 30–60% and 45–60%, respectively. The polyacrylamide gels were run at 
60°C in 1 × TAE buffer at 90 V for 10 min, and then at 50 V for 16 h. After electrophoresis, gels 
were stained with EuroSafe Nucleic Acid Stain (Euroclone, Milan, Italy) for 15 min, washed and 
photographed under UV illumination. 
DGGE ladders for the electrophoretic runs were prepared by mixing equal amounts of amplicons 
obtained from selected reference species using primers HDA1-GC and HDA2, as previously 
described (Marzotto et al., 2006). 
DGGE patterns were analysed with BioNumerics software (Version 7.5; Applied Maths, Sint-
Martens-Latem, Belgium). Similarities between DGGE profiles were determined using the Dice 
coefficient, and the unweighted pair group method with the arithmetic average (UPGMA) was 
used to construct the corresponding dendrogram. 
 
Quantitative PCR analyses 
Quantitative real-time PCR (qPCR) assays were used for the detection of Prevotella spp., 
Bifidobacterium spp., Faecalibacterium prausnitzii and Fusicatenibacter saccharivorans in fecal 
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samples. Enumeration of species and genera mentioned above was conducted using the primers 
reported in Table 5.1.  
Quantitative PCR assays were performed with a LightCycler Nano System (Roche, Mannheim, 
Germany), using the FastStart DNA Master SYBR Green kit (Roche, Mannheim, Germany), in a 
final volume of 20 μL, containing 5 μL of each fecal DNA preparation, 0.25 μM of each primer, 
MasterMix buffer 1 × and PCR grade water. No-template controls were included in each assay. 
The thermal cycling conditions used for each species or genera analysed consisted in one cycle 
of 95°C for 10 min, followed by 45 cycles with denaturation at 95°C for 15 s, primer annealing 
at the temperature reported in Table 5.1 (Ta) for 15 seconds, and extension at 72°C for the time 
reported in Table 5.1. 
Standard curves were constructed using 10-fold serial dilutions of genomic DNA of known 
concentration from the reference strains (i.e. Prevotella copri DSM 18205T, Bifidobacterium 
adolescentis LMG 11037T, Faecalibacterium prausnitzii DSM A2-165T and Fusicatenibacter 
saccharivorans DSM HT03-11T). For each dilution, the genomic copies were plotted against the 
cycle number at which the fluorescence signal increased above the threshold value (CT value). 
For all primer pairs, qPCR amplification efficiency was obtained from the equation E=10(-1/slope). 
Cell numbers of bacteria in fecal samples were calculated by comparing the threshold cycle 
values with the standard curve, and expressed as CFU per gram of feces. All PCR analyses were 
carried out in technical triplicate, and presented data are the mean values obtained. 
 
Table 5.1. Primer sequences and specifications for qPCR assays (annealing temperature and extension 
time). 
Target Primer Sequence (5’-3’) Lenght (bp) Ta (°C) 
Extension 
time (sec) Reference 
Prevotella spp. PrevF 
PrevR 
 
CACCAAGGCGACGATCA 
GGATAACGCCYGGACCT 
283 62 12 Larsen et al., 
2010 
Bifidobacterium 
spp. 
Bif164 
Bif662 
 
GGGTGGTAATACCGGATG 
CCACCGTTACACCGGGAA 
520 63 20 Satokari et al., 
2001 
Faecalibacterium 
prausnitzii 
FPR-2F 
Fprau645R 
 
GGAGGAAGAAGGTCTTCGG 
AATTCCGCCTACCTCTGCACT 
248 60 11 Ramírez-Farias 
et al., 2009 
Fusicatenibacter 
saccharivorans 
s-Fsac-F 
s-Fsac-R 
CTGCATTGGAAACTGTCTGG 
CGTTACGGGCCGGTCATC 
389 59 16 Kurakawa et 
al., 2015 
 
Clinical data 
Anthropometric and blood analyses (e.g. glucose metabolism, inflammatory status) were 
performed at the Department of Clinical and Experimental Medicine, University of Parma. 
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Statistical analysis 
SPSS was used to compare qPCR microbiological results at time 0 months and time 3 months, 
for each microbial taxa of interest, and to compare microbiological and clinical results. 
Statistical analyses were performed at the Department of Food and Drug, University of Parma. 
 
5.3. Results and discussion 
Assessment of modulation of resident gut microbiota through PCR-DGGE analyses 
PCR-DGGE analyses were performed on the subjects who ingested the functional pasta, in order 
to reveal modulations of the gut microbiota due to this product, if any. 
Preliminary analyses of total microbiota, conducted with universal primers HDA1-GC and 
HDA2, were performed for three subjects (2, 5, 13) at the different times of the clinical trial, i.e. 
at the beginning of the intervention period, and after 1, 2 and 3 months (T0, T1, T2 and T3). 
Moreover, analyses on the same subjects were performed with primer Bif164 and Bif662, 
targeting Bifidobacterium species. The aim of these analyses was to assess the stability of the gut 
microbiota during the whole duration of the treatment with the functional pasta. 
a.         b. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Profiles obtained from PCR-DGGE analyses of a) the total microbiota and b) Bifidobacterium 
population, for 3 subjects (2, 5, 13) who ingested the functional pasta, at the beginning (T0) and after 1, 2 
and 3 months (T1, T2, T3).  
 
Profiles from total microbiota (Figure 5.1a) appeared particularly complex, and substantially 
stable; in fact, few bands were observed to appear or disappear during time for any subject. In 
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order to assess stability of the profiles also for a subpopulation, PCR products derived from 
Bifidobacterium spp. were analysed. In particular this microbial group was analysed since it was 
expected to be modulated following the intervention with the whole grain product, further 
enriched with β-glucans. Results showed considerably simpler profiles (Figure 5.1b), and 
confirmed the stability observed from the analyses of the total microbiota. 
Basing on this findings, following analyses were performed on the overall group of subjects who 
ingested the functional pasta focusing on the beginning (T0) and the end (T3) of the intervention 
period. Both the total microbiota population and the Bifidobacterium spp. were analysed at these 
two times. Regarding total microbiota, subjects exhibited very rich and complex profiles (Figure 
5.2). The average number of the bands observed at T3 (18.8 ± 2.3) did not differed significantly 
from that observed at T0 (20.2 ± 2.5), according to previous findings (Abell et al., 2008).  
a)       b) 
 
       c) 
 
Figure 5.2. Profiles obtained from PCR-DGGE analyses of the total microbiota for the 20 subjects who 
ingested the functional pasta, at the beginning (T0) and at the end (T3) of the clinical trial. a) subjects 2 to 
31, T0; b) subjects 2 to 31, T3; c) subjects 32 to 50, T0 and T3. 
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Punctual differences were observed in terms of bands that appeared or disappeared in different 
individuals from the beginning to the end of the intervention period with the functional pasta; 
however, common bands that could indicate a specific effect of the functional product were not 
retrieved among the overall group of subjects in the T3 samples (Figure 5.2). 
An inter-individual variability in the profiles of the subjects was observed, both at T0 and at T3. 
Moreover, the patterns of the total microbiota profiles at the beginning and at the end of the trial 
was maintained for each individual (Figure 5.2). This was confirmed also from the similarity 
analysis of the profiles (Figure 5.3). In fact, as revealed from the graph, profiles mostly clustered 
basing on individuals (16/20) and not on the sampling point, showing that inter-individual 
differences are stronger that the effects of the treatment. Few subjects represented an exception: 
profiles from subjects 19, 21 and 28 resulted intermixed with those from other subjects; profiles 
from subject 13 resulted in a subcluster with profiles from subject 39. The fact that differences 
among individuals can be greater than differences observed for a certain individual between 
different analysis times following a certain dietary intervention was previously observed (Abell 
et al., 2008, Walker et al., 2011). 
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Figure 5.3. Dendrogram obtained from the profiles of the total microbiota for the 20 subjects who 
ingested the functional pasta, at the beginning (T0) and at the end (T3) of the clinical trial. 
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Analyses of Bifidobacterium population showed less complex profiles, with a low average band 
number (T0 = 5.35 ± 2.2; T3 = 5.85 ± 1.7) than that observed for the total microbiota (Figure 
5.4). Subjects exhibited, again, a certain inter-individual variability, even if, respect to profiles 
obtained for total microbiota, patterns are more similar among individuals, due to the lower 
number of bands obtained. Stability in the profiles was observed for most individuals during 
time, as also reported previously (Salazar et al., 2015); some specific subjects (e.g. 6, 39) 
exhibited more marked differences in terms of bands between the beginning and the end of the 
intervention period. However, no bands differentially present at the beginning or at the end of the 
treatment and shared among the overall group of subjects were detected. As shown from the 
similarity analyses, profiles clustered according to the different individuals, and not according 
time, T0 or T3 (Figure 5.5). 
       a)          b) 
 
       c) 
 
Figure 5.4. Profiles obtained from PCR-DGGE analyses of Bifidobacterium population for the 20 
subjects who ingested the functional pasta, at the beginning (T0) and at the end (T3) of the clinical trial. 
a) subjects 2 to 18, T0 and T3; b) subjects 19 to 31, T0 and T3; c) subjects 32 to 50, T0 and T3. 
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Figure 5.5. Dendrogram obtained from the profiles of the Bifidobacterium population for the 20 subjects 
who ingested the functional pasta, at the beginning (T0) and at the end (T3) of the clinical trial. 
10
0
95908580757065605550454035
6T0
6T3
39T0
39T3
46T0
46T3
32T0
32T3
36T0
36T3
19T0
19T3
21T0
21T3
2T0
2T3
8T0
8T3
31T0
31T3
23T0
23T3
28T0
28T3
15T0
15T3
18T0
18T3
13T0
13T3
5T0
5T3
27T0
27T3
41T0
41T3
43T0
43T3
50T0
50T3
Chapter V 
103 
 
Investigation of specific microbial taxa through qPCR 
Considering the substantial stability in the microbiota profiles of the subjects before and at the 
end of the intervention with the functional pasta, observed through PCR-DGGE, qPCR analyses 
were performed in order to investigate quantitative changes of specific microbial groups, 
expected to be modulated from the different ingredients of the functional pasta. Thus, the genera 
Prevotella and Bifidobacterium, and the species Faecalibacterium prausnitzii and 
Fusicatenibacter saccharivorans species were investigated. In this case qPCR analyses were 
performed also on the subjects who were assigned to the treatment with the control pasta. 
Quantifications of the genera Prevotella and Bifidobacterium and the species F. prausnitzii and 
F. saccharivorans were performed through the use of standard curves presenting the equations:  
y = -3.67x + 36.49, y = -3.98x + 42.67; y = -3.68x + 37.31, y = -3.40x + 29.95, respectively. 
Efficiency with the used primer pairs ranged from 1.78 to 1.97. The limit of detection were 104 
CFU/g of fecal sample with respect to genus Bifidobacterium and F. prausnitzii, and 103 CFU/g 
of fecal sample regarding genus Prevotellla and F. saccharivorans. 
The genus Prevotella was selected as it is reported to be associated with a Mediterranean diet, 
based on a large consumption of cereals, fruits and vegetables (De Filippis et al., 2015). In 
addition, studies aimed at assessing the effects of fiber content in foods showed increases in this 
microbial genus (Kovatcheva-Datchary et al., 2015; Vitaglione et al., 2015). 
For the analysis of such genus, the 39 subjects of the trial were combined into one large group, 
because of the fact that the amount of total fibre contained in the cooked pasta, functional and 
control, is comparable for the two products (Chapter 1). 
At the end of the clinical trial, increases or decreases of the genus Prevotella were observed, for 
different subjects, with a more or less marked trend (Figure 5.6). 
Considering the value of one logarithm as a threshold for defining a relevant modulation, five (2, 
9, 19, 24, 38) out of the 39 subjects exhibited such an increase, while a decrease was observed in 
two subjects (23, 51). Among the subjects with an increase in Prevotella, subject 19 exhibited a 
two logarithm increase, while a two logarithm decrease was observed for subject 51. However, 
considering the whole group of subjects, there were no statistically significant changes between 
the quantities of Prevotella measured at the beginning and at the end of the trial (Figure 5.7). 
 
 Figure 5.6. Quantification of Prevotella
the intervention period. 
 
Figure 5.7. Box-plot representation of the amounts of 
(month 0) and at the end (month 3) of the intervention period.
 
Subjects were then stratified according to their BMI, and divided into two groups, overweight 
(BMI ≤ 29.9 kg/m2) and obese (BMI 
subjects, and the second consisting in 16 obese subjects (Figure 5.8).
Even with this stratification, there were no significant variations in the quantities of 
at the beginning and end of treatment (Figure 5.9)
Prevotella levels was observed in the group of the obese subjects, after 12
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 Figure 5.9. Box-plot representation of the amounts of 
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Figure 5.8. Quantification of Prevotella
at the beginning (T0) and at the end (T3) of the intervention period.
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In conclusion, the results obtained by qPCR analysis showed a great variability in the modulation 
of Prevotella among subjects after consumption of the functional or control pasta, together with 
a pronounced variability observed at the baseline of the intervention. Following the treatment, 
increases or decreases in Prevotella levels depended on the subjects. The fact that individuals  
can be more or less responsive to a fibre containing treatment was also reported by Kovatcheva-
Datchary and colleagues (2015); in this study, the authors showed how the consumption of the 
test product increases Prevotella levels only in some of the participants. In particular, the product 
improved glucose tolerance in specific individuals (subjects defined responders), which also 
showed an increase in the abundance of Prevotella, and specifically, in the species Prevotella 
copri (Kovatcheva-Datchary et al., 2015). In the study of Vitaglione and colleagues (2015), 
Prevotella levels significantly increased after administration of whole grain products. Our results 
indicated a trend in Prevotella increase after the consumption of the products in the obese 
subjects. 
 
The genus Bifidobacterium was selected as a second group of interest for the analysis, on the 
basis of several evidences showing that the consumption of whole grain foods, and/or enriched in 
β-glucans, increased abundance of bifidobacteria in the gastrointestinal tract (Costabile et al., 
2008; Christensen et al., 2013; Mitsou et al., 2010; Mårtensson et al., 2005). 
For the analysis of the genus Bifidobacterium, the two groups of subjects, those assigned to the 
functional pasta and those assigned to the control pasta, were considered separately. In fact, even 
if the ingestion of both types of pasta, both whole grain products, could lead to an increase of 
bifidobacteria, added β-glucans could further strengthen this bifidogenic effect. 
Also for these microorganisms, analyses showed a varied response among subjects; for some of 
them an increase in Bifidobacterium was shown, and for others a decrease (Figure 5.10a, b). 
Regarding subjects who ingested the functional pasta, the threshold value of one logarithm, 
indicative of a relevant modulation, was observed for only two subjects, 19 and 21, that 
exhibited an increase in this genus. Decreases were observed for three subjects, 13, 28 and 39; 
subject 28 showed a two log unit decrease (Figure 5.10a). 
 For subjects belonging to the control group, no relevant increases were observed, while relevant 
decreases were observed in four subjects (9, 10, 26, 51). Subjects 10 and 51 exhibited decreases 
greater and around 2 log, respectively (Figure 5.10b). Statistical analysis on the whole groups of 
subjects, treated and control (Figure 5.11) did not show significant differences between the 
amounts in bifidobacteria, at the beginning and end of treatment, for both groups. 
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(a) 
 
 
(b) 
Figure 5.10. Quantification of Bifidobacterium spp. in the treated (a) and control (b) groups of subjects, 
at the beginning (T0) and at the end (T3) of the intervention period. 
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 Figure 5.11. Box-plot representation of 
and at the end (month 3) of the intervention period. Treated group is represented in light grey, control 
group is represented in dark grey.
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subjects and 10 obese subjects
group and 6 subjects constituted the obese one 
 
 
0
1
2
3
4
5
6
7
8
9
10
2 5 8 13 15
Lo
g 1
0
Bi
fid
ob
ac
te
riu
m
sp
p.
 g
en
om
es
/g
108 
the amounts of Bifidobacterium spp. at the beginning (month 0) 
 
The treated group included 
. In the control group, 13 subjects constituted the overweight 
(Figure 5.12a, b). 
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(b) 
Figure 5.12. Quantification of Bifidobacterium spp. in the treated (a) and control (b) groups of subjects, 
at the beginning (T0) and at the end (T3) of the intervention period. Subjects are stratified according to 
their BMI, in overweight (left) and obese (right). 
 
As a result of this stratification, in the overweight subjects who consumed the functional pasta 
(light grey), a significant decrease in the population of Bifidobacterium spp. was observed during 
time (Figure 5.13; ¥: p <0.05, Wilcoxon Test). For the control group (dark grey), stratified in 
overweight and obese subjects, no significant differences at the beginning and at the end of the 
treatment were observed, for any of the two groups (Figure 5.13). 
An interesting result emerged from the inter-group comparison, among treated and control 
groups, with reference to the subgroups of obese subjects. The amount of bifidobacteria in the 
obese control subjects (Figure 5.13) was statistically higher than the amount of bifidobacteria in 
the obese treated subjects, both at the beginning and at the end of the trial (#: p < 0.05, Mann-
Whitney test). 
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 Figure 5.13. Box-plot representation of 
and at the end (month 3) of the intervention period. Treated group is represented in light grey, control 
group is represented in dark grey.
obese (right). 
 
Thus, differently to what reported in many studies in 
grain pasta, and furthermore, of the functional pasta with added 
increase of the genus Bifidobacterium
BMI, it was observed a statistically significant decrease of bifidobacteria in 
with the functional pasta. A 
prebiotics has been reported in a study that monitored the modulation of the microbiota in mice, 
following ingestion of prebiotics for a prolonged 
authors proposed that the continuous consumption of one type of prebiotic, FOS or inulin in the 
specific case, for a period longer than four
Bifidobacterium species anymore; moreover, it can even lead to a repression of present 
bifidobacteria, probably due to the development and competition with other microorganisms (Li 
et al., 2015). Although that study was conducted in an animal model, and the type of prebiotic 
administered was different, a similar mechanism could explain the effects observed in 
present clinical trial. 
Moreover, although most studies investigating 
some works showing contrasting results. For example, the study performed by De Angelis and 
colleagues (2015), which assessed the ef
110 
the amounts of Bifidobacterium spp. at the beginning (month 0) 
 Subjects are stratified according to their BMI, in overweight (left) and 
literature, the ingestion of the two whole 
β-glucan
. On the contrary, stratifying subjects according to their 
decrease in Bifidobacterium spp. following the consumption of 
period (Li et al., 2015). In that study, the 
-weeks, did not promotes the growth of 
β-glucans reported a bifidogenic effect, there are 
fects of a pasta enriched in β-glucans in a group of 
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normal weight subjects, did not report modulations related to the genus Bifidobacterium. In 
another study, examining the effects of a high fibre rye bread on the microbiota, bifidobacteria 
were not modulated from the intervention (Gråsten et al., 2007). 
 
Analyses of the species Faecalibacterium prausnitzii showed again a inter-individual variability 
in response to the treatments with the functional and control pasta (Figure 5.14a, b). 
 
(a) 
 
(b) 
Figure 5.14. Quantification of F. prausnitzii in the treated (a) and control (b) groups of subjects, at the 
beginning (T0) and at the end (T3) of the intervention period. 
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 Regarding analyses of the treated group, only for one volunteer, subject 19, a 
two log units was observed, while a decrease of one log unit was obser
5.14a). For the control group, a one log increase was observed for subject 48, and a decrease of 
more than 2 log was observed in two subject
groups of subjects, control and treated, 
F. prausnitzii between the beginning and the end of the treatment were observed 
 
Figure 5.15. Box-plot representation of 
the end (month 3) of the intervention period. Treated group is represented in light grey, control 
represented in dark grey. 
 
Even stratifying the subjects in subgroups, according to their BMI
emerged (Figure 5.16a, b; Figure 5.17)
comparison, treated and control
112 
ved for subject 50 (Figure 
s, 3 and 51 (Figure 5.14b). 
no statistically significant differences in the amount
the amounts of F. prausnitzii at the beginning (month 0) and at 
, no significant modulations 
. Finally, no results were found from the inter
, stratified or not. 
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(a) 
 
 
(b) 
Figure 5.16. Quantification of F. prausnitzii in the treated (a) and control (b) groups of subjects, at the 
beginning (T0) and at the end (T3) of the intervention period. Subjects are stratified according to their 
BMI, in overweight (left) and obese (right). 
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 Figure 5.17. Box-plot representation of 
the end (month 3) of the intervention period. Treated group is represented in light grey, control 
represented in dark grey. Subjects are 
(right). 
 
F. prausnitzii has been investigated because i
the probiotic strain B. coagulans
et al., 2014; Nyangale et al.
evidences; in fact, in the present study, 
following consumption of the funct
This could be attributed to different
and colleagues had different characteristics than the subjects of the present clinical trial; in
particular, they had normal weight, which can probably lead to a different response to the 
treatment. In addition, in the mentioned trial, which is the only one available in literature dealing 
with the effects of the consumption of the probiotic strain on
BC30 was administered as a supplement, and not included in a food with other functional 
ingredients. In the present study
reduced the stimulation of F. 
glucans lead to a significant decrease in the levels of 
Angelis et al., 2015). 
 
Finally, the effects of the functional and control pasta were 
species Fusicatenibacter saccharivorans
114 
the amounts of F. prausnitzii at the beginning (month 0) and at 
stratified according to their BMI, in overweight (left) and obese 
t is assumed to be stimulated from the ingestion of 
 BC30, as observed both in vitro and in a clinical trial 
, 2015). Obtained results were contrasting with these previous 
a statistically significant increase in this species 
ional pasta containing the probiotic strain was
 factors. Firstly, subjects analysed in the work of Nyangale 
 the gut microbiota, 
, the effect of β-glucans in combination with fibre could have 
prausnitzii. In fact, the consumption of a pasta enriched in 
F. prausnitzii in a recent clinical 
investigate with reference to the 
. Few information about this species is available. It
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B. coagulans 
β-
trial (De 
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resulted decreased in hospitalized children suffering from a chronic inflammatory disease 
(enthesitis-related arthritis, ERA) together with a decrease in F. prausnitzii; these findings lead 
to the hypothesis that these reductions may be related to the onset of the disease condition (Stoll 
et al., 2014). In the present work, F. saccharivorans was investigated since it was found that the 
probiotic strain BC30 could promote its growth (Chapter 4). 
 
 
(a) 
 
(b) 
Figure 5.18. Quantification of F. saccharivorans in the treated (a) and control (b) groups of subjects, at 
the beginning (T0) and at the end (T3) of the intervention period. 
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 Results obtained from the quantification of this specie
functional pasta (Figure 5.18a) showed a relevant increase only for subject 19, while no relevant 
decreases were observed. Regarding the analyses of
in one logarithmic unit was observed for subject 17, while a decrease was observed for subject 
51. On the overall groups, treated and control, no significant modulations of 
were observed (Figure 5.19)
overweight or obese subjects (Figure 5.20
from the intergroup comparisons
 
Figure 5.19. Box-plot representation of 
at the end (month 3) of the intervention period. Treated group is represented in light grey, control 
represented in dark grey. 
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s in the subjects that consumed th
 the control group (Figure 5.18
. No differences were pointed out considering stratification
a, b; Figure 5.21), in the treated or control group, or 
. 
the amounts of F. saccharivorans at the beginning (month 0) and 
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(a) 
 
(b) 
Figure 5.20. Quantification of F. saccharivorans in the treated (a) and control (b) groups of subjects, at 
the beginning (T0) and at the end (T3) of the intervention period. Subjects are stratified according to their 
BMI, in overweight (left) and obese (right). 
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 Figure 5.21. Box-plot representation of 
at the end (month 3) of the intervention period. Treated group is represented in light grey, 
represented in dark grey. Subjects are stratified according to their BMI
(right). 
 
So, results of the present study did not confirm previous findings. It should be considered that 
the evidence of the increase of this specie
carried out in an in vitro system, inoculated with the microbiota from a small number of subjects 
(n = 2). Thus, it is conceivable that extending the analysis to a larger number of subjects, 
observed effects can be different.
 
In general, the four microbial groups investigated did 
intervention with the functional
that compared a diet high in whole grain products with a diet with a lower content of these 
products. Also in this study no modulations were observed, for none of the 
groups (Ampatzoglou et al., 2015).
Variations of the analysed microbial 
variability of the individual response did not 
whole groups, as reported elsewhere (
One of the reason could be attributed to the fact that
restricted to a specific diet; in fact, they were only asked to substitute the portion of pasta they 
usually had, with the functional or control pasta, keeping, for the rest, their own diets.
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the amounts of F. saccharivorans at the beginning (month 0) and 
, in overw
s after BC30 ingestion derived from a single study 
 
not resulted modulated
 and/or control pasta. A similar result was observed in a study 
 
taxa have been observed in specific subjects, but the 
allow to identify significant differences in the 
Kovatcheva-Datchary et al., 2015, Martínez 
 the subjects of the clinical trial were not 
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 following the 
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et al., 2013a). 
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A strategy used in order to decrease the individual variability is the definition of subgroups of 
subjects with more homogeneous characteristics. In the present study, the stratification of 
individuals according to their BMI lead to a significant relationship between the intake of the 
functional pasta and the reduction of bifidobacteria in the overweight subjects. In addition, at the 
end of the trial, the amount of bifidobacteria found in the fecal samples of the obese subjects 
who consumed the functional pasta was significantly lower than the level found in samples of the 
obese subjects who consumed the control pasta, further confirming a non-bifidogenic effect of 
the functional pasta. 
Since significant modulations of microbial taxa that were expected to be potentially responsive 
to the treatments were not observed, it is possible that the tested products had an effect on other 
microbial groups, or on certain species belonging to the investigated genera. In this perspective, 
the use of an open technique, such as a metagenomic approach, could provide a more complete 
view, and with a greater resolving power, about changes that may occur following a nutritional 
intervention. For example, investigation of other microbial groups involved in carbohydrates 
degradation, or of bacteria related to protein degradation would be interesting, considering the 
amounts of these components in the functional pasta (Chapter I). 
 
Correlation with clinical data 
In the contest of the clinical trial, a complete range of clinical parameters was monitored at the 
Department of Food and Drug, University of Parma. The most relevant results, observed after the 
consumption of the functional pasta, were related to positive effects about the modulation of 
specific metabolic and inflammatory markers (Angelino et al., 2015). 
A trend in decreasing the fasting glucose levels was observed, probably due to the presence of β-
glucans (Cloetens, 2012). Regarding inflammatory markers, subjects who consumed the 
functional pasta exhibited significantly lower levels of C-reactive protein, comparing to subjects 
who ingest the control pasta, at the end of second and third month of the trial. Moreover, it was 
observed a significant decrease in PAI-1 levels (Plasminogen Activator Inhibitor-1) in the last 
four weeks, in subjects who consumed the functional pasta. Such anti-inflammatory effects may 
be imputable to both the β-glucans (Kristensen and Bügel, 2011), or the probiotic strain BC30 
(Mandel et al., 2010). 
The microbiological data obtained in the study were compared with the clinical results, and two 
interesting correlations emerged. The first, as reported previously, dealt with the decrease in the 
level of bifidobacteria following the treatment with the functional pasta in overweight subjects 
 (BMI <30 kg / m2). Since bifidobacteria are considered as positive bacteria in the gut (Arboleya 
et al., 2016), their decrease may appear, at first, as a negative effect
outcome related to this evidence
metabolism are acetate and lactate (De Vuyst 
investigated the possible role of acetate in adipogenesis (Hong 
has recently been proposed that an increase in acetate production could promote obesity (Perry 
al., 2016). In this perspective, a food able to lower 
production of acetate, could be considered as beneficial for individuals in a overweight or 
obesity condition, and it will need further investigation
Another interesting finding emerged when stratifying the subjects according to their blood 
glucose level, by setting the threshold of 
Federation as a criterion for metabolic syndrome (Cloetens 
period of the trial, in individuals with glucose levels equal or above 100 mg/d
consumed the functional pasta (in light grey) showed higher levels of 
subjects who consumed the control pasta (in dark 
Figure 5.22. Box-plot representation of the amounts of 
the end (month 3) of the intervention period. Treated group is represented in light grey, 
represented in dark grey. Subjects are stratified according to their 
(left) or equal or above 100 mg/d
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; however, a possible positive
 can be speculated. The main products of bifidobacteria 
et al., 2014). Studies in murine models have 
et al., 2005
Bifidobacterium levels and, consequently, the 
. 
100 mg/dL, defined by the International Diabetes 
et al., 2012).
F. prausnitzii
grey) (Figure 5.22). 
 
F. prausnitzii at the beginning (month 0) and at 
glucose levels
L (right).  
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F. prausnitzii is a positive microorganism in human gut microbiota, and it is able to influence 
host metabolism and health status, since it is a butyrate producer, and it presents 
immunomodulation properties (Miquel et al., 2014). F. prausnitzii results decreased in various 
pathological conditions, and moreover, it is decreased in obese subjects compared to lean 
subjects (Walters et al., 2014). Therefore, an increase in this species, which could positively 
enrich the intestinal microbiota, as well as acting on other clinical parameters, could certainly 
represent a positive outcome of a nutritional treatment. 
 
As a final comment, with respect to clinical trials, a high inter-individual variability in response 
to a dietary intervention have been highlighted at both gut microbiota level and systemic level 
(Kovatcheva-Datchary et al., 2015; Lampe et al., 2013), that make not possible to define 
interventions that can be applied with the same expected output on large numbers of individuals, 
also considering the initial variability among individuals. For example, with regard to glucose 
metabolism, recent studies have emphasised how the glycemic response to a same nutritional 
intervention is individual-dependent (Kovatcheva-Datchary et al., 2015; Zeevi et al., 2015), and 
this variability is due to a combination of different factors, including the gut microbiota 
composition. The study of the characteristics of an individual, including microbiota, and their 
integration, constitutes the first step in the development of predictive systems about the response 
to a specific nutritional intervention (Lampe et al., 2013). Such an approach will lead in the 
direction of the so-called “personalised nutrition”, aimed at ensuring, for example, controlled 
glucose levels in the blood, thus reducing the risk of developing diabetes and obesity (Zeevi et 
al., 2015). 
 
5.4. Concluding remarks 
 
This study evaluated the effects of the consumption of a novel whole grain functional pasta, 
enriched in β-glucans and in the probiotic strain B. coagulans BC30 on gut microbiota of 
overweight/obese subjects, in a 12-week parallel trial. 
Overall modulations of total microbiota composition following ingestion of the functional 
product were investigated through PCR-DGGE analyses. Results showed that the functional 
pasta did not substantially modified microbiota profiles of the subjects. The different subjects 
were characterized by an inter-individual variability, at the beginning and at the end of the trial, 
and shared trends in terms of bands that characterised the profiles at the end of the trial were not 
observed. Similar results were obtained with PCR-DGGE on Bifidobacterium population. 
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Four bacterial taxa, that could be influenced by the different ingredients of the functional pasta, 
i.e. the genera Bifidobacterium and Prevotella, and the species Faecalibacterium prausnitzii and 
Fusicatenibacter saccharivorans, were specifically quantified through qPCR analyses, both in 
the treated and control groups of subjects. Results showed a marked inter-individual variability 
in the response to the consumption of the two food products. Considering the whole groups of 
subjects, the genus Prevotella was not significantly increased following the consumption of the 
two pasta, as well as the bifidogenic effect expected after assumption of whole grain fibre and β-
glucans was not observed. Finally, F. prausnitzii and F. saccharivorans, that were expected to 
increase due to the probiotic strain, were not significantly modulated following the ingestion of 
the functional pasta. Only in restricted groups of subjects the expected modulations were 
observed. However, the stratification of the subjects based on their BMI resulted a successful 
approach to obtain more homogeneous subgroups of subjects, and it revealed a non-bifidogenic 
effect of the functional pasta, in overweight and obese subjects. A reduction of Bifidobacterium 
spp. could lead to a decreased production of acetate, and this could be considered a beneficial 
outcome for subjects presenting characteristics of overweight or obesity. Furthermore, an 
increase of F. prausnitzii was observed following treatment with the functional pasta in the 
subgroup of individuals with glucose levels exceeding 100 mg/dL, and it represented a positive 
effect of the consumption of the functional product. 
In conclusion, even if investigated bacterial groups were not modified by the treatments in a 
significant manner, the correlation of microbiological and clinical data lead to some interesting 
findings. Extending the analysis to other microbial groups, e.g. through the use of a 
metagenomic approach, might reveal deeper modulation of the microbiota, in terms of 
composition and/or functions, which may help to clarify the results observed at the systemic 
level, on some clinical parameters. 
 
 
 
 
 
 
 
This study was supported by the Italian Ministry for Development in the framework of the project 
“Pass-World - pasta e salute nel mondo - Industria 2015” [MI01_00138]. 
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4. Conclusions 
 
The area of functional foods has being receiving much attention in the last years, since foods are 
not intended any more as pure sources of nutrients and energy, but also as factors that can exert 
positive effects on the consumer, contributing to the maintenance of a healthy status. In this 
contest, cereal based product present a range of beneficial features and, moreover, they can be 
used as vehicles of specific functional ingredients, for example probiotics and prebiotics. These 
functional components can directly act on gut microbiota, that has a deep impact on the overall 
health status. 
The present thesis was developed in the contest of an expansive research aimed at the creation of 
a novel whole grain functional pasta, enriched with a spore-forming probiotic strain, Bacillus 
coagulans GBI-30, 6086 (BC30), and β-glucans from barley, that was performed in collaboration 
with many academic and industrial partners. In particular, the objectives of the present study 
have been the evaluation of the microbiological aspects related to the novel product and the 
assessment of its impact on gut microbiota. 
In the first part of the dissertation, the production and the characterisation of the new functional 
food and of a respective control pasta has been shortly outlined, indicating that the novel pasta 
presented positive nutritional properties. The specific focus of this first part regarded the 
investigation of the stability of the probiotic strain, through culture-dependent and molecular 
analyses. On one hand, the technological properties of the probiotic strain during the pasta 
manufacturing process and preparation of the food have been investigated, showing that the 
probiotic strain survived the pasta production and cooking processes; in fact, B. coagulans BC30 
was found at high levels in the cooked product (above 106 CFU/g), corresponding to a dose of 
approximately 108 CFU for 100 g of ingested pasta. On the other hand, the probiotic strain was 
confirmed to resist to the transit in the gastrointestinal tract and to transiently colonise the gut 
compartment; in fact it was recovered in fecal samples at a concentration above 106 CFU/g, 
during a 12-week trial in which the functional pasta was consumed daily. These finding 
expanded available knowledge on the stability of the probiotic strain B. coagulans BC30, and 
specifically indicated that the functional pasta represented an effective vehicle for the probiotic 
strain. 
In the second part of the thesis, dealing with Type 1 diabetes (T1D) contest, a first case-control 
study was performed for assessing gut microbiota composition in children at risk for T1D 
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compared with healthy children. Even if a clear-cut differentiation between Cases and Controls 
was not observed, certain differences in composition were found trough PCR-DGGE analyses, 
but no with 16S rRNA gene profiling, thus highlighting the impact of the use of different 
techniques in gut microbiota studies. With the first approach, three species, namely Dialister 
invisus, Gemella sanguinis and Bifidobacterium longum, were found to be associated to the pre-
diabetic condition, together with an increase in gut permeability. Noteworthy, a species 
belonging to Bifidobacterium genus was found in the pre-pathologic condition, and another 
species, Bifidobacterium adolescentis, was found in pre-diabetic and diabetic microbiota at the 
baseline of the subsequent in vitro study. Thus, deepening the relevance of this microbial group 
for T1D development could be important, also considering the application of Bifidobacterium 
spp. in probiotic use. 
An in vitro study was conducted with the TIM-2 model of the proximal colon, and it provided 
information about the effects (i.e. modulation of microbiota composition and short-chain fatty 
acid production) of the newly developed pasta and the functional ingredients on fecal microbiota 
from children with different susceptibility to T1D. In term of composition, despite the variability 
in the response to a treatment observed in the different microbiota, specific diet-microbiota 
relationships were individuated, basing on the fact that a certain treatments produced certain 
same effects in the three microbiota. With this study new insights about the functional 
ingredients were obtained, e.g. the probiotic strain BC30 induced the growth of specific bacterial 
groups when administered alone (e.g. increase in Bifidobacterium spp.) or in combination with 
other ingredients (e.g. increases in Eubacterium and Lactobacillus spp., when administrated with 
β-glucans and concentrated starch, respectively). Regarding metabolite production, the 
functional pasta lead to the highest butyrate yield in healthy and diabetic microbiota, that 
represented a positive output. However, since microbiota derived from a small number of 
children, this study represent a preliminary research, and further studies are needed also in the 
perspective of planning an intervention in children. 
Finally, in the last part of the thesis, the effects of the consumption of the functional and control 
pasta were investigated in a 12-week clinical trial involving overweight/obese subjects. The 
consumption of the functional pasta did not substantially change the microbiota profiles of the 
subjects, as shown from PCR-DGGE analyses. Moreover, modulations of specific microbial 
groups reported to increase following administration of the different ingredients of the functional 
pasta were investigated through qPCR (Prevotella and Bifidobacterium spp., Faecalibacterium 
prausnitzii and Fusicatenibacter saccharivorans). Expected modulations were not observed in 
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the overall group of subjects, due to the higher inter-individual variability at the baseline and in 
the response to the treatment. Reducing this inter-individual variability by stratifying the 
population in smaller groups with more homogeneous characteristics resulted a successful 
strategy that unveil two interesting findings related to the consumption of the functional pasta, 
and obtained correlating microbiological and clinical data, i.e. a decrease in Bifidobacterium spp. 
in overweight subjects and an increase in F. prausnitzii in subjects with high glucose level. 
In conclusion, the present research indicated that the novel developed pasta constitutes a high-
quality product for its nutritional properties, for positive effects observed in vitro at the gut level, 
for certain beneficial evidences revealed from the clinical point of view, and from specific 
correlations between microbiological and clinical data. Further study would be helpful to deepen 
the knowledge of the effects of this new product, strengthen the integrated clinical-
microbiological approach, and investigating subjects with homogeneous characteristics, in the 
future perspective of the so-called personalised diet. 
Finally, the outline of this thesis could be proposed as a pipeline for the development of a new 
functional food, moving from the overall characterisation of the product, to the preliminary in 
vitro assessment of its effects at the gut microbiota level, to the integrated evaluation of its 
effectiveness in a clinical trial. 
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